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Chapter 1 
 
 
Introduction and overview 
 
INTRODUCTION AND OVERVIEW OF THE THESIS 
Percutaneous coronary intervention is a major treatment strategy for patients with coronary artery 
disease, and currently coronary stents are widely used in the world.1 Although stent implantation itself 
has shown to reduce restenosis by preventing both early elastic recoil and late vascular remodeling 
compared to balloon angioplasty, in-stent restenosis (ISR) still occurs in 10-40% of patients and has 
been the ‘Achilles’ heel’ of coronary interventions, frequently resulting in repeated revascularization.2,3
Restenosis after coronary stenting occurs secondary to the accumulation of smooth muscle cells and 
extracellular matrix proteoglycans.4 Despite the sophistication of the new techniques and enormous 
advance in devices, ISR requiring repeat procedure has been considered as a main limitation of 
coronary stenting.  
The advent of drug eluting stents (DES), which consist of a drug (immunosuppressive or antiproliferative 
drug),  a polymer and a metallic platform, has revolutionized the practice of interventional cardiology by 
significantly reducing the rates of restenosis and repeat revascularization as compared to bare metal 
stents.5 After the first approval of DES, a large number of patients with coronary artery disease have 
undergone percutaneous revascularization with DES. However, many trials conducted in the ‘real world’ 
showed that the problem of restenosis was not completely resolved and still persists. Effect of DES for 
patients at high risk for ISR, such as acute myocardial infarction, small coronary vessels, aorto-ostial 
lesions, or lesions of chronic total occlusion (Part 1 of this thesis), have not been fully investigated. In 
addition, certain potential safety concerns regarding the widespread use of DES have arisen. The most 
notable drawback of DES is that they could increase the risk of thrombotic complication, especially late 
stent thrombosis6, although its incidence is low.7 The increased risk of thrombosis with DES utilization 
may be associated with altered endothelial function8 and/or delayed vascular healing9 induced by 
cytotoxic and cytostatic drug use. Localized hypersensitivity reactions to the polymer coating of DES and 
drug itself may also contribute to stent thrombosis.10 To retain the positive clinical aspects of DES and 
overcome their drawbacks, new concept stents have been developed (Part 2 of this thesis).
Part 1: Efficacy of drug eluting stent for complex patients and lesions
Many randomized clinical trials showed that sirolimus and paclitaxel eluting stents are remarkably 
reduced ISR and target lesion revascularization, compared to bare metal stents. However, these trials 
had many exclusion criteria. The efficacy of DES for patients and lesions at high risk for restenosis has 
not been evaluated in detail. To assess the safety and efficacy of unrestricted utilization of sirolimus and 
paclitaxel eluting stents in a patient population representing the “real world”, several registries were 
conducted at the Thoraxcenter, Erasmus University (RESEARCH: Rapamycin-Eluting Stent Evaluated 
At Rotterdam Cardiology Hospital Registry and T-SEARCH: Taxus-Stent Evaluated At Rotterdam
Cardiology Hospital Registry). In these registries, sub-analysis for “complex patients and lesions” such 
as patients with acute myocardial infarction (Chapter 2 and 3), small vessel disease (Chapter 4 and 5),
aorto-ostial lesions (Chapter 6) or lesions of chronic total occlusion (Chapter 7 and 8) were analyzed. 
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Part 2: New concept stents for percutaneous coronary intervention
Stent thrombosis is the most considerable drawback of DES. To overcome this undesirable complication, 
new concept stents have been developed. One of these stents is the MAHOROBA tacrolimus eluting 
stent and this device may have the potential to reduce both ISR and stent thrombosis (Chapter 9). In
Chapter 10, the MAHOROBA trial, which is the first clinical investigation using the MAHOROBA 
tacrolimus eluting stents in de novo coronary artery stenoses, was reported. Fully absorbable polymer 
stent is also one of the new concept stents. This may diminish chronic inflammation between foreign 
body (stents) and surrounding tissue, accelerate healthy endothelialization of treated vessels and 
prevent stent thrombosis. The bioabsorbable everolimus eluting stent (BVS), which is composed of 
poly-L-lactic acid backbone, coated with bioabsorbable polymer containing the antiproliferative drug 
everolimus, has been developed and its safety and feasibility in diseased coronary artery were assessed 
in the ABSORB trial. In Chapter 11 and 12, mechanical properties of the BVS were reported. Potential 
advantages for the assessment of in-stent lumen of the BVS over metallic stents were also evaluated 
(Chapter 13 and 14).
Part 3: New imaging modality for coronary intervention 
Optical coherence tomography is a new intravascular imaging modality using infrared light. Because this 
modality has 10 times higher image resolution compared to intravascular ultrasound, detailed 
information of coronary structures were obtained (Chapter 15). In Chapter 16 and 17, ex vivo and in 
vivo quantitative analysis of optical coherence tomography was performed and its measurement 
accuracy was investigated.  
Chapter 1
14
References
1. Brophy JM, Belisle P, Joseph L. Evidence for use of coronary stents. A hierarchical bayesian 
meta-analysis. Ann Intern Med. 2003;138:777-86. 
2. de Feyter PJ, Kay P, Disco C, Serruys PW. Reference chart derived from post-stent-implantation 
intravascular ultrasound predictors of 6-month expected restenosis on quantitative coronary 
angiography. Circulation. 1999;100:1777-83. 
3. Serruys PW, Kay IP, Disco C, Deshpande NV, de Feyter PJ. Periprocedural quantitative coronary 
angiography after Palmaz-Schatz stent implantation predicts the restenosis rate at six months: 
results of a meta-analysis of the BElgian NEtherlands Stent study (BENESTENT) I, 
BENESTENT II Pilot, BENESTENT II and MUSIC trials. Multicenter Ultrasound Stent In 
Coronaries. J Am Coll Cardiol. 1999;34:1067-74. 
4. Farb A, Kolodgie FD, Hwang JY, Burke AP, Tefera K, Weber DK, Wight TN, Virmani R. 
Extracellular matrix changes in stented human coronary arteries. Circulation. 2004;110:940-7. 
5. Serruys PW, Kutryk MJ, Ong AT. Coronary-artery stents. N Engl J Med. 2006;354:483-95. 
6. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, Suddath WO, Weissman NJ, 
Torguson R, Kent KM, Pichard AD, Satler LF, Waksman R, Serruys PW. Late thrombosis in 
drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet.
2004;364:1519-21. 
7. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Juni P, Sianos G, 
Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW. Early 
and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine 
clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369:667-78. 
8. Hofma SH, van der Giessen WJ, van Dalen BM, Lemos PA, McFadden EP, Sianos G, Ligthart 
JM, van Essen D, de Feyter PJ, Serruys PW. Indication of long-term endothelial dysfunction after 
sirolimus-eluting stent implantation. Eur Heart J. 2006;27:166-70. 
9. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani 
R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am 
Coll Cardiol. 2006;48:193-202. 
10. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, 
Valsecchi O, Kolodgie FD. Localized hypersensitivity and late coronary thrombosis secondary to 
a sirolimus-eluting stent: should we be cautious? Circulation. 2004;109:701-5. 
Introduction
15
 
 
 
 
 
 
 
 
 
 
Part 1 
 
 
Efficacy of drug eluting stent for complex patients and lesions 
 
 
 
 
 
 
 
 
 
 
Chapter 2 
 
 
Drug-eluting stent implantation in acute myocardial infarction.  
Do we need another randomized trial? 
 (TYPHOON, PASSION and HORIZONS trials) 
 
Tanimoto S, Tsuchida K, Daemen J, Boersma E. 
 
EuroIntervention. 2006;2: 23-27 
 
Drug-eluting stent implantation in acute myocardial infarction.
Do we need another randomised trial?
(TYPHOON, PASSION and HORIZONS trials)
Shuzou Tanimoto, MD; Keiichi Tsuchida, MD, PhD; Joost Daemen, MD; Eric Boersma*, MSc, PhD
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The goal of treatment of patients with acute myocardial infarction
(AMI) is to achieve optimal and rapid restoration of coronary blood
flow in the infarct-related vessel and to maintain the initial result at
follow-up. There are two main treatment methods of re-opening an
occluded artery: administrating a thrombolytic agent and primary
percutaneous coronary intervention (PCI) with or without stenting.
In the 1990s and the beginning of the 2000s, many randomized
studies comparing these two reperfusion procedures have shown
that primary PCI with routine stent implantation for AMI has a bet-
ter outcome than thrombolytic therapy1,2 or balloon angioplasty3-5.
A recent meta-analysis also indicated that primary PCI was more
effective than thrombolytic therapy for the treatment of ST-segment
elevation myocardial infarction (STEMI)6.
In the last 3 to 4 years, drug-eluting stents (DES), either sirolimus-
eluting stents (SES) or paclitaxel-eluting stents (PES), have been
used in various clinical settings and have revolutionized the inter-
ventional cardiology practice by reducing restenosis and revascu-
larization rates in comparison to bare metal stents (BMS). Two piv-
otal trials using DES in relative high risk patients with complex
lesions reported single-digit restenosis rates and a lower incidence
of revascularization than BMS7,8. These trials, however, only includ-
ed elective procedures. Despite the lack of sufficient evidence, the
experience in stable patients was extrapolated to patients with
unstable angina pectoris, non ST-segment elevation acute coronary
syndrome (NSTE-ACS) and ST-segment elevation acute coronary
syndrome (STE-ACS); thereby the large number of DES currently
used in urgent procedures.
Previous studies suggested that sirolimus could alter and decrease
endothelial function in vitro9 and in humans10, enhance agonist-
induced platelet aggregation11 and tissue factor expression12, and
delay vascular healing13-15. Moreover, a hypersensitivity reaction 
to the polymer coating of SES was observed16-18. As for paclitaxel, 
a recent study suggested PES also induced a hypersensitivity reac-
tion18. These features of DES can increase the risk of thrombotic
complications and have led to prolonged antiplatelet treatment and
cautious use of DES in the acute phase of unstable angina and
myocardial infarction. Indeed, discontinuation of antiplatelet drugs
was a strong independent factor of DES thrombosis19-21 and 
a recent publication reported on patients treated with PES for 
AMI who presented with late stent thrombosis after cessation 
of antiplatelet drugs22.
So far, only 7 reports about DES implantation in AMI patients were
published (see Table). One study evaluated clinical and angio-
graphic outcomes of SES implantation in a consecutive series of
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89 patients23. Another study analysed short-term clinical outcomes
of consecutive 43 patients treated with PES implantation24. The lat-
est report made a comparison of the efficacy between PES and
SES25. The other 4 studies26-29 assessed the advantage of SES over
BMS. We compiled the results of these 4 studies and performed 
a meta-analysis, as there were no published trial comparing PES
with BMS in the clinical setting of AMI. The range of clinical follow-
up time varied between 6 and 10 months.
It should be mentioned that the study design and methodology 
of the four studies included in the present meta-analysis were vari-
able, and all of them were conducted in one single centre. The
STRATEGY (Single High Dose Bolus Tirofiban and Sirolimus Eluting
Stent vs Abciximab and Bare Metal Stent in Myocardial Infarction)
trial28, was the only prospective, single blind, randomized controlled
study presenting 8 months of follow-up. The Rotterdam study26, as
a part of the Rapamycin-Eluting Stent Evaluated At Rotterdam
Cardiology Hospital (RESEARCH) registry, and the German study27
adopted a similar methodology. Patients treated with SES were
prospectively enrolled and compared to control patients treated with
BMS in the immediate preceding period before the introduction of
SES.  Enrolled patients were followed for 10 and 6 months, respec-
tively. The last study was a retrospective analysis29. SES implanted
patients were compared to patients treated with BMS in the preceding
5-year period before the approval of SES, and followed up to
6 months. The robustness of each study is variable, so that some
limitations may be created in the result of our tentative meta-analysis,
which –as we should point out– does not collect individual data of
enrolled patients in the 4 studies.
The result of the meta-analysis is shown in the accompanying figure 1.
Overall, SES is associated with a 28% relative reduction in all-cause
deaths, an 80% relative reduction in target vessel revascularization
(TVR), and a 53% relative reduction in major adverse cardiac
events (MACE), which include all-cause mortality, non-fatal myocar-
dial infarction, and TVR (we could not analyse the non-fatal myocar-
dial infarction rates because one study26 did not state the incidence
of this complication separately). These results provide for a better
outcome after SES utilization in patients with AMI. Noteworthy, the
rate of TVR is similar to values reported in randomized trials of elec-
tive SES use.
At follow-up, the incidence of death in patients treated with SES was
comparable in 3 studies with the exception of the German study; it
was approximately 7% to 8%, which seemed similar to the one
observed in the control arms (approximately 8% to 10%). As the
German study included patients with not only STE-ACS but also
NSTE-ACS and excluded patients presenting cardiogenic shock,
this might be the explanation that its mortality rate is lower than in
the other studies. In the pooled data, short-term (30 days) mortali-
ty rate was 3.8% in the SES arm and 3.4% in the BMS arm.
Moreover, no angiographic stent thrombosis, including acute, sub-
acute and late thrombosis, was seen in patients treated with SES. 
In the BMS arm, the subacute thrombosis rate was 1.1%, which is
comparable with the incidence of BMS thrombosis in the treatment
of patients for stable coronary lesions30. No late stent thrombosis
was observed in the BMS arm. The fact that patients with DES tend-
ed to take antiplatelet therapy during longer period than control
patients might affect these results. However, SES is likely to be as
safe as BMS and does not seem to increase the thrombogenic com-
plications in the clinical setting of AMI at least in both short- and
medium-term.
In each study, the medium-term TVR rate in the SES arm was
remarkably lower than in the BMS arm. The TVR rate of the pooled
data in patients treated with SES was only 2.3%, whereas 11.3% 
of patients treated with BMS underwent revascularization and this
rate was close to the result of previous studies1-3. In the STRATEGY
trial, the TVR rates in both stent arms were higher than those
observed in the other 3 non-randomized trials. The reason for this
discrepancy is not readily apparent. The lesions of patients who
were enrolled in the STRATEGY trial might have been more complex
than those in the other trials. It might also reflect the fact that differ-
ent glycoprotein IIb/IIIa inhibitors were used in each arm; abciximab
Table 1. Published and non-published trials on drug-eluting stent implantation in patients with acute myocardial infarction
Study Year Trial design No. of patients Follow-up time Follow-up methods
BMS SES PES
Published
RESEARCH26 2004 Non-randomized 183 186 ••• 10 months Clinical
Weber et al.27 2004 Non-randomized 50 50 ••• 6 months Clinical & angiographic
STRATEGY28 2005 Randomized 88 87 ••• 8 months Clinical & angiographic
Cheneau et al.29 2005 Non-randomized 504 103 ••• 6 months Clinical
Saia et al.23 2003 Single arm registry ••• 89 ••• 6 months Clinical & angiographic
Margheri et al.24 2004 Single arm registry ••• ••• 43 4 months Clinical
T-SEARCH25 2005 Non-randomized ••• 186 136 12 months Clinical
Non-published
TYPHOON39 2006 Randomized 357 355 ••• 12 months Clinical & angiographic
PASSION40 2006 Randomized 310 ••• 309 12 months Clinical
RESEARCH: Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital, STRATEGY: Single High Dose Bolus Tirofiban and Sirolimus Eluting Stent 
vs Abciximab and Bare Metal Stent in Myocardial Infarction, T-SEARCH: Taxus-Stent Evaluated At Rotterdam Cardiology Hospital, TYPHOON: Trial to Assess
the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty, PASSION: Paclitaxel-Eluting Stent versus Conventional Stent 
in ST-segment Elevation Myocardial Infarction, BMS: bare metal stent, SES: sirolimus-eluting stents, PES: paclitaxel-eluting stents.
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was administrated in the BMS arm and single high dose bolus
tirofiban (25 μg/kg) in the SES arm.
Among the 4 studies, angiographic assessment was systematically
performed for enrolled patients in the STRATEGY trial and the
German study. Only the first 89 consecutive patients in 
the RESEARCH registry also underwent angiographic analysis23. The
late lumen loss in SES arms ranged from –0.22 mm to 0.12 mm and
the binary restenosis rate varied from 0% to 11%. Negligible, or very
small late lumen loss is associated with a lower incidence of angio-
graphic restenosis as well as a reduced need for TVR, which was well
described in many previous trials investigating patients with stable
coronary disease31-34. Such an angiographic analysis indicated that
SES retained its ability of inhibiting neointimal formation even in the
clinical setting of AMI. Consequently, the medium-term MACE rate in
the SES arm was significantly lower in comparison with the BMS arm
(10.8 % vs 23.2%, respectively;  p < 0.001). Low TVR rates account-
ed for lower MACE rates in patients treated with SES.
Recent head-to-head (SES vs PES) trials indicated that SES was sig-
nificantly better at reducing neointimal hyperplasia and had a slight-
ly advantage over PES in clinical outcomes, such as target lesion
revascularization (TLR) and TVR35-37. Similarly, the study of Hofma
et al.25, which was the only study comparing the efficacy of SES and
PES in the clinical setting of AMI and published as a subanalysis 
of the Taxus-Stent Evaluated At Rotterdam Cardiology Hospital 
(T-SEARCH) registry38, showed a higher rate of TLR, TVR and MACE
in the PES arm than in the SES arm. In the PES arm, 2.9% of all
patients experienced stent thrombosis, whereas in the present meta-
analysis we did not find any stent thrombosis in the pooled SES arms
as mentioned previously. Different drug-release kinetics and mecha-
nism of neointimal inhibition between SES and PES might have con-
tributed to the observed difference in their performance. At the pres-
ent time, we cannot conclude that PES is inferior to SES in patients
with AMI. Further investigations are needed to identify which DES is
more effective in this clinical setting.
In conclusion, our analysis suggests that SES is a safe and effective
device for the prevention of restenosis in the clinical setting of AMI. As
a result, the use of SES leads to low TVR and MACE rates, and seems
to be superior to BMS even in this subset of patients. SES appears to
Editorial
Figure 1. Rates and the relative and absolute reduction in the risk of death, TVR and MACE among patients treated with SES, as compared with
those treated with BMS, at six to ten months. Open boxes represent patients treated with SES. Shaded boxes represent patients treated with
BMS. Off-white boxes represent overall results. BMS: bare metal stents, SES: sirolimus-eluting stents, RESEARCH: Rapamycin-Eluting Stent
Evaluated At Rotterdam Cardiology Hospital, STRATEGY: Single High Dose Bolus Tirofiban and Sirolimus Eluting Stent vs Abciximab and Bare
Metal Stent in Myocardial Infarction, TVR: target vessel revascularization, MACE: major adverse cardiac events, CI: confidential intervals.
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be an attractive therapeutic approach for patients admitted with AMI.
However, the number of enrolled patients in each study was too small
so that they are underpowered to assess definitely the effect of SES on
the rate of TVR or MACE. As for PES utilization in AMI, only a few tri-
als were published. Much more information are needed to confirm
whether PES implantation in patients with AMI is safe and feasible
compared to BMS or SES. To establish the safety and advantage of both
DES in AMI, larger randomized trials are imperative.
At the American College of Cardiology 2006 Scientific Sessions, two
multi-centre and randomized trials about DES implantation in the
clinical setting of AMI were presented: the TYPHOON39 (Trial to
Assess the Use of Cypher stent in Acute Myocardial Infarction treat-
ed with Angioplasty) trial and the PASSION40 (Paclitaxel-Eluting
Stent versus Conventional Stent for ST-segment Elevation
Myocardial Infarction) trial. The TYPHOON trial included 712 patients
and assessed the effectiveness and safety of SES as compared 
to BMS at 1 year. The TVR rate in patients treated with SES was 
significantly lower than those who received BMS (5.6% vs 13.4%,
p < 0.001). The MACE rate was also lower in the SES group (5.9%
vs 14.6% in the BMS group, p < 0.001). These clinical outcomes
confirm the result of our meta-analysis, if not quantitatively at least
qualitatively. The PASSION trial, which enrolled 619 patients, was
the first trial comparing PES with BMS in the clinical setting of AMI.
This trial failed to find an advantage of PES over BMS in terms 
of MACE (8.7% and 12.6%, p = 0.12) and TLR (6.2% and 7.4%,
p = 0.23) at 1 year. These findings are at variance with the results
of the TYPHOON trial. We will have to wait for the results of the
HORIZONS trial, in which 3400 patients will be randomized and 
the superiority of PES over BMS will be investigated.
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Comparison of Three-Year Clinical Outcome of Sirolimus- and
Paclitaxel-Eluting Stents Versus Bare Metal Stents in Patients
With ST-Segment Elevation Myocardial Infarction
(from the RESEARCH and T-SEARCH Registries)
Joost Daemen, MD, Shuzou Tanimoto, MD, Héctor M. García-García, MD, Neville Kukreja, MRCP,
Meike van de Sande, BSc, Georgios Sianos, MD, PhD, Peter P.T. de Jaegere, MD, PhD,
Ron T. van Domburg, PhD, and Patrick W. Serruys, MD, PhD*
Sirolimus-eluting stents (SESs) recently proved to be superior to bare metal stents (BMSs)
in decreasing the need for repeat revascularization in patients with ST-segment elevation
myocardial infarction (STEMI) at 1 year. Whether this also holds for paclitaxel-eluting
stents (PESs) is currently unclear and the long-term relatively efficacy of the 2 drug-eluting
stents is currently unknown. We investigated the 3-year efficacy of SESs and PESs versus
BMSs in patients with STEMI. Primary angioplasty was performed in a consecutive group
of 505 patients (BMSs in 183, SESs in 186, PESs in 136). At 3 years, the cumulative
mortality rate was comparable in the 3 groups: 13.3% in the BMS group, 11.5% in the SES
group, and 12.4% in the PES group (nonsignificant for all). The rate of target vessel
revascularization (TVR) was 12.0% in the BMS group compared with 8.0% and 7.7% in the
SES and PES groups, respectively (p  0.12 for BMS vs SES, 0.30 for BMS vs PES, 0.62
for SES vs PES). The cumulative incidence of death, MI, or TVR was 25.5% in the BMS
group compared with 17.9% and 20.6% in the SES and PES groups, respectively (p  0.06
for BMS vs SES, 0.32 for BMS vs PES, 0.45 for SES vs PES). Angiographic stent thrombosis
occurred in 2.4% of all patients (BMS 1.6%, SES 2.7%, PES 2.9%). In conclusion, in this
relatively small consecutive patient cohort, the use of SESs and PESs was no longer
associated with significantly lower rates of TVR and major adverse cardiace events in
patients with STEMI after 3 years of follow-up. A high frequency of stent thrombosis was
observed in the 2 drug-eluting stent groups. © 2007 Elsevier Inc. All rights reserved. (Am
J Cardiol 2007;99:1027–1032)
Primary percutaneous coronary intervention, with or with-
out stenting, has been shown to result in superior long-term
outcome compared with thrombolytic therapy in patients
with acute myocardial infarction (MI).1 Recently, several
studies have reported that sirolimus-eluting stents (SESs)
and paclitaxel-eluting stents (PESs) are more effective in
decreasing restenosis and the frequency of repeat interven-
tions than are bare metal stents (BMSs), which rapidly
resulted in an unrestricted use of drug-eluting stents also in
patients with ST-segment elevation MI (STEMI).2–4 Shortly
after the introduction of SESs in 2002 the first studies
appeared, hypothesizing that the therapeutic range of SESs
could be extended to use in patients presenting with MI.
Compared with BMSs, SESs were associated with less
restenosis and target vessel revascularization (TVR) up until
1 year of follow-up.3,5 Currently it is unclear whether this
also holds for PESs.4,6 To date, there are no data on the
long-term outcome of the use of SESs and PESs in patients
with STEMI, a growing high-risk subgroup that is becom-
ing a substantial recipient of the total number of percutane-
ous coronary interventions in many centers all over the
world. For that reason, we evaluated the 3-year clinical
outcomes of a series of consecutive patients with STEMI
treated with BMSs, SESs, or PESs as part of a primary
percutaneous coronary intervention strategy.
Methods
On April 16, 2002, our institution commenced the use of
SESs (Cypher, Cordis Corp., Warren, New Jersey) as the
default strategy for every percutaneous coronary interven-
tion, with the aim of including a patient population repre-
senting the “real world.”7 Up until January 2003, 186 con-
secutive patients were treated with primary angioplasty
using exclusively SESs for STEMI. In February 2003 the
PES replaced the SES as the device of choice for all per-
cutaneous coronary interventions. Until September 2003,
136 primary percutaneous coronary interventions were per-
formed using exclusively PESs for STEMI. A control group
of 183 consecutive patients with STEMI treated with BMSs
immediately before April 2002 was retrospectively selected.
Of note, the 2 study groups were part of the Rapamycin-
Eluting Stent Evaluated at Rotterdam Cardiology Hospital
Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands.
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(RESEARCH) and Taxus-Stent Evaluated at Rotterdam
Cardiology Hospital (T-SEARCH) registries, respectively.
All patients were enrolled in the analysis including patients
in cardiogenic shock (defined as systolic blood pressure
persistently90 mm Hg or the need for inotropic support or
intra-aortic balloon pump implantation to maintain a blood
pressure 90 mm Hg with evidence of organ end failure
and increased left ventricular filling pressures). Patients
who underwent rescue percutaneous coronary intervention
after failed thrombolysis or who had previous brachyther-
apy were not included in this study. This protocol was
approved by the hospital ethics committee and is in accor-
dance with the Declaration of Helsinki. Written informed
consent was obtained from every patient.
All procedures were performed according to current
standard procedural guidelines and their details have been
reported previously.8,9 Baseline and postprocedural flows
were evaluated offline according to the Thrombolysis In
Myocardial Infarction criteria by cardiologists blinded to
stent group and clinical outcomes. All patients were advised
to maintain lifelong aspirin. At least 1 month of clopidogrel
treatment (75 mg/day) was recommended for patients
treated in the BMS group. In the 2 drug-eluting stents
groups, clopidogrel was prescribed for 3 months unless
multiple SES implantation (3 stents), total stented length
36 mm, persistent total occlusion, or bifurcations was
present. In these cases clopidogrel was prescribed for 6
months.
Patients were prospectively followed for the occurrence
of major adverse cardiac events (defined as a composite of
all-cause death, nonfatal MI, or TVR). Reinfarction was
diagnosed by recurrent symptoms and/or new electrocardio-
graphic changes in association with increases in creatine
kinase and creatine kinase myoglobin levels of 1.5 times
the previous value, if within 48 hours, or3 times the upper
normal limit, if 48 hours after the index infarction.10,11 TVR
was defined as a reintervention driven by any lesion located
in the same coronary artery. A secondary end point was
Table 1
Baseline and procedural characteristics of patients treated with bare metal, sirolimus, or paclitaxel-eluting stents
Variable BMS Group SES Group PES Group p Value
(n  183) (n  186) (n  136)
Men 79% 75% 84% 0.2
Age (yrs) 57  12 60  12 59  12 0.1
Diabetes mellitus 12% 12% 6% 0.1
Hypercholesterolemia* 34% 37% 46% 0.1
Hypertension 26% 27% 24% 0.8
Current smoker 48% 47% 42% 0.5
Previous MI 24% 14% 11% 0.006
Previous coronary angioplasty 9% 7% 6% 0.6
Previous coronary bypass grafting 3% 2% 2% 0.6
No. of coronary arteries narrowed 50% 0.6
1 48% 55% 52%
2 29% 27% 29%
3 24% 18% 19%
Cardiogenic shock 10% 13% 12% 0.6
Time from symptom onset to angioplasty (h) 3.5  3.8 3.3  2.1 3.2  2.4 0.8
Infarct-related coronary vessel 0.7
Left anterior descending 57% 53% 52%
Left circumflex 10% 8% 9%
Right coronary 30% 37% 36%
Left main 1% 2% 2%
Bypass graft 2% — 2%
TIMI flow at baseline 0.8
Grade 0/1 73% 73% 78%
Grade 2 15% 17% 11%
Grade 3 13% 10% 10%
TIMI flow after angioplasty 0.6
Grade 0/1 4% 2% 2%
Grade 2 17% 15% 12%
Grade 3 79% 83% 86%
Bifurcation lesion 4.4% 9.1% 9.6% 0.13
No. of implanted stents 1.7  1.0 1.9  1.2 1.8  1.1 0.1
Total stented length (mm) 30.3  20 34.7  24 35.9  23 0.055
Clopidogrel prescription (mo) 2.3  1.6 4.2  2.0 5.7  1.0 0.001
Glycoprotein IIb/IIIa inhibitor 56% 37% 55% 0.001
Peak creatinine kinase (U/L) 3,957  5,135 3,126  3,126 2,875  2,713 0.1
Peak creatinine kinase-MB (IU/L) 319  230 296  255 320  306 0.7
Values are percentages of patients or means  SDs.
* Defined as a fasting total serum cholesterol level 5.5 mmol/L (210 mg/dl) or use of lipid-lowering therapy.
TIMI  Thrombolysis In Myocardial Infarction.
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target lesion revascularization, defined as treatment of a
lesion in stent or within 5 mm of the stent borders. Subacute
stent thrombosis was defined as an angiographically docu-
mented complete occlusion (Thrombolysis In Myocardial
Infarction grade 0 or 1 flow) or a flow-limiting thrombus
(Thrombolysis In Myocardial Infarction grade 1 or 2 flow)
in the first 30 days after a successful procedure. Late stent
thrombosis was defined as angiographically defined throm-
bosis with Thrombolysis In Myocardial Infarction grade 0
or 1 flow or the presence of a flow limiting thrombus
occurring 1 month after drug-eluting stent implantation
accompanied by acute symptoms.12
Three-year survival status was obtained through munic-
ipal civil registries. Health questionnaires were subse-
quently sent to all living patients and inquired about post-
discharge repeat coronary interventions (surgical or
percutaneous) and MI. If a patient had an MI or a reinter-
vention at another center, medical records or discharge
letters were requested and systematically reviewed. Local
cardiologists or general practitioners were contacted if nec-
essary. Follow-up was available for 98% of patients with
BMSs, 98% of patients with SESs, and 97% of patients with
PESs.
Continuous variables are presented as mean  SD. Cat-
egorical variables are expressed as percentages. Compari-
sons across the 3 groups were performed by the F test from
an analysis of variance for continues variables and Pearson
chi-square test for categorical variables. The cumulative
incidence of adverse events was estimated according to the
Kaplan-Meier method. Patients were censored at 1, 2, and 3
Figure 1. Kaplan-Meier survival curves of (A) TVR and (B) combined cumulative incidence of major adverse cardiac events (MACE; death, MI, and TVR).
  change.
Table 2
Major adverse cardiac events at one year and two and three years
Variable BMS Group SES Group PES Group p Value
(n  183) (n  186) (n  136)
Events in first year
All-cause mortality 17 (9.3%) 15 (8.1%) 11 (8.1%) 0.89
MI 6 (3.3%) 2 (1.1%) 6 (4.4%) 0.17
TVR (all) 14 (7.7%) 3 (1.6%) 9 (6.6%) 0.021
Stent thrombosis 3 (1.6%) 1 (0.5%) 4 (2.9%) 0.22
Hierarchical MACEs 34 (18.6%) 18 (9.7%) 21 (15.4%) 0.048
Events in second year
All-cause mortality 5 (2.7%) 4 (2.2%) 3 (2.2%) 0.92
MI — 1 (0.5%) — 0.42
TVR (all) 4 (2.2%) 5 (2.7%) 1 (0.7%) 0.45
Stent thrombosis — 1 (0.5%) — 0.423
Hierarchical MACEs 8 (4.4%) 9 (4.8%) 4 (2.9%) 0.69
Events in third year
All-cause mortality 2 (1.1%) 2 (1.1%) 2 (1.5%) 0.94
MI — 3 (1.6%) — 0.075
TVR (all) 2 (1.1%) 4 (2.2%) — 0.21
Stent thrombosis — 3 (1.6%) — 0.075
Hierarchical MACEs 4 (2.2%) 6 (3.2%) 2 (1.5%) 0.76
MACEs  major adverse cardiac events.
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years to report the cumulative incidence of major adverse
cardiac events and TVR in the 2 Kaplan-Meier curves.
Overall incidences were tested using log-rank test. Cox
proportional hazards regression analyses were performed to
correct for independent predictors of adverse events and
differences across groups. Independent predictors were de-
termined for each end point in the 3 compared groups (SES
vs BMS, SES vs PES, PES vs BMS) by using all univariate
significant (p 0.1) baseline and procedural characteristics
listed in Table 1. Independent predictors of outcome were
forced into the model, together with stent type used. The
final results are presented as adjusted hazard ratios. Patients
lost to follow-up were considered at risk until the date of
final contact, when they were censored.
Results
Clinical baseline characteristics were comparable among
groups, with the exception of previous MI, which was more
frequent in the BMS group (24%) than in the SES and PES
groups (14% and 11%, respectively, p  0.006; Table 1).
There were few differences in procedural characteristics
among groups: Glycoprotein IIb/IIIa inhibitor use was
higher in the BMS (56%) and PES (55%) groups than in the
SES group (37%, p 0.001), and as defined by the study
protocol clopidogrel prescription was longer in the 2 drug-
eluting stent groups than in the BMS group.
Thirty-day and 1-year outcome have been reported pre-
viously.8,9 At 3 years, the cumulative mortality rate was
comparable in the 3 groups (13.3% in the BMS group,
11.5% in the SES group, and 12.4% in the PES group;
log-rank p  0.63 for BMS vs SES, 0.78 for BMS vs PES,
0.86 for SES vs PES). Cause of death was cardiac in 62%,
unknown in 18%, and noncardiac in 20% of patients. In the
BMS group 3.5% developed a new MI compared with 4.0%
in the SES group and 4.7% in the PES group (log-rank p 
0.99 for BMS vs SES, 0.62 for BMS vs PES, 0.52 for SES
vs PES). Target lesion revascularization was performed in
8.4% of patients in the BMS group compared with 6.2% in
the SES group and 6.1% in the PES group (log-rank p 
0.27 for BMS vs SES, 0.56 for BMS vs PES, 0.58 for SES
vs PES). There was a trend toward a higher incidence of
TVR in the BMS group (12.0%) compared with the SES
(8.0%) and PES (7.7%) groups (Figure 1). The combined
cumulative incidence of major adverse cardiac events was
25.5% in the BMS group compared with 17.9% in the SES
group and 20.6% in the PES group (Figure 1). Events
occurring in the second and third years of follow-up are
presented in Table 2.
At 3 years, 12 patients (2.4%) presented with angio-
graphically documented stent thrombosis. Three patients
(1.6%) in the BMS group developed stent thrombosis com-
pared with 5 (2.7%) in the SES group and 4 (2.9%) in the
PES group (p  0.72 for SES vs BMS, 0.46 for PES vs
BMS). Stent thrombosis occurred relatively soon after the
index percutaneous coronary intervention at a mean of 8.7
days (range 6 to 11) and 3.5 days (range 0 to 6) in the BMS
and PES groups, respectively. In contrast, in the SES group
stent thrombosis occurred much later, at a mean of 685 days
(range 18 to 1,074). Three of 4 patients with stent throm-
bosis after 1 year were on single antiplatelet therapy with
aspirin and 1 stopped using aspirin 2 days before the event.
Two patients presented with unstable angina and 2 with MI.
One patient in the PES group had 3 recurrent thrombotic
events at 4, 8, and 11 days after the procedure and died
during the third event of a subsequent MI despite being on
dual antiplatelet therapy. Although beyond the scope of the
present analysis, it is worth mentioning that 1 patient in the
PES group developed stent thrombosis at 1,100 days after
the procedure, 2 days after stopping dual antiplatelet ther-
apy, because of an elective surgical procedure. All cases of
stent thrombosis were treated using balloon angioplasty
with 100% glycoprotein IIb/IIIa use and additional stents
were used in 4 cases.
In Cox multivariate analysis performed in the total pop-
ulation, bifurcation treatment (in which 2 stents were used
in 92% of patients) proved to be the strongest predictor of
stent thrombosis (hazard ratio 7.84, 95% confidence interval
2.12 to 29.03) followed by female gender, which had a
cardioprotective effect (hazard ratio 0.17, 95% confidence
interval 0.05 to 0.58). Cox multivariate regression models
were also used to correct for differences and independent
predictors of adverse events between each pair of groups
(SES vs BMS, PES vs BMS, and PES vs SES; Table 3).
After adjustment, no significant differences were seen in the
3 comparisons in any clinical end point (death, nonfatal MI,
TVR, and major adverse cardiac events).
Discussion
The main findings of the present analysis of 505 consecutive
patients presenting with STEMI are (1) the superiority of
Table 3
Major adverse cardiac events up to three years
Variable BMS Group
(n  183)
SES Group
(n  186)
PES Group
(n  136)
Relative Risk (95% CI)
SES vs BMS PES vs BMS PES vs SES
Mortality at 1 yr 9.4% 8.1% 8.1% 0.81 (0.36–1.81) 1.01 (0.66–1.53) 1.24 (0.52–2.95)
Mortality at 3 yrs 13.3% 11.5% 12.4% 0.78 (0.41–1.51) 1.08 (0.77–1.52) 1.62 (0.80–3.27)
Nonfatal MI at 1 yr 3.5% 1.2% 4.7% 0.30 (0.06–1.53) 1.11 (0.62–1.99) 5.40 (1.07–27.6)
Nonfatal MI at 3 yrs 3.5% 4.0% 4.7% 0.95 (0.30–2.98) 1.11 (0.62–1.99) 2.03 (0.63–6.51)
TVR at 1 yr 8.2% 1.7% 6.9% 0.23 (0.06–0.85) 1.11 (0.72–1.72) 10.45 (1.76–62.2)
TVR at 3 yrs 12.0% 8.0% 7.7% 0.65 (0.30–1.37) 0.98 (0.66–1.46) 1.69 (0.70–4.07)
MACEs (death, MI, and TVR) at 1 yr 18.7% 9.7% 15.5% 0.57 (0.32–1.03) 0.99 (0.75–1.31) 1.49 (0.79–2.82)
MACEs (death, MI, and TVR) at 3 yrs 25.5% 17.9% 20.6% 0.77 (0.48–1.23) 0.97 (0.76–1.24) 1.17 (0.69–1.97)
CI  confidence interval; other abbreviation as in Table 2.
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SESs in decreasing TVR compared with BMSs and PESs at
1 year was no longer present at 3 years, (2) PESs were not
superior to BMS in decreasing the incidence of adverse
cardiac events at 1, 2, and 3 years of follow-up, and (3) stent
thrombosis in this high-risk subgroup occurred with an
overall incidence of 2.4% at a mean of 289 days after the
procedure (median 10 days, interquartile range 4.5 to 757)
and did not differ significantly across the 3 groups.
Previous (non)randomized studies have reported that the
use of the 2 types of drug-eluting stent result in similar rates
of death and MI compared with BMSs.13,14 A recent meta-
analysis of randomized trials comparing SESs with PESs
also showed no significant difference in these end points.15
The results of the present study concur with those of the
previously mentioned studies and are supported by a recent
meta-analysis of the results of SES implantation in patients
with acute MI.5
The success of drug-eluting stents is primarily driven by
their capability to decrease restenosis and the need for
repeat interventions, but the currently available long-term
follow-up is based on randomized studies, which excluded
patients with STEMI.14 At 1 year, we observed a relative
decrease of 80% in the risk for TVR with the use of SESs
compared with BMSs (p  0.006). However, at 2 and 3
years, the relative decreases were 59% (p 0.003) and 44%
(p 0.12), respectively. PESs showed no significant benefit
in decreasing TVR compared with BMSs at 1 years or 2 or
3 years. These 1-year results concur with those of the Trial
to Assess the Use of the Cypher Stent in Acute Myocardial
Infarction Treated with Balloon Angioplasty (TYPHOON)
trial, which randomized 700 patients and showed that
SESs were superior to BMSs in patients presenting with
acute MI.3 With regard to PESs, the randomized Paclitaxel-
Eluting Stent versus Conventional Stent in Myocardial In-
farction with ST-Segment Elevation (PASSION) trial con-
firmed our findings that PESs were not superior to BMSs in
each clinical end point at 1 year of follow-up.4 The favor-
able results of the SESs in the TYPHOON trial might have
been influenced by the high TVR rate in the BMS control
arm and the angiographic follow-up in a considerable num-
ber of patients.
The loss of the superiority of SESs compared with BMS
after 1 year of follow-up might be partly explained by the
occurrence of late stent thrombosis, which occurred in 4
patients (2.1%) in the SES group in the third year of fol-
low-up compared with a 0% incidence in the BMS group.
These 4 cases of late stent thrombosis comprised 50% of the
total number of TVRs performed in the third year of fol-
low-up and accounted for 100% of all MIs occurring be-
tween the first and third year. The increased incidence in
very late stent thrombosis in the SES group is in accordance
with a recent report by Togni et al,16 which showed a trend
toward a higher incidence of very late stent thrombosis in
patients treated with SESs. Although stenting in the setting
of MI proved to be a consistent predictor of stent thrombo-
sis, current reports about the occurrence of stent thrombosis
after 1 year and especially after 2 years are still scarce.17–19
The total incidence of stent thrombosis in this high-risk
patient population was 2.4% and was, although mostly due
to the longer follow-up, higher than that in previous reports
in which stent thrombosis rates were 1.0% to 1.7%.12,20,21
The incidence of stent thrombosis in the BMS group in the
present study was 1.6% and in is agreement with that in
previous reports.22 Stent thrombosis occurred in 2.9% of
patients in the PES group, all within the first week after the
index percutaneous coronary intervention. No late stent
thrombosis was observed from 1 year to 3 years. This latter
observation does not concur with a previous study, which
reported late stent thrombosis rates of 0.8% in patients
treated with PESs.23 However, the occurrence and rate of
early stent thrombosis in the PES group was comparable to
that in the BMS group, occurring mainly within the first 2
weeks after stent implantation.24 It is unknown whether the
late deaths of unknown cause were due to stent thrombosis.
Dual antiplatelet therapy was not able to prevent the 10
early thrombotic events. Whether it would have prevented
the late cases of stent thrombosis remains unclear. Thus, the
relative efficacy of dual antiplatelet therapy remains un-
known, even when taking into account the increased costs,
higher bleeding risk, and possibility of aspirin and/or clo-
pidogrel resistance.25–28
A limitation of the present study is that the results are
based on a nonrandomized patient population without com-
pletely identical groups. An example of this is glycoprotein
IIb/IIIa prescription, which was lower in the SES group.
However, its use did not prove to be protective against
adverse events and short- and long-term outcomes in the
present study, which is in accordance with the current lit-
erature.29 Further, the results are based on a relatively small
patient cohort and therefore may have lack of power. Nev-
ertheless, the present study is the first in the world to
complete longer-term follow-up of this high-risk patient
subset because Europe was the first to grant Conformité
Européenne mark approval for the 2 types of drug-eluting
stent, whereas approval by the US Food and Drug Admin-
istration was granted 1 year later.
The recently published 1-year results of the randomized,
controlled PASSION and TYPHOON trials showed dis-simi-
lar outcomes with respect to the different drug-eluting stents
used.3,4 However, until they are able to present longer-term
follow-ups, the present single-center prospective registry,
which aims to represent a real-world patient population, shows
that the “unrestricted” use of SESs and PESs might not be
justified in patients presenting with STEMI when taking into
account the long-term adverse events.
Appendix
The following operators were involved in the procedures of
the discussed patient population: Chourmouzios A. Aram-
patzis, MD, Eugene McFadden, MD, PhD, Pim J. de Feyter,
MD, PhD, Willem J. van der Giessen, MD, PhD, Sjoerd H.
Hofma, MD, PhD, Angela Hoye, MBChB, MRCP, Peter
P.T. de Jaegere, MD, PhD, Patrick W. Serruys, MD, PhD,
Evelyn Regar, MD, PhD, Georgios Sianos, MD, PhD, and
Pieter C. Smits, MD, PhD.
1. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intra-
venous thrombolytic therapy for acute myocardial infarction: a quan-
titative review of 23 randomised trials. Lancet 2003;361:13–20.
2. Serruys PW, Kutryk MJ, Ong AT. Coronary-artery stents. N Engl
J Med 2006;354:483–495.
3 year follow-up of DES in MI
33
3. Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carrie D, Slama
MS, Merkely B, Erglis A, Margheri M, et al. Sirolimus-eluting versus
uncoated stents in acute myocardial infarction. N Engl J Med 2006;
355:1093–1104.
4. Laarman GJ, Suttorp MJ, Dirksen MT, van Heerebeek L, Kiemeneij F,
Slagboom T, van der Wieken LR, Tijssen JG, Rensing BJ, Patterson
M. Paclitaxel-eluting versus uncoated stents in primary percutaneous
coronary intervention. N Engl J Med 2006;355:1105–1113.
5. Tanimoto S, Tsuchida K, Daemen J, Boersma E. Drug-eluting stent
implantation in acute myocardial infarction. Do we need another
randomized trial? (TYPHOON, PASSION and HORIZONS trials).
Eur Interv 2006;1:23–27.
6. Schwalm JD, Ahmad M, Velianou JL, Xie C, Natarajan MK. Primary
and rescue percutaneous coronary intervention with paclitaxel-eluting
stent implantation in ST-elevation myocardial infarction. Am J Cardiol
2006;97:1308–1310.
7. Lemos PA, Lee C, Degertekin M, Saia F, Tanabe K, Arampatzis CA,
Hoye A, van Duuren M, Sianos G, Smits PC, et al. Early outcome after
sirolimus-eluting stent implantation in patients with acute coronary
syndromes. Insights from the Rapamycin-Eluting Stent Evaluated At
Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll
Cardiol 2003;41:2093–2099.
8. Lemos PA, Saia F, Hofma SH, Daemen J, Ong AT, Arampatzis CA,
Hoye A, McFadden E, Sianos G, Smits PC, et al. Short- and long-term
clinical benefit of sirolimus-eluting stents compared to conventional
bare stents for patients with acute myocardial infarction. J Am Coll
Cardiol 2004;43:704–708.
9. Hofma SH, Ong AT, Aoki J, van Mieghem CA, Rodriguez Granillo
GA, Valgimigli M, Regar E, de Jaegere PP, McFadden EP, Sianos G,
et al. One year clinical follow up of paclitaxel eluting stents for acute
myocardial infarction compared with sirolimus eluting stents. Heart
2005;91:1176–1180.
10. Grines CL, Cox DA, Stone GW, Garcia E, Mattos LA, Giambar-
tolomei A, Brodie BR, Madonna O, Eijgelshoven M, Lansky AJ,
O’Neill WW, Morice MC. Coronary angioplasty with or without stent
implantation for acute myocardial infarction. Stent Primary Angio-
plasty in Myocardial Infarction Study Group. N Engl J Med 1999;341:
1949–1956.
11. Saia F, Lemos PA, Lee CH, Arampatzis CA, Hoye A, Degertekin M,
Tanabe K, Sianos G, Smits PC, McFadden E, et al. Sirolimus-eluting
stent implantation in ST-elevation acute myocardial infarction: a clin-
ical and angiographic study. Circulation 2003;108:1927–1929.
12. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT,
Serruys PW. Late angiographic stent thrombosis (LAST) events with
drug-eluting stents. J Am Coll Cardiol 2005;45:2088–2092.
13. Daemen J, Ong A, Stefanini G, Tsuchida K, Spindler H, Sianos G, De
Jaegere P, Van Domburg R, Serruys P. Three-year clinical follow-up
of the unrestricted use of the sirolimus-eluting stent compared to the
use of a standard bare metal stent as part of the Rapamycin-Eluting-
Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH)
Registry. Am J Cardiol 2006;98:895–901.
14. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC,
Colombo A, Schampaert E, Grube E, Kirtane AJ, et al. Safety and
efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl
J Med 2007;356:998–1008.
15. Kastrati A, Dibra A, Eberle S, Mehilli J, Suarez de Lezo J, Goy JJ,
Ulm K, Schomig A. Sirolimus-eluting stents vs paclitaxel-eluting
stents in patients with coronary artery disease: meta-analysis of ran-
domized trials. JAMA 2005;294:819–825.
16. Togni M, Billinger M, Wenaweser P, Morger C, Cook S, Meier B,
Hess OM, Windecker S. Late and very late stent thrombosis in patients
with drug-eluting stents. J Am Coll Cardiol 2006;47(suppl B).
17. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C,
Kukreja N, Jüni P, Sianos G, Hellige G, et al. Early and late coronary
stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in
routine clinical practice: data from a large two-institutional cohort
study. Lancet 2007;369:667–678.
18. Urban P, Gershlick AH, Guagliumi G, Guyon P, Lotan C, Schofer J,
Seth A, Sousa JE, Wijns W, Berge C, Deme M, Stoll HP. Safety of
coronary sirolimus-eluting stents in daily clinical practice: one-year
follow-up of the e-Cypher registry. Circulation 2006;113:1434–1441.
19. Park DW, Park SW, Park KH, Lee BK, Kim YH, Lee CW, Hong MK,
Kim JJ, Park SJ. Frequency of and risk factors for stent thrombosis
after drug-eluting stent implantation during long-term follow-up. Am J
Cardiol 2006;98:352–356.
20. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G,
Airoldi F, Chieffo A, Montorfano M, Carlino M, et al. Incidence,
predictors, and outcome of thrombosis after successful implantation of
drug-eluting stents. JAMA 2005;293:2126–2130.
21. Leon M, Weisz G, Moses J, Schofer J, Morice MC, Schampaert E,
Wang P. Late stent thrombosis in sirolimus-eluting versus bare metal
stents in 4 randomized clinical trials with 3-year follow-up. J Am Coll
Cardiol 2006;47(suppl B).
22. Wenaweser P, Rey C, Eberli FR, Togni M, Tuller D, Locher S,
Remondino A, Seiler C, Hess OM, Meier B, Windecker S. Stent
thrombosis following bare-metal stent implantation: success of emer-
gency percutaneous coronary intervention and predictors of adverse
outcome. Eur Heart J 2005;26:1180–1187.
23. Lee CH, Lim J, Low A, Tan HC, Lim YT. Late angiographic stent
thrombosis of polymer based paclitaxel eluting stent. Heart 2006;92:
551–553.
24. Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL. What is the risk of
stent thrombosis associated with the use of paclitaxel-eluting stents for
percutaneous coronary intervention? A meta-analysis. J Am Coll Car-
diol 2005;45:941–946.
25. Cheng X, Chen WH, Simon DI. Aspirin resistance or variable response
or both? Am J Cardiol 2006;98(suppl):S11–S17.
26. Wiviott SD. Clopidogrel response variability, resistance, or both? Am J
Cardiol 2006;98(suppl):S18–S24.
27. Eriksson P. Long-term clopidogrel therapy after percutaneous coro-
nary intervention in PCI-CURE and CREDO: the “Emperor’s New
Clothes” revisited. Eur Heart J 2004;25:720–722.
28. Wenaweser P, Dorffler-Melly J, Imboden K, Windecker S, Togni M,
Meier B, Haeberli A, Hess OM. Stent thrombosis is associated with an
impaired response to antiplatelet therapy. J Am Coll Cardiol 2005;45:
1748–1752.
29. Eisenberg MJ, Jamal S. Glycoprotein IIb/IIIa inhibition in the setting
of acute ST-segment elevation myocardial infarction. J Am Coll Car-
diol 2003;42:1–6.
Chapter 3
34
 
 
 
 
 
 
 
 
 
Chapter 4 
 
 
Two-year clinical outcome after coronary stenting of  
small vessels using 2.25mm sirolimus- and paclitaxel-eluting 
stents: Insight into the RESEARCH and T-SEARCH registries. 
 
Tanimoto S, Daemen J, Tsuchida K, Garcia-Garcia H, de Jaegere P,  
van Domburg R, Serruys PW. 
 
Cathet Cardiovasc Intervent. 2007;69: 94-103 
 
Two-Year Clinical Outcome After Coronary Stenting
of Small Vessels Using 2.25-mm Sirolimus- and
Paclitaxel-Eluting Stents: Insight Into the
RESEARCH and T-SEARCH Registries
Shuzou Tanimoto, MD, Joost Daemen, MD, Keiichi Tsuchida, MD, PhD,
He´ctor M. Garcı´a-Garcı´a, MD, Peter de Jaegere, MD, PhD, Ron T. van Domburg, PhD,
and Patrick W. Serruys,* MD, PhD
Objectives: To evaluate long-term outcomes after drug-eluting stents (DES) implanta-
tion in small coronary vessels. Background: Sirolimus-eluting stents (SES) and pacli-
taxel-eluting stents (PES) have been reported to improve both the angiographic and
clinical outcomes compared with bare metal stents even in ‘real world’ settings.
Currently, no data is available on long-term outcomes after DES implantation in small
vessels. Methods: Since April 2002, our institution has implanted DES, either SES or
PES, as a default strategy in all patients irrespective of their clinical presentation.
Between October 2002 and September 2003, 197 consecutive patients were enrolled:
107 consecutive patients received at least one 2.25-mm SES (SES group) and 90 con-
secutive patients received at least one 2.25-mm PES (PES group). Results: The two
cohorts presented with high-risk characteristics. At 2 years, the cumulative incidence
of major adverse cardiac events (MACE) in the SES group was significantly lower
than that in the PES group (10.3% vs. 23.3%, P = 0.02). There were two subacute
angiographic stent thromboses in the PES group and none in the SES group. By multi-
variate analysis, PES utilization (HR 2.37, 95% CI 1.07–5.26), presentation with acute
coronary syndromes (ACS) (HR 3.34, 95% CI 1.44–7.70) and multi-vessel disease
(MVD) (HR 3.91, 95% CI 1.27–12.0) were identified as independent predictors of
MACE. Conclusions: In an unselected population treated for small vessel disease, SES
were associated with significantly better 2-year clinical outcomes than PES. The use of
PES and the presentation with ACS and MVD were identified as independent predictors
of MACE. ' 2006 Wiley-Liss, Inc.
Key words: coronary artery disease; drug-eluting stents; sirolimus; paclitaxel
INTRODUCTION
Percutaneous coronary intervention (PCI) is a major
treatment strategy for patients with ischemic heart disease,
and currently coronary stents are widely used [1]. Bare
metal stents (BMS) reduce coronary restenosis and signifi-
cantly improve the angiographic and clinical outcomes in
vessels with a reference diameter (RD) more than 3 mm
by their ability to prevent both early elastic recoil and late
vascular remodeling, as compared to balloon angioplasty
[2–4]. On the other hand, several randomized trials have
failed to show an advantage of BMS over balloon angio-
plasty in vessels with a RD less than 3 mm [5,6]. There-
fore, whether stent implantation in small vessels improves
outcomes compared to balloon angioplasty alone still
remains controversial. At present, however, PCI in small
vessels of less than 3 mm accounts for almost 50% of all
revascularization procedures and leads to a higher inci-
dence of restenosis and adverse cardiac events [7].
In the last 3–4 years, drug-eluting stents (DES), ei-
ther sirolimus-eluting stents (SES) or paclitaxel-eluting
stents (PES), have revolutionized the interventional
cardiology practice by reducing restenosis and the need
for repeat revascularizations as compared to BMS. Se-
veral multicenter randomized trials have evaluated the
efficacy of DES for the treatment of vessels with a RD
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less than 3 mm and shown a significant reduction in
both restenosis and clinical events [8–11]. More re-
cently, several trials comparing SES with PES were
performed [12–17]. The general conclusion from a
meta-analysis of these trials is that SES are signifi-
cantly better at reducing neointimal hyperplasia and
confer an advantage over PES in terms of clinical out-
comes [18]. However, there is limited information on
the relative safety and efficacy of SES compared to
PES in patients with small vessel disease [19,20].
Some recent studies have also cautioned that either
SES or PES could increase thrombotic complications
compared to BMS, especially late stent thrombosis
[21,22], due to decreased endothelial function [23], de-
layed vascular healing [24], and/or hypersensitivity
reactions to the polymer coating of the DES and the
drug itself [25,26]. Although BMS implantation in
small vessels had been previously cited as a risk factor
for stent thrombosis [27], improved techniques of opti-
mal stent deployment and dual antiplatelet regimens
appear to have largely resolved this problem so that
the risk of stent thrombosis in small vessel stenting
now seems to be similar to that in larger vessel stent-
ing [28]. But, DES implantation in small vessels may
increase the risk of stent thrombosis because of their
features as mentioned earlier. Therefore, long-term fol-
low-up as well as short- and medium-term follow-up
are needed to determine whether DES implantation is
safe in the subset of patients with small vessel disease.
To the best of our knowledge, there is currently no
available publication comparing the long-term efficacy of
SES and PES for the treatment of small coronary arteries.
The present study, which is derived from our previous
study population [19], is conducted to compare clinical
outcomes in terms of safety and efficacy at 2 years after
implantation of 2.25-mm diameter SES and PES.
MATERIALS AND METHODS
Study Design and Patient Population
Since April 2002, SES (Cypher1; Cordis Corpora-
tion, Warren, NJ) have been implanted as the default
strategy for every PCI in our institution as part of the
Rapamycin-Eluting Stent Evaluated At Rotterdam Car-
diology Hospital (RESEARCH) registry [29]. This
strategy continued until February 2003, when PES
(TaxusTM; Boston Scientific Corporation, Galway, Ire-
land) implantation became the default strategy for all
patients with coronary artery disease as part of the
Taxus-Stent Evaluated At Rotterdam Cardiology Hos-
pital (T-SEARCH) registry [30]. The methods and
design of both studies have been described previously
[29,30]. Both trials evaluated the safety and efficacy of
SES and PES implantation for patients treated in daily
practice. All patients were included irrespective of
their clinical presentation and lesion characteristics.
Between October 2002 and September 2003, a total of
197 consecutive patients were enrolled: 107 patients
received at least one 2.25-mm diameter SES (SES group)
and 90 patients received at least one 2.25-mm diameter
PES (PES group). The study protocol was approved by
the institutional ethics committee, and all patients pro-
vided written informed consent.
Procedures and Postinterventional Medications
All procedures were performed in accordance with
standard techniques. The interventional strategy and use of
glycoprotein IIb/IIIa inhibitors were left entirely to the dis-
cretion of the operator. All patients were advised to take
aspirin lifelong (at least 80 mg/day). A loading dose of
300 mg clopidogrel was given before the intervention.
Postprocedural clopidogrel treatment (75 mg/day) differed
between the two groups. For patients treated with SES,
clopidogrel was prescribed for at least 3 months, unless
one of the following was present (in which case clopidog-
rel was maintained for at least 6 months): multiple SES
implantation (3 stents), total stent length 36 mm,
chronic total occlusion, and bifurcations. Patients treated
with PES were prescribed at least 6 months of clopidogrel
in accordance with the product labeling and instructions
for use, based on existing data from randomized, con-
trolled trials [31]. The methodology of quantitative coro-
nary angiography (QCA) evaluation has been described
previously [19].
Definition and Follow-Up
Patients were prospectively followed-up for the inci-
dence of major adverse cardiac events (MACE), which
included all-cause mortality, nonfatal myocardial infarc-
tion, and target lesion revascularization (TLR) or target
vascular revascularization (TVR). Myocardial infarction
(MI) was diagnosed by a rise in the creatine kinase-MB
fraction (CK-MB) of more than three times the upper
limit of normal, according to the American Heart Asso-
ciation/American College of Cardiology guidelines [32].
TLR was defined as a repeat intervention (surgical or
percutaneous) to treat a luminal stenosis within the stent
or in the 5-mm distal or proximal segments adjacent to
the stent. TVR was defined as a reintervention driven by
any lesions located in the same treated epicardial vessel.
Stent thrombosis was defined as angiographically docu-
mented complete occlusion (TIMI flow grade 0 or 1) or
flow-limiting thrombus (TIMI flow grade 1 or 2) in pre-
viously successfully treated artery. Information about the
in-hospital outcomes was derived from our institutional
electronic clinical database and by review of the hospital
g
Chapter 4
38
records of those discharged to referring hospitals. Postdi-
scharge survival status was obtained from the municipal
civil registries. Health questionnaires were subsequently
sent to all living patients, inquiring about postdischarge
repeat coronary interventions (either surgical or percuta-
neous) and the occurrence of MI. All repeat interven-
tions and rehospitalizations were prospectively collected
during follow-up. Referring physicians and institutions
were contacted for additional information if required.
Statistical Analysis
Continuous variables were presented as mean 6 SD
and were compared by means of the Student’s un-
paired t test. Categorical variables were presented as
counts and percentages and compared by means of the
v2 test or Fisher’s exact test. The cumulative incidence
of adverse events was estimated according to the
Kaplan–Meier method and compared by the log rank
test. Patients lost to follow-up were considered at risk
until the date of last contact, at which point they were
censored. Multivariate analyses were performed to
identify independent predictors of adverse events,
using all clinical, angiographic, and procedural varia-
bles included in Tables I and II. Cox proportional haz-
ards survival models were used to assess risk reduction
of adverse events. The hazard ratio (HR) and its 95%
confidence intervals (CI) were computed for outcome
measures. A P value of <0.05 was considered statisti-
cally significant.
RESULTS
Patient Characteristics
Table I shows baseline characteristics of the study
population. No significant differences were observed be-
tween both groups apart from a higher prevalence of
smoking and family history of coronary artery disease in
the PES group. A large number of patients with previous
history of MI (38.1%), multi-vessel disease (MVD)
(71.1%), and acute coronary syndromes (ACS) (42.6%)
were enrolled. The number of implanted stents and total
stent length per patient were similar in both groups.
Baseline Angiographic and Procedural
Characteristics
Baseline angiographic and procedural data are dis-
played in Table II. There were 127 lesions in the
SES group and 97 lesions in the PES group. A larger
stent, in addition to 2.25-mm stent, was deployed in
76.6 and 85.6% of SES and PES patients (P ¼ 0.11).
The reasons for stenting with a 2.25-mm device were
reported in detail in a previous paper [19]. A high
TABLE I. Baseline Characteristics
SES (n ¼ 107) PES (n ¼ 90) P value
Age (years 6 SD) 61.3 6 11.1 62.9 6 12.4 0.34
Male, n (%) 75 (70.1) 59 (65.6) 0.54
Diabetes mellitus, n (%) 20 (18.7) 20 (22.2) 0.6
Type I, n (%) 6 (5.6) 6 (6.7) 0.77
Type II, n (%) 14 (13.1) 14 (15.6) 0.68
Hypertension, n (%) 47 (43.9) 44 (48.9) 0.57
Hypercholesterolemia, n (%) 72 (67.3) 55 (61.1) 0.38
Family history, n (%) 35 (32.7) 48 (53.3) 0.004
Current smoking, n (%) 20 (18.7) 28 (31.3) 0.047
Previous myocardial infarction, n (%) 35 (32.7) 40 (44.4) 0.11
Previous angioplasty, n (%) 28 (26.2) 25 (27.8) 0.87
Previous coronary bypass surgery, n (%) 9 (8.4) 6 (6.7) 0.79
Vessel disease 0.91a
1-vessel disease, n (%) 33 (30.8) 24 (26.7)
2-vessel disease, n (%) 42 (39.3) 44 (48.9)
3-vessel disease, n (%) 32 (29.9) 22 (24.4)
Multivessel disease, n (%) 74 (69.2) 66 (73.3) 0.53
Clinical presentation 0.86a
Stable angina, n (%) 61 (57.0) 52 (57.8)
Unstable angina, n (%) 33 (30.8) 28 (31.1)
Acute myocardial infarction, n (%) 13 (12.1) 10 (11.1)
Acute coronary syndrome, n (%) 46 (43.0) 38 (42.2) 1.00
Left ventricular ejection fraction (%) 50.4 6 9.70 51.2 6 9.50 0.61
Number of implanted stents/patients 6 SD 1.40 6 0.69 1.31 6 0.57 0.32
Total stent length/patient (mm 6 SD) 23.4 6 14.5 21.6 6 11.1 0.35
Number of lesions/patient 6 SD 1.50 6 0.71 1.63 6 0.77 0.19
Glycoprotein IIb/IIIa use, n (%) 33 (30.8) 30 (33.3) 0.76
aAcross all groups.
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prevalence of bifurcation lesions was observed in the
entire cohort (25.0%). The prevalence of target
lesions located at an ostium was significantly higher
in the SES group than in the PES group (28.3% vs.
15.5%, P ¼ 0.025). The mean maximal pressure at
stent deployment was significantly higher in the SES
group (16.0 6 3.3 atm vs. 14.9 6 3.0 atm in the
PES group, P ¼ 0.046). The number of implanted
stents and total stent length per lesion were compara-
ble between the two groups. By QCA analysis, the
minimal lesion diameter both pre- and post-PCI was
smaller in the SES group (0.47 6 0.38 mm and
1.73 6 0.31 mm vs. 0.57 6 0.38 mm and 1.82 6 0.36
mm in the PES group; P ¼ 0.06 and 0.06, respectively),
whereas lesion length was significantly longer in the
PES group than in the SES group (16.4 6 10.4 mm vs.
13.0 6 8.5 mm; P ¼ 0.02).
Clinical Outcome
Two-year follow-up data were obtained for 105
patients (98.1%) in the SES group and 89 patients
(98.9%) in the PES group. MACE was analyzed at 1
month (30 days), 1 year (365 days), and 2 years (730
days) (Table III).
One-Month (30 Days) and One-Year (365 Days)
Follow-Up
The 1-month and 1-year clinical outcomes have been
previously reported [19]. Briefly, three patients died in
the first month (2 PES and 1 SES); all these patients pre-
sented with MVD and ACS on their admission and died
of cardiac cause. There were two episodes of angio-
graphically documented subacute thrombosis in the PES
group (2.2%) and none in the SES group (P ¼ 0.21).
These two patients who presented with stent thrombosis
were alive at 2-year follow-up.
At 1 year, one patient (0.9%) died in the SES group,
and four patients (4.3%) died in the PES group (P ¼
0.18): their causes of death were cardiac. The inci-
dence of TLR, TVR, and TVR-MACE was more fre-
quent in the PES group, but it did not reach statistical
significance (11.1, 12.2, and 18.9% vs. 6.5, 7.5, and
9.3% in the SES group; P ¼ 0.31, 0.33, and 0.06,
respectively). TLR-MACE rate was significantly lower
TABLE II. Angiographic and Procedural Characteristics
SES (n ¼ 127) PES (n ¼ 97) P value
Treated vessel
Right coronary artery, n (%) 20 (15.7) 9 (9.3) 0.17
Left anterior descending, n (%) 29 (22.8) 25 (25.8) 0.64
Diagonal, n (%) 31 (24.4) 18 (18.6) 0.33
Left circumflex, n (%) 35 (27.6) 25 (25.8) 0.88
Obtuse or intermediate marginal, n (%) 12 (9.4) 18 (18.6) 0.07
Bypass graft, n (%) 0 (0) 2 (2.1) 0.19
ACC/AHA modified lesion classification
Type A or B1, n (%) 58 (45.7) 38 (39.2) 0.34
Type B2 or C, n (%) 69 (54.3) 59 (60.8) 0.34
Calcification (moderate/severe), n (%) 15 (11.8) 7 (7.2) 0.37
Thrombus, n (%) 10 (7.9) 8 (8.2) 1.00
Ostial, n (%) 36 (28.3) 15 (15.5) 0.025
Bifurcation, n (%) 32 (25.2) 24 (25.3) 1.00
Total occlusion, n (%) 33 (26.0) 22 (22.7) 0.64
TIMI grade 3 flow post procedure, n (%) 122 (96.0) 95 (97.9) 0.70
Number of stent/lesion 6 SD 1.17 6 0.42 1.21 6 0.48 0.58
Total stent length/lesion (mm 6 SD) 19.8 6 10.9 19.8 6 9.5 0.99
Direct stenting, n (% 6 SD) 65 (51.2) 58 (60.4) 0.22
Postdilatation, n (% 6 SD) 30 (23.6) 18 (18.6) 0.41
Max. pressure (atm 6 SD) 16.0 6 3.3 14.9 6 3.0 0.046
Quantitative coronary angiography analysis
Pre
Reference diameter (mm 6 SD) 1.86 6 0.37 1.95 6 0.38 0.15
Minimal lesion diameter (mm 6 SD) 0.47 6 0.38 0.57 + 0.38 0.06
Diameter stenosis (% 6 SD) 74.8 6 20.1 70.3 6 19.3 0.10
Lesion length (mm 6 SD) 13.0 6 8.5 16.4 6 10.4 0.02
Post
Minimal lesion diameter (mm 6 SD) 1.73 6 0.31 1.82 6 0.36 0.06
Diameter stenosis (% 6 SD) 12.3 6 10.0 14.0 6 9.80 0.19
ACC, American College of Cardiology; AHD, American Heart Association; TIMI, Thrombolysis In
Myocardial Infarction.
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in the SES group (8.4% vs. 18.9% in the PES group;
P ¼ 0.04). Angiographic late stent thrombosis, which
was defined as occurring 30 days after stent implanta-
tion, was not seen during the first year.
Two-Year (730 Days) Follow-Up
At 2 years, there were two deaths (1.9%) in the SES
group and seven deaths (7.6%) in the PES group (P ¼
0.08). The combined endpoint of death and MI was sig-
nificantly different between the two groups (4.7% in the
SES group and 13.3% in the PES group; P ¼ 0.04). An
event-free survival rate of this composite endpoint is
shown in Fig. 1 (log rank P ¼ 0.031, by Kaplan–Meier
estimate). The prevalence of TLR and TVR was lower
in the SES group compared to the PES group, but did
not achieve statistical significance (P ¼ 0.22 and 0.24,
respectively). The 2-year incidence of TVR-MACE was
significantly higher in the PES group (23.3% vs. 10.3%
in the SES group; P ¼ 0.02), with a MACE-free sur-
vival rate of 76.6 and 89.7% in patients treated with
PES and SES, respectively (log rank P ¼ 0.012, by
Kaplan–Meier estimate) (Fig. 2).
Events From One (365 Days) to Two Years
(730 Days)
Between 1 and 2 years, five events occurred. There
was one death in the SES group and three deaths in
the PES group (P ¼ 0.33); noncardiac death was
observed in one patient in the SES group, the causes
of death in the PES group were one cardiac and two
unknown. No patient in either group experienced MI
or late angiographic stent thrombosis during this period.
Including TLR, there was only one additional TVR
in the PES group and none in the SES group (P ¼
0.46).
Multivariate Predictors of Outcomes
Cox regression analysis was performed to identify
independent predictors of MACE and the composite
endpoint of death and MI at 2 years (Table IV). PES
utilization (HR 2.37, 95% CI 1.07–5.26; P ¼ 0.03),
the presentation with ACS (HR 3.34, 95% CI 1.44–
7.70; P ¼ 0.005) and MVD (HR 3.91, 95% CI 1.27–
12.0; P ¼ 0.017) were found to be significant inde-
pendent predictors of the 2-year MACE rate. Signifi-
cant predictors of the 2-year composite endpoint of
death or MI included PES utilization (HR 4.48, 95%
CI 1.19–16.79; P ¼ 0.03), the presentation with ACS
(HR 4.46, 95% CI 1.14–17.46; P ¼ 0.03) and diabetes
mellitus (HR 5.54, 95% CI 1.65–18.62; P ¼ 0.006).
Hypercholesterolemia was found to be a protective fac-
tor for the 2-year composite endpoint of death or MI
(HR 0.16, 95% CI 0.04–0.59; P ¼ 0.006).
DISCUSSION
The main findings of this study were (1) SES im-
plantation significantly reduced the incidence of MACE
at 2 years as compared to PES implantation, (2) the use
of PES and the presence of ACS and MVD were inde-
pendent factors of 2-year MACE, and (3) the efficacy of
the SES was maintained up to 2 years in a very challeng-
ing real world population.
Study Population
It is noteworthy that the overall population included
in this study had a markedly increased risk of adverse
outcomes. We included clinical and procedural subsets
commonly excluded from most studies such as patients
with acute MI, totally occluded vessels, left ventricular
TABLE III. Major Adverse Cardiac Events
Events
SES
(n ¼ 107)
PES
(n ¼ 92) P valuea
30 days Death, n (%) 1 (0.9) 2 (2.2) 0.59
MI, n (%) 3 (2.8) 6 (6.7) 0.31
TLR, n (%) 3 (2.8) 5 (5.6) 0.47
TVR, n (%) 3 (2.8) 5 (5.6) 0.47
Death or MI, n (%) 4 (3.7) 7 (7.8) 0.35
TLR MACE, n (%) 5 (4.7) 11 (12.2) 0.07
TVR MACE, n (%) 5 (4.7) 11 (12.2) 0.07
Stent thrombosisb 0 (0) 2 (2.2) 0.21
365 days Death, n (%) 1 (0.9) 4 (4.3) 0.18
MI, n (%) 3 (2.8) 7 (7.8) 0.19
TLR, n (%) 7 (6.5) 10 (11.1) 0.31
TVR, n (%) 8 (7.5) 11 (12.2) 0.33
Death or MI, n (%) 4 (3.7) 9 (10.0) 0.09
TLR MACE, n (%) 9 (8.4) 17 (18.9) 0.04
TVR MACE, n (%) 10 (9.3) 17 (18.9) 0.06
Stent thrombosisb 0 (0) 2 (2.2) 0.21
730 days Death, n (%) 2 (1.9) 7 (7.6) 0.08
MI, n (%) 3 (2.8) 7 (7.6) 0.19
TLR, n (%) 7 (6.5) 11 (12.2) 0.22
TVR, n (%) 8 (7.5) 12 (13.3) 0.24
Death or MI, n (%) 5 (4.7) 12 (13.3) 0.04
TLR MACE, n (%) 10 (9.3) 21 (23.3) 0.01
TVR MACE, n (%) 11 (10.3) 21 (23.3) 0.02
Stent thrombosisb 0 (0) 2 (2.2) 0.21
366–730 days Death, n (%) 1 (0.9) 3 (3.3) 0.33
MI, n (%) 0 (0) 0 (0)
TLR, n (%) 0 (0) 1 (1.1) 0.46
TVR, n (%) 0 (0) 1 (1.1) 0.46
Death or MI, n (%) 1 (0.9) 3 (3.3) 0.33
TLR MACE, n (%) 1 (0.9) 4 (4.3) 0.18
TVR MACE, n (%) 1 (0.9) 4 (4.3) 0.18
Stent thrombosisb 0 (0) 0 (0)
MI, myocardial infarction; TLR, target lesion revascularization; TVR,
target vessel revascularization; MACE, major adverse cardiac events.
aBy Fisher’s exact test or the v2-test.
bAngiographically documented stent thrombosis.
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dysfunction, and thrombotic and calcified lesions.
Indeed, there was a marked high prevalence of patients
with MVD (71.1%), ACS (42.6%), and chronic total
occlusion (24.4%) in the present study. In addition,
mean RD of the target vessels was particularly small
(1.90 6 3.8 mm).
Fig. 1. Survival free of the composite of death or myocardial infarction of patients treated
with sirolimus-eluting stents (SES) versus paclitaxel-eluting stents (PES) by Kaplan–Meier
estimate up to 2 years.
Fig. 2. Survival free of major adverse cardiac events (MACE) of patients treated with siroli-
mus-eluting stents (SES) versus paclitaxel-eluting stents (PES) by Kaplan–Meier estimate up
to 2 years.
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Clinical Results
Small vessel size is known to be an independent
predictive factor of restenosis after PCI [33]. It
remains controversial whether BMS placement in small
vessels less than 3 mm in diameter is actually superior
to balloon angioplasty. The latest meta-analysis on
small vessel stenting reported that rates of restenosis
and MACE in patients treated with BMS were 27.8
and 17.6%, respectively [34]. This high restenosis rate
is due to the fact that absolute late lumen loss after
stenting in small vessels is similar to that in large ves-
sels so that even a small volume of neointimal hyper-
plasia induce a diameter stenosis more than 50% in
small vessels more easily than in large vessels [28].
The high incidence of angiographic restenosis could
lead to high MACE rates in this clinical setting.
The advent of DES, which markedly inhibited neo-
intimal hyperplasia and reduced restenosis, created the
expectation of reducing restenosis substantially in
patients with small vessels. Indeed, several randomized
studies have demonstrated that both DES resulted in
remarkably low angiographic restenosis rates (0–6%)
and revascularization rates (3–4%) as compared to
BMS for the treatment of vessels with a RD of less
than 3 mm [8–11]. But in some trials, which focused
on DES implantation in small vessels (mean RD less
that 2.5 mm), the incidence of cardiac events was rela-
tively high and differed between SES and PES utiliza-
tion (Table V). The SES-SMART trial [35], which
enrolled patients with small vessels (mean RD
was 2.2 mm), showed that the incidence of TLR and
MACE in the SES arm was 7.0 and 9.3%, respec-
tively. The subanalysis of TAXUS V trial [36], in
which patients treated with 2.25-mm diameter PES
were included and mean RD was 2.08 mm, indicated
that the TLR and MACE rates were 10.4 and 18.9%,
respectively. The most important conclusion of the
subanalysis of TAXUS V was that there was no signif-
icant difference between the MACE rates in the PES
and BMS arms despite considerably lower rates of
angiographic restenosis and TLR in the PES arm when
compared with the BMS arm. The ISAR-SMART 3
study [20] was a head-to-head comparative trial (SES
vs. PES) for patients with small vessel disease (mean
RD was about 2.4 mm), and reported that SES was
more effective in reducing restenosis and TLR when
compared with PES (8.0 and 6.6% in the SES group
vs. 14.9 and 14.7% in the PES group; P ¼ 0.04 and
0.008, respectively). Interestingly, our clinical results
TABLE IV. Independent Predictors of MACE and the Composite Endpoint of Death or MI at 2-Year Follow-Up
MACE at 2 years Death or MI at 2 years
HR P value HR P value
PES utilization 2.37 (1.07–5.26)a 0.03 4.48 (1.19–16.79) 0.03
Acute coronary syndrome 3.34 (1.44–7.70) 0.005 4.46 (1.14–17.46) 0.03
Multivessel disease 3.91 (1.27–12.0) 0.02 2.32 (0.46–11.74) 0.31
Diabetes mellitus 1.56 (0.66–3.68) 0.31 5.54 (1.65–18.62) 0.006
Hypercholesterolemia 0.55 (0.25–1.19) 0.13 0.16 (0.04–0.590) 0.006
MACE, major adverse cardiac events; MI, myocardial infarction; PES, paclitaxel-eluting stents; HR, hazard ratio; CI, confidence intervals.
aValues in parentheses are 95% CI.
TABLE V. Published Papers on Drug-Eluting Stent Implantation in Patients With Very Small Vessels
Study
SES-SMART [35]
TAXUS V
subanalysis [36] ISAR-SMART 3 [20] The present study
Trial design Randomized trial Randomized trial Randomized trial Nonrandomized
Clinical follow-up (month) 8 9 12 24
Angiographic follow-up 8 9 6–8 NA
Stent SES BMS P value PES BMS P value SES PES P value SES PES P value
No. of patients, n 129 128 108 95 198 204 107 92
Reference diameter (mm) 2.22 2.17 0.15 2.07 2.10 0.46 2.44 2.40 0.34 1.86 1.95 0.15
Lesion length (mm) 13.0 10.7 <0.01 16.6 16.4 0.91 12.9 11.7 0.12 13.0 16.4 0.02
In-stent restenosis (%) 4.9 49.1 <0.01 24.7 44.7 <0.01 8.0 14.9 0.04 NA NA NA
TLR (%) 7.0 21.1 <0.01 10.4 21.5 0.03 6.6 14.7 0.008 6.5 12.2 0.22
MACE (%) 9.3 31.3 <0.01 18.9 26.9 0.23 NA NA NA 10.3 23.3 0.02
Stent thrombosis (%) 0.8 3.1 0.21 1.0 1.1 >0.99 NA NA NA 0.0 2.2 0.21
TLR, target lesion revascularization; MACE, major adverse cardiac events; SES, sirolimus-eluting stents; PES, paclitaxel-eluting stents; BMS, bare
metal stents; NA, not available.
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in the two arms at 1 year were comparable to these
three trials, though the mean RD of the entire cohort
was smaller (mean RD 1.90 mm) and the present pop-
ulations were at higher risk of clinical events as men-
tioned above. In addition, our results, like those in the
ISAR-SMART 3 trial, also indicated that the SES
tended to have a lower 1-year TLR rate as compared
to the PES (6.5% vs. 11.1%; P ¼ 0.31). Moreover, by
multivariate analysis, the use of SES rather than PES
was found to be an independent protective factor for
the prevention of MACE at 2 years in the present
study.
Considering these results, it can be said that the
SES is likely to be more effective than the PES in this
clinical setting. This propensity was verified by the
results of recent large head-to-head, randomized con-
trolled trials [13–15,17,18], which indicated that SES
was significantly better at reducing neointimal hyper-
plasia and had a slight advantage in clinical outcomes
when compared with PES. Different drug-release
kinetics and mechanisms of inhibiting neointimal hy-
perplasia between SES and PES presumably accounts
for the observed difference in their performance. How-
ever, it is difficult to directly compare previous trials
with the present study because the inclusion criteria
and endpoints of each study were different. In addi-
tion, the number of enrolled patients in each study was
too small and underpowered to definitely assess the
effect of DES on the rate of TVR or MACE in this
patient population. Moreover, it is worth emphasizing
that to date the ISAR-SMART 3 trial is the only
randomized controlled prospective study comparing the
efficacy of SES with that of PES in patients with small
vessels. Further investigations are needed to identify
which DES is more effective than the other in this par-
ticular clinical setting.
Safety Concerns of DES Implantation
in Small Vessels
After DES were approved, these devices were im-
planted in a large number of patients with coronary ar-
tery disease and many trials indicated the use of them
to be feasible and safe. Recently, however, certain
potential issues with their use have been raised. One
of the problems was delayed restenosis, which was
usually called a \late catch-up phenomenon" and
noticed as a complication following brachytherapy.
This concern has been fueled by findings in the por-
cine model [37,38]. In humans, continued hyperplastic
growth of neointima during the follow-up period was
noted in some trials in which serial intravascular ultra-
sound analyses were performed [39–41]. The precise
reason for this observation is still unclear. Delayed
neointimal hyperplasia could cause a high incidence of
TLR and MACE with long-term follow-up. The pres-
ent study showed only one patient treated with PES
presented with TLR in the second year of follow-up.
This result might suggest an absence of the late catch-
up phenomenon within these small vessels. All we can
mention with certainty in the present study is that the
efficacy of DES, especially SES, was maintained up to
2 years.
Late stent thrombosis is another topical issue follow-
ing DES deployment. Our result demonstrated that in
the entire cohort the overall angiographic stent throm-
bosis rate was 1.0% and no late stent thromboses were
seen. This incidence rate seems acceptable. However,
it should be mentioned that not all patients suffering
from stent thrombosis underwent coronary angiogra-
phy. Indeed, as indicated in the results section, three
patients in our study who died suddenly during the
first month after stent implantation were suspected of
having subacute stent thrombosis but they could not be
confirmed as having stent thrombosis in the absence of
coronary angiography. To assess this rare and unex-
pected late complication precisely, a much larger sam-
ple size and long-term follow-up are needed. Neverthe-
less, this study provides some reassurance about this
safety concern for both DES in the small vessel sub-
sets.
Independent Factors of Late Cardiac Events
Besides the use of PES, the presence of ACS and
MVD were also independent predictive factors of 2-
year TVR-MACE. These factors are well known to be
predictors of restenosis and late cardiac adverse events.
The patients receiving small vessel stenting, who pre-
sented with ACS and MVD on admission, should be
attended and followed-up carefully. ACS as well as di-
abetes mellitus, in addition to the use of PES, were
also significant predictive factors for the composite
endpoint of death or MI. To prevent the onset of ACS,
detecting vulnerable patients early is very important. It
is imperative that intensive glucose control physically
and pharmaceutically is implemented to reduce late
cardiac events. Curiously, in our multivariate analysis,
the presence of hypercholesterolemia was a protective
factor for the composite endpoint of death or MI. This
result is not easy to explain.
Study Limitation
This study presents several limitations related to its
small sample size, nonrandomized nature, and lack of
a true control group. The fact that a large percentage
of the population enrolled in the present study were
simultaneously treated with larger stent size DES
(more than 2.25 mm) might have influenced the accu-
racy of our result. Another potential limitation is that
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each group was treated in different time periods. This
might lead to some bias in terms of patient selection
and affect procedural characteristics, as treatment strat-
egy has evolved over time. However, it should be
noted that this study enrolled consecutive patients
treated in daily practice: we enrolled all comers and
had no exclusion criteria. To definitively address the
efficacy and safety of each DES in patients with small
coronary arteries, larger head-to-head randomized trials
are needed.
CONCLUSIONS
In an unselected population treated for small vessel
disease, SES was associated with significantly better 2-
years clinical outcomes, especially MACE, when com-
pared with PES. The use of PES and the presence of
MVD and ACS were independent predictors of 2-year
MACE. The efficacy and safety of SES utilization was
maintained up to 2 years.
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Abstract: Small vessel size (3 mm) has been identifi ed as an independent predictive factor 
of restenosis after percutaneous coronary intervention when using bare metal stents (BMS). It 
remains controversial whether BMS placement in small vessels has an advantage over balloon 
angioplasty in terms of angiographic and clinical outcomes. The advent of drug eluting stents 
(DES), either paclitaxel-eluting stents (PES) or sirolimus-eluting stents (SES), has strongly 
impacted interventional cardiology by signifi cantly reducing restenosis and the need for repeat 
revascularization. Therefore, it was also expected that DES could substantially reduce restenosis 
in smaller vessels. However, even in the DES era, small vessel size remains an independent 
predictor of angiographic and clinical restenosis. To date, only a few studies systematically 
investigate the clinical effect of DES placement in small vessels. In addition, some potential 
issues with the use of DES have been raised, such as late stent thrombosis and late restenosis. 
In order to (i) establish the superiority of DES over BMS; (ii) verify the effi cacy and safety 
of DES; and (iii) critically assess the superiority of one DES over the other in patients with 
small coronary arteries, further multicenter, randomized clinical trials with larger sample size 
are warranted.
Keywords: paclitaxel, stent, coronary artery disease, restenosis
Introduction
Percutaneous coronary intervention (PCI) is a major treatment strategy for patients 
with coronary artery disease (CAD), and currently coronary stents are widely 
used in the world (Brophy et al 2003). As compared to balloon angioplasty, bare 
metal stents (BMS) prevent both early elastic recoil and late vascular remodeling. 
These abilities of BMS reduce coronary restenosis and significantly improve the 
angiographic and clinical outcomes in vessels with a reference vessel diameter 
(RVD) typically more than 3 mm as assessed by quantitative coronary angiogra-
phy (QCA) (Serruys et al 1994; Fischman et al 1994; Macaya et al 1996; Betriu 
1999; Kiemeneij 2001). On the contrary, in terms of stent implantation in vessels 
with a RVD = 3 mm, several randomized trials have failed to show an advantage 
of BMS over balloon angioplasty (Kastrati et al 2000; Park et al 2000; Koning 
et al 2001; Moer et al 2001). A recent meta-analysis of small vessel BMS stent-
ing reported that rates of restenosis, repeat revascularization and major adverse 
cardiovascular events (MACE; defined as death, myocardial infarction (MI), and 
repeat revascularization) were 27.8 %, 14.9% and 17.6%, respectively (Agostini 
et al 2005). The high observed restenosis rate (27.8%) may be attributed to a 
comparable absolute late lumen loss after stenting in both small and large ves-
sels: a similar small volume of neointimal hyperplasia would induce a diameter 
stenosis = 50% in small vessels more easily compared to large vessels by virtue 
of their smaller RVD (Akiyama et al 1998). The higher angiographic restenosis 
rate may translate into high repeat revascularization and MACE rates in the 
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clinical setting. In addition, small vessel size is known 
to be an independent predictive factor of restenosis after 
PCI (Bauters et al 1998; Serruys et al 1999). Therefore, 
it remains controversial whether BMS implantation in 
small vessels improves outcomes compared to balloon 
angioplasty alone. At present, however, PCI in small 
vessels with a RVD 3 mm accounts for almost 50% 
of all revascularization procedures and leads to a higher 
incidence of restenosis and adverse cardiac events (Wong 
et al 2000).
In the last 3 to 4 years, drug-eluting stents (DES), either 
sirolimus-eluting stents (SES: Cypher®; Cordis Corpora-
tion, Warren, NJ) or paclitaxel-eluting stents (PES: TAX-
US™; Boston Scientific Corporation, Natick, MA), have 
revolutionized the interventional cardiology practice by 
dramatically reducing restenosis and the need for repeated 
revascularization as compared to BMS (Moses et al 
2003; Schofer et al 2003; Schampaert et al 2004; Stone 
et al 2004a). The superiority of DES over BMS has been 
observed not only in simple lesions but also in complex 
lesions, such as chronic total occlusions, diffused long 
lesions, saphenous vein graft lesions, restenotic lesions, 
and acute coronary syndromes. Consequently, the advent 
of DES creates the expectation of reducing restenosis 
substantially in patients with small vessels.
Many clinical trials indicated DES implantation to be 
feasible and safe. However, certain potential safety issues 
of DES usage have arisen with its widespread used. Some 
recent studies have cautioned that either SES or PES could 
increase thrombotic complications compared to BMS, 
especially late stent thrombosis (occurring 30 days after 
stent placement) (McFadden et al 2004; Iakovou et al 
2005; Ong et al 2005; Moreno et al 2005). As another 
problem, delayed restenosis (occurring beyond the first 
6 to 9 months after stent placement), usually referred to 
as the “late catch-up phenomenon”, has been discussed 
emphasizing the need for long-term follow-up data. This 
complication was especially noted after brachytherapy, a 
procedure whose use has been discontinued. Since PCI in 
small vessels constitutes a more complicated treatment 
strategy than simple lesions, which leads to a higher 
incidence of adverse cardiac events after procedure, 
physicians should carefully follow patients treated with 
small vessel DES stenting.
In this review, we describe effi cacy and safety results 
from clinical trials of the TAXUS® stent system placement 
in small vessels and compare the angiographic and clinical 
outcomes of 3 direct comparison (PES vs SES) trials.
Paclitaxel and TAXUS® stent system
Paclitaxel is an anti-tumor agent used to treat several kinds 
of solid tumors, most commonly tumors of the breast and 
ovary. This drug interferes with microtubule organization by 
interrupting mitosis (M phase) and extracellular secretion. 
Microtubular dynamics regulate many of the infl ammatory 
and profi brotic steps of the restenostic cascade. Paclitaxel 
interrupts this cascade at multiple levels and inhibits cell 
proliferation and migration (Axel et al 1997; Hui et al 1998; 
Giannakakou et al 2001).
Use of the TAXUS® stent system in patients with 
CAD has been fully investigated in the TAXUS trials 
(see Table 1). Results from a total of 6 TAXUS trials have 
been reported to date (Grube et al 2003; Colombo et al 
2003; Tanabe et al 2003; Stone et al 2004a; Stone et al 2005, 
Dawkins et al 2005). Follow-up of patients in 4 TAXUS 
trials (TAXUS II, IV, V, and VI) are still ongoing as of 
the date of this review. Several versions of the TAXUS 
stent technology using different platform types (NIRx, 
EXPRESS, EXPRESS2) and drug release kinetics (slow-
release and moderate-release) but similar polymers, stent 
materials and drug concentrations (1.0 μg/mm2 of pacli-
taxel), were used among these 6 trials (see also Table 1).
The TAXUS NIRx stent was a slotted-tube stainless steel 
stent coated with paclitaxel incorporated into a slow-release 
(SR) or a moderate-release (MR) copolymer carrier system 
with biphasic drug release. The initial release is over the fi rst 
48 hours followed by SR over the next 10 days. Release kinet-
ics of the TAXUS NIRx MR stent in vivo has been shown 
to be faster than that of the TAXUS NIRx SR stent, result-
ing in a 3-fold higher in vivo drug release at 10 days. The 
TAXUS EXPRESS stent consists of a balloon-expandable 
EXPRESS stent with TRANSLUTE™ polymer-coating con-
taining paclitaxel. The TAXUS EXPRESS2 stent is composed 
of a balloon-expandable EXPRESS2 stent with a triblock 
copolymer coating with paclitaxel. This coating serves as 
a carrier to provide uniform and controlled biphasic release 
of the drug into the vessel wall. SR and MR formulations of 
the polymer are available in the TAXUS EXPRESS2 stent. 
The MR formulation also results in approximately 3-fold 
higher drug release than the SR polymer. The SR polymer 
formulation of the TAXUS EXPRESS2 stent is commercially 
available now.
PES versus BMS in small vessels
So far, no dedicated, prospective multicenter, randomized 
clinical study comparing the PES to BMS in patients with 
small vessel disease has been conducted. However, the 
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existing PES versus BMS clinical studies have reported 
substudy results in small vessels as a subgroup analysis, thus 
restricting the interpretation of the results (see Table 2). Small 
vessel subgroup analyses from 3 of the 4 larger controlled, 
multicenter TAXUS trials are briefl y described below.
TAXUS IV trial
In the TAXUS IV trial (Stone et al 2004a, 2004b), various 
types of subgroup analyses were performed. With regard to 
vessel size, enrolled patients were divided into the following 
3 groups per RVD; = 2.5 mm, 2.5 mm to 3.0 mm and 
= 3.0 mm. In the smallest RVD group (= 2.5 mm, n = 176), 
the 9-month angiographic restenosis rate in the PES group 
was signifi cantly lower than in the BMS group (PES, 10.2% 
versus BMS, 38.5%; p  0.001). In addition, 12-month target 
lesion revascularization (TLR) rate was signifi cantly lower in 
the PES group (5.6%) as compared to the BMS group (20.6%, 
p  0.0001). Moreover, in multivariate analysis, the RVD 
was not related with 12-month TLR rate in the PES group, 
while it was an independent predictor of 12-month TLR rate 
in the BMS group. No other angiographic parameters and 
clinical outcomes in this subgroup analysis were reported 
in this trial.
TAXUS V trial
In the TAXUS V trial (Stone 2005), subgroups of patients 
with complex lesions, requiring 2.25 mm or 4.0 mm long 
stents and multiple stents (1 stent), were investigated. In 
the patient group treated with the 2.25 mm stent, which con-
sisted of 17.6% of total enrolled population, the mean RVD 
was 2.08 mm. Both treatment groups (PES and BMS) had 
similar acute clinical outcomes. At the 9-month follow-up, 
the restenosis rate as well as repeat revascularization rate was 
signifi cantly lower in the PES group than in the BMS group 
(31.2% and 10.4% [PES] versus 49.4% and 21.5% [BMS]; 
p = 0.01 and 0.03, respectively), although both parameters in 
the PES group were still high. In this underpowered posthoc 
analysis, numerical differences in the 9-month MACE rate 
between both treatment groups did not reach statistical 
signifi cance (18.9% [PES] versus 26.9% [BMS]; p = 0.23). 
Table 1  An overview of the TAXUS trials
 TAXUS I TAXUS II TAXUS III
 (Grube et al 2003) (Colombo et al 2003) (Tanabe et al 2003)
Published year 2003 2003 2003
Trial design Randomized Randomized Single arm
Used device TAXUS NIRx TAXUS NIRx TAXUS NIRx
Release kinetics SR SR and MR SR
Patient number TAXUS 31 TAXUS SR 131, SR control 136 TAXUS 28
 Control 30 TAXUS MR 135, MR control 134 
Lesion morphology Single de novo or restenotic lesion Single de novo lesion in In-stent restenosis in
 in a native coronary artery a native coronary artery a native coronary artery
   with evidence of ischemia
Lesion length = 12 mm = 12 mm = 30 mm
Vessel diameter 3.0 to 3.5 mm 3.0 to 3.5 mm 3.0 to 3.5 mm
Primary endpoint MACE at 30 days Mean % stent volume obstructed  N/A
  by neointimal proliferation 
  measured by IVUS at 6 months 
 TAXUS IV TAXUS V TAXUS VI
 (Stone et al 2004a) (Stone et al 2005) (Dawkins et al 2005)
Published year 2004 2005 2005
Trial design Randomized Randomized Randomized
Used device TAXUS EXPRESS TAXUS EXPRESS2 TAXUS EXPRESS2
Release kinetics SR SR MR
Patient number TAXUS 662  TAXUS 577 TAXUS 219
 Control 652 Control 579 Control 227
Lesion morphology Single de novo lesion in Single de novo lesion in De novo lesion within
 a native coronary artery a native coronary artery a single native coronary artery
Lesion length 10 to 28 mm 10 to 46 mm 18 to 40 mm
Vessel diameter 2.5 to 3.75 mm 2.25 to 4.0 mm 2.5 to 3.75 mm
Primary endpoint Ischemia driven TVR at 9 months Ischemia driven TVR at 9 months TVR at 9 months
IVUS, intravascular ultrasound; MACE, major adverse cardiac events; N/A, not available; MR, moderate release; SR, slow release; TVR, target vessel revascularization.
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Of note, the rate of periprocedural MIs in the PES arm was 
numerically higher than in the BMS arm without any statisti-
cal signifi cance (5.7% versus 2.2%, p = 0.27). Designed as 
a trial assessing outcomes in more complex lesions, most 
of the affected patients were characterized by an overlap of 
multiple complexities such as treatment of longer lesions in 
smaller vessels often with multiple overlapping stents.
TAXUS VI trial
In the TAXUS VI trial (Dawkins 2005), angiographic and 
clinical outcomes were followed up to 9 months. Some 
subgroup analyses were performed per classic risk factors 
for restenosis, including clinical outcomes in patients with 
small vessels (RVD 2.5 mm). In this subgroup, in-stent late 
lumen loss was considerably smaller in the PES group than 
in the BMS group (PES, 0.23 ± 0.45 mm versus BMS, 0.95 ± 
0.52 mm; p  0.0001), explaining the signifi cantly lower 
angiographic restenosis observed in the PES group (7.3% 
[PES] versus 40.4% [BMS]; p  0.0001). The incidence of 
TLR was also signifi cantly lower in the PES group (5.0% 
[PES] versus 29.7% [BMS]; p = 0.0003).
Taking these results into the consideration, PES seems to 
confer clinical benefi t in patients with small vessels compared 
to BMS. As shown in angiographic assessments, PES mark-
edly inhibit in-stent and in-segment (including implanted 
stent and 5 mm distal and proximal to the stent) neointimal 
hyperplasia, contributing to the signifi cantly lower TLR rate 
observed in these patients (see Table 2). To date, however, 
PES implantation in small vessels has not been studied pro-
spectively in a dedicated study. Only subgroup analysis data 
exist and the number of study patients is very small. Future 
multicenter randomized trials with large sample size, which 
focus on patients treated with PES for small vessel CAD, are 
required to better understand whether PES is more effective 
in patients with small vessels than BMS.
SES versus BMS in small vessels
SES is another commercially available DES promising 
improved clinical and angiographic results in patients with 
small vessel disease as compared to BMS. In contrast to 
paclitaxel, only a single stent type coated with one specifi c 
dose formulation for controlled release of sirolimus has been 
Table 2 Clinical and angiographic results in patients with small vessel disease in the TAXUS trials
 TAXUS IV subanalysis  TAXUS V subanalysis  TAXUS VI subanalysis 
 RVD <2.5 mm 2.25 mm stent implantation RVD <2.5 mm
 (Stone et al 2004a, 2004b) (Stone et al 2005) (Dawkins et al 2005)
 PES BMS p value PES BMS p value PES BMS p value
Clinical outcomes         
Acute phase     30 days   
Death    0 0    
MI    5.6% 1.1% 0.12   
TLR    0.9% 1.1% 1.00   
TVR    1.9% 2.1% 1.00   
MACE    5.6% 2.1% 0.29   
Stent thrombosis    0.9% 1.1% 1.00   
Follow up   12 months  9 months   9 months
Death    1.9% 1.1% 1.00   
MI    5.7% 2.2% 0.29   
TLR 5.6% 20.6% <0.0001 10.4% 21.5% 0.03 5.0% 29.7% 0.0003
TVR    16.0% 24.7% 0.16   
MACE    18.9% 26.9% 0.23   
Stent thrombosis    1.0% 1.1% 1.00   
Baseline QCA         
RVD    2.07 ± 0.31 2.10 ± 0.33 0.46   
Lesion length    16.6 ± 9.7 16.4 ± 9.2 0.91   
Follow-up QCA  9 months   9 months   9 months
Late Loss (instent)    0.49 ± 0.61 0.90 ± 0.63 <0.001 0.23 ± 0.45  0.95 ± 0.52 <0.0001
Late Loss (segment)    0.36 ± 0.53 0.61 ± 0.59 0.004   
Restenosis (instent)    24.7% 44.7% 0.007 7.3% 40.4% <0.0001
Restenosis (segment) 10.2% 38.5% <0.001 31.2% 49.4% 0.01   
BMS, bare metal stent; MACE, major adverse cardiac events; MI, myocardial infarction; PES, paclitaxel-eluting stent; QCA, quantitative coronary angiography; RVD, reference 
vessel diameter; TLR, target lesion revascularization; TVR, target vessel revascularization.
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investigated over the last several years: the SES consists of 
the Bx Velocity stent loaded with 1.4 ug/mm2 sirolimus. Siro-
limus is a macrolide with immunosuppressive, antiprolifera-
tive and antifungal properties. Different from the mechanism 
of paclitaxel, sirolimus prevents progression from the G1 
phase (cell growth) to the S phase (DNA replication), result-
ing in inhibition of the growth of vascular smooth muscle 
cells, which is a major process of in-stent restenosis.
The SIRIUS trial showed that SES had a signifi cant lower 
1-year TLR rate than BMS in patients with RVD 2.75 mm 
(6.6% [SES] versus 22.3% [BMS]; p  0.0001) (Holmes 
et al 2004). In an angiographic substudy of the SIRIUS trial 
(Popma et al), patients were categorized into tertiles accord-
ing to RVD and angiographic outcomes between SES and 
BMS were assessed. The smallest tertile had mean RVD of 
2.32 mm in the SES group and 2.31 mm in the BMS group 
(p = 0.683). Angiographic restenosis rate in the SES group 
was signifi cantly lower than in the BMS group (17.6% vs 
42.7%, p  0.001). The SES-SMART trial (Ardisso et al 
2004), which enrolled patients with small vessels (mean RVD 
2.2mm), indicated that the incidence of TLR and MACE in 
the SES arm was 7.0% and 9.3% versus 21.1% and 31.3% 
in the BMS arm (p = 0.002 and p  0.001, respectively). In 
addition, angiographic restenosis rate in the SES arm was 
also signifi cantly lower compared to the BMS arm (9.8% vs 
53.1 %, p  0.001).
These results indicated that SES is no less effective than 
PES in patients with small vessel CAD. However, which 
DES is superior to the other in small vessel stenting still 
remains controversial.
PES versus SES in small vessels
Several recent trials (de Lezo et al 2005; Kastrati et al 2005a; 
Dibra et al 2005; Windecker et al 2005; Goy et al 2005; 
Morice et al 2006) and a meta-analysis (Kastrati et al 2005b) 
have compared PES with SES. While suggesting advantages 
of SES in reducing neointimal hyperplasia, many of the 
comparative trials have been limited by inadequate sample 
size, execution in single center, and use of institutional rather 
than independent core labs and event committees limiting the 
acceptability of these datasets for establishment of formal 
treatment guidelines. Indeed, when these comparative trials 
are scored by Silver score (Silber 2005) (see Table 3), which 
rate the level of evidence provided by the various DES trials 
(range from 0 to 10) and intend to help physicians evaluate 
the strength of evidence, calculated scores are relatively low 
(high scores can be considered strong evidence): CORPAL 
study (de Lezo et al 2005) is 1, ISAR-DESIRE (Kastrati 
et al 2005a) 4, ISAR-DIABETES(Dibra et al 2005) 4, SIR-
TAX (Windecker et al 2005) 6, TAXi (Goy et al 2005) 5 
and REALITY (Morice et al 2006) 4. In addition, there is 
limited information on the relative effi cacy and safety of 
PES compared to SES in patients with small vessel disease. 
Only 3 trials were reported: 1 randomized trial and 2 non-
randomized trials (see Table 4). We describe these 3 trials 
in the section below.
Table 3 Silver score system
Evaluation Parameter Possible points
Clinical Primary Endpoint (TLR, TVR, TVF, MACE) Yes = 3
 No = 0
Double-Blind (including physicians) Yes = 1
 No = 0
Evaluation Interval of Primary Endpoint 6 Months Yes = 1
 No = 0
Multi-Center (at least 3 centers) Yes = 1
 No = 0
Clinical Events Committee/Data Safety Monitoring Board Independent and External from Steering Committee Yes = 1
 No = 0
Primary Endpoint Reached Yes = 1
 No = 0
Power of 80% for Primary Endpoint Achieved Yes = 1
 No = 0
Follow-up Percentage 80% for Angiographic Primary Endpoint or Follow-up Percentage of 95% for Clinical Primary Endpoint Yes = 1
 No = 0
Maximum Silber Score 10
Minimum Silber Score 0
TLR, target lesion revascularization; TVF, target vessel failure; TVR, target vessel revascularization; MACE, major adverse cardiac events. 
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The ISAR-SMART 3 trial was a first head-to-head 
comparative (PES vs SES) randomized trial for patients 
with small vessel disease (mean RVD was about 2.4 mm) 
(Mehilli et al 2006). Angiographic and clinical outcomes 
were followed up to 8 months. SES was more effective in 
reducing restenosis and TLR than PES (11.4 and 6.6% in the 
SES group vs 19.0 and 14.7% in the PES group, p = 0.047 
and 0.008, respectively). These results indicated that PES 
induced a greater late lumen loss and were less effective in 
reducing restenosis in small coronary vessels as compared 
to SES. Consequently, SES was associated with a lower 
incidence of angiographic restenosis as well as a reduced 
need of repeat revascularization.
There were 2 additional non-randomized trials com-
paring the efficacy between PES and SES in patients 
with small vessel disease. One was a study of Park et al 
, which was a retrospective study including 197 patients 
with a mean RVD of nearly 2.45 mm (Park et al 2006) . 
Angiographic restenosis rate at 6 months and TLR rate 
at 9 months were 6.7 and 3.3% in the SES group, while 
27.7 and 14.4% in the PES group (p < 0.01 and < 0.01, 
respectively).
Table 4 Clinical and angiographic results of the studies comparing PES to SES implantation in patients with small vessel disease
        RESEARCH and T-SEARCH
 ISAR-SMART 3  Park et al   subanalysis
 (Mehilli et al 2006)  (Park et al 2006)  (Rodriguez-Granillo et al 2005; 
       Tanimoto et al 2006)
  SES PES p value SES PES p value SES PES p value
Patient number n = 180 n = 180   n = 121 n = 76   n = 107 n = 92  
Trial design Randomized trial  Non-randomized trial  Non-randomized trial
Clinical outcomes            
Acute phase 30 days   In hospital   30 days
Death     0% 0% 1 0.9% 2.2% 0.59
MI 3.9% 3.3% 0.78 12.4% 13.2% 0.54 2.8% 6.7% 0.31
TLR 0% 0.6% 0.32 0% 0% 1 2.8% 5.6% 0.47
TVR         2.8% 5.6% 0.47
MACE     12.4% 13.2% 0.54 4.7% 12.2% 0.07
Stent thrombosis 0% 0% >0.99 0% 0% 1 0% 2.2% 0.21
Follow up 12 months   9 months   12 months
Death 1.7% 2.2% >0.99 0% 0% 1 0.9% 4.3% 0.18
MI 3.9% 3.3% 0.78 12.4% 13.2% 0.54 2.8% 7.8% 0.19
TLR 6.6% 14.7% 0.008 3.3% 14.4% <0.01 6.5% 11.1% 0.31
TVR         7.5% 12.2% 0.33
MACE     15.7% 27.6% <0.01 9.3% 18.9% 0.06
Stent thrombosis         0% 2.2% 0.21
Baseline QCA             
RVD 2.44 ± 0.34 2.40 ± 0.38 0.34 2.47 ± 0.21 2.44 ± 0.25 0.19 1.86 ± 0.37 1.95 ± 0.38 0.15
MLD 0.99 ± 0.40 1.03 ± 0.39 0.33 0.86 ± 0.33 0.81 ± 0.42 0.31 0.47 ± 0.38 0.57 ± 0.38 0.06
DS 59.4 ± 15.3 57.2 ± 14.4 0.15 65.4 ± 13.0 67.5 ± 16.0 0.22 74.8 ± 20.1 70.3 ± 19.3 0.10
Lesion length 12.9 ± 8.0 11.7 ± 6.7 0.12 25.2 ± 14.7 27.1 ± 12.7 0.34 13.0 ± 8.5 16.4 ± 10.4 0.02
Post-PCI QCA             
MLD (instent) 2.44 ± 0.36 2.44 ± 0.37 0.8     1.73 ± 0.31 1.82 ± 0.36 0.06
MLD (segment) 2.04 ± 0.47 2.00 ± 0.47 0.41 2.52 ± 0.33 2.42 ± 0.35 0.45 12.3 ± 10.0 14.0 ± 9.8 0.19
DS (instent) 5.6 ± 7.5 6.3 ± 7.7 0.36        
DS (segment) 16.7 ± 7.7 18.5 ± 7.2 0.05 3.7 ± 7.1 5.8 ± 8.3 0.06    
Follow-up QCA 6 months   6 months    
MLD (instent) 2.21 ± 0.66 1.88 ± 0.67 <0.001        
MLD (segment) 1.91 ± 0.61 1.67 ± 0.63 <0.001 2.32 ± 0.56 1.77 ± 0.77 <0.01    
DS (instent) 17.2 ± 21.5 26.7 ± 21.8 <0.001        
DS (segment) 28.4 ± 19.7 35.0 ± 20.6 <0.002 5.38 ± 22.5 31.7 ± 34.9 <0.01    
Late loss (instent) 0.25 ± 0.55 0.56 ± 0.59 <0.001        
Late loss (segment) 0.13 ± 0.56 0.34 ± 0.57 <0.001 0.29 ± 0.42 0.69 ± 0.62 <0.01    
Restenosis (instent) 8.0% 14.9% 0.04        
Restenosis (segment) 11.4% 19.0% 0.047 6.7% 27.7% <0.01    
DS, diameter stenosis; MACE, major adverse cardiac events; MI, myocardial infarction; MLD, minimal lumen diameter; PES, paclitaxel-eluting stent; QCA, quantitative coro-
nary angiography; RVD, reference vessel diameter; SES, sirolimus-eluting stent; TLR, target lesion revascularization; TVR, target vessel revascularization.
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Another was a substudy of the RESEARCH and 
T-SEARCH registries, which adopted a non-randomized 
design (Rodoriguez-Granillo et al 2005, Tanimoto et al 2006). 
This substudy was the only 1 investigating long-term follow-
up (up to 2 years) of patients treated with PES or SES in small 
coronary vessels. Patients treated with 2.25 mm diameter PES 
or SES were evaluated in terms of clinical outcomes without 
systematic angiographic follow-up and therefore evaluated 
only clinical benefi t. The incidence of 1 year TLR and MACE 
was numerically more frequent in the PES group, but they 
did not reach statistical difference (11.1 and 18.9% vs 6.5 
and 9.3% in the SES group; p = 0.31 and 0.06, respectively). 
TLR at 2 years was observed more frequently in the PES 
group (12.2% vs 6.5% in the SES group, p = 0.22); only 1 
patient in the PES arm underwent repeat revascularization 
in the second year. The 2-year MACE rate was signifi cantly 
higher in the PES group than in the SES group (23.3% vs 
10.3%, p = 0.02).
Considering these results, SES has been implied to offer 
slight advantages over PES in small vessel stenting regarding 
angiographic and sometimes even clinical outcomes. 
Nevertheless, the root cause for such differences between 
PES and SES remains unclear. The mechanical differences 
of both DES may affect angiographic restenosis as a study 
of Briguori et al which showed that strut thickness was an 
independent predictor of angiographic restenosis in small 
coronary arteries (RVD of 2.75 to 2.99 mm); thinner-strutted 
stents were associated with lower incidence of restenosis 
than thicker-strutted stents (Briguori et al 2002). But the strut 
thicknesses of PES and SES are very similar (0.132 mm and 
0.140 mm, respectively) so that such a mechanical property 
does not infl uence the result of angiographic outcomes 
obtained by both DES implantations. Different mechanisms 
of inhibiting neointimal hyperplasia and drug-release kinetics 
between PES and SES presumably accounts for the observed 
difference in their performance.
At the moment, however, it is difficult to conclude 
that SES is superior to PES in small vessel stenting. It is 
underscored that to date only one randomized controlled trial 
(ISAR-SMART 3) was performed to compare differences 
between PES and SES in small vessel stenting. This 
randomized study was open-labeled trial and was conducted 
at only 2 investigative sites, therefore the Silver score is 3 out 
of 10. In addition, this study excluded patients with diabetes 
mellitus, which was a famous independent predictor leading 
to worse angiographic and clinical outcomes. Moreover, the 
number of enrolled patients in each study was too small and 
underpowered to defi nitely assess the effectiveness of both 
DES for small coronary artery lesions regarding with TLR, 
TVR or MACE. The other 2 trials comparing the effi cacy of 
PES and SES in small vessels were non-randomized studies 
so that their strength of evidence were low. Inclusion and 
exclusion criteria of each study varied. It must be noted that 
larger, multicenter (at least 3), randomized, blinded trials, 
with a defi ned clinical endpoint in patients with small vessels 
are required to fi rmly determine a clinical advantage of one 
DES over the other. As of present, limited results from these 
3 trials do not confi rm a signifi cant advantage of SES over 
PES in this patient population.
Safety concern of small vessel DES 
stenting
After DES were approved, these devices have been implanted 
in a large number of patients with CAD including several 
kinds of clinical and anatomic situations such as acute MI, 
bifurcation lesions and overlapping stent deployment. Their 
use seems to be feasible and safe. Recently, however, certain 
potential issues have been raised.
One of the issues is stent thrombosis. Although rare, some 
studies have cautioned that as compared to BMS, either PES 
or SES could increase the incidence of this complication, 
especially that of late stent thrombosis (occurring >30 days 
after stent placement) (McFadden et al 2004; Iakovou et al 
2005; Ong et al 2005; Moreno et al 2005). Increased risk for 
thrombosis may be associated with the decreased endothelial 
function (Hofma et al 2006), and/or delayed vascular heal-
ing (Degertekin et al 2002; Guagliumi et al 2003; Joner et al 
2006) induced with DES. In addition, hypersensitivity reac-
tions to the polymer coating of the DES and the drug itself 
may also contribute to stent thrombosis (Virmani et al 2004; 
Nebeker et al 2006). Although BMS implantation in small 
vessels had been previously cited as a risk factor for stent 
thrombosis (Karrillon et al 1996; Mak et al 1996; Moussa 
1997), improved techniques of optimal stent deployment and 
dual antiplatelet regimens appear to have largely resolved 
this problem so that the risk of stent thrombosis of BMS 
in small vessel stenting now seems to be similar to that in 
larger vessel stenting (Akiyama 1998; Lau et al 2000). But, 
DES implantation in small vessels may increase the risk 
of stent thrombosis because of their features as mentioned 
above. The incidence of stent thrombosis in small vessel 
DES stenting has not been shown to differ between PES and 
BMS or SES. In a subanalysis conducted in the TAXUS V 
clinical trial, both acute and late stent thrombosis rate were 
similar between PES and BMS (0.9% versus 1.1% and 1.0 % 
versus 1.1%, p = 1.00 and 1.00, respectively) (Table 2). In 
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the ISAR-SMART 3 trial and a study of Park et al, no acute 
stent thrombosis was reported in both the SES and PES arms, 
while there was no information about late stent thrombosis in 
either trial (see Table 4). In a subanalysis of the RESEARCH 
and T-SEARCH registries, 2.2% of patients had acute stent 
thromboses in the PES arm; no thrombosis was observed in 
the SES arm (see also Table 4). This observation was not 
signifi cant (p = 0.21). No late stent thrombosis occurred 
in either arm. It should be mentioned that the defi nition of 
stent thrombosis varied (clinical or angiographic) and treated 
lesion type differed among clinical trials. In addition, though 
most trials reported their outcomes within 1 year, late stent 
thrombosis often occurred more than 1 year after DES place-
ment. To better understand this adverse event, a much larger 
sample size and longer-term follow-up are warranted.
Delayed restenosis, which is also called a “late catch-up 
phenomenon”, is another issue after DES deployment. This 
event was fi rst observed in the porcine model (Farb et al 2001; 
Carter et al 2004). Also in humans, continued neointimal 
growth of during the follow-up period was noted in some tri-
als in which serial intravascular ultrasound (IVUS) analyses 
were performed (Aoki et al 2005a; Aoki et al 2005b; Aoki 
et al 2005c). The precise reason for this phenomenon is still 
unclear. Delayed neointimal hyperplasia could lead to higher 
incidence rates of TLR and MACE observed during long-term 
follow-up. This is especially relevant with small vessel DES 
stenting, since even a small volume of neointimal tissue can 
affect the incidence of angiographic restenosis by virtue of 
the smaller RVD. With respect to small vessel stenting, few 
long-term follow-up data exist (Table 5). In a subanalysis of 
the SIRIUS 2-year outcomes (Weisz et al 2006), TLR rate in 
the second year was 1.7% in the SES group and 0.8% in the 
BMS group (p = 0.17). In a substudy of the RESEARCH and 
T-SEARCH registries, only 1 patient (1.1%) treated with PES 
presented with TLR in the second year (0% in the SES arm, p 
= 0.46). In these 2 studies, angiographic parameters were not 
reported, thus the increase of neointima was unknown during 
the second year. However, according to these results, it may 
be inferred that if late catch-up phenomenon occurred after 
small vessel DES stenting, its effect might be restrictive in 
this clinical setting. The effi cacy of DES was ascertained up 
to 2-years even in treatment of small vessel CAD.
Table 5 Long-term clinical follow-up trials in small vessel DES stenting
  SIRIUS subanalysis   RESEARCH and T-SEARCH
 RVD < 2.75 mm   subanalysis
 (Weisz et al 2006)   (Tanimoto et al 2006)
  SES BMS p value SES PES p value
Patient number n = 533 n = 525   n = 107 n = 92  
Trial design Randomized trial   Non-randomized trial
1-year follow up      
death     0.9% 4.3% 0.18
MI     2.8% 7.8% 0.19
TLR 6.6% 22.3% <0.0001 6.5% 11.1% 0.31
TVR     7.5% 12.2% 0.33
MACE     9.3% 18.9% 0.06
Stent thrombosis     0% 2.2% 0.21
2-year follow up      
death     1.9% 7.6% 0.08
MI     2.8% 7.6% 0.19
TLR 8.3% 23.0% <0.0001 6.5% 12.2% 0.22
TVR     7.5% 13.3% 0.24
MACE     10.3% 23.3% 0.02
Stent thrombosis     0% 2.2% 0.21
1-year to 2-year        
death     0.9% 3.3% 0.33
MI     0% 0%  
TLR 1.7% 0.8% 0.17 0% 1.1% 0.46
TVR     0% 1.1% 0.46
MACE     0.9% 4.3% 0.18
Stent thrombosis     0% 0%  
BMS, bare metal stent; MI, myocardial infarction; MACE, major adverse cardiac events; PES, paclitaxel-eluting stent; SES, sirolimus-eluting stent; TLR, target lesion revascular-
ization; TVR, target vessel revascularization.
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At present, small vessel stenting by using either PES or 
SES seems to be safe and does not increase adverse cardiac 
events in short- and medium-term follow-up. However, 
long-term follow-up and larger sample multicenter studies 
are needed to determine whether DES implantation is safe 
in patients with small vessel CAD.
Conclusion
In this manuscript, we reviewed the placement of BMS, 
PES, and SES in small vessels with respect to effi cacy and 
safety. At present, the following general conclusions about 
small vessel stenting can be made: (1) PES considerably 
reduce the incidence of angiographic restenosis and TLR 
as compared to BMS; (2) a trend is observed with regard 
to better angiographic and clinical outcomes of SES over 
PES, but there is little and weak information to support this 
result; and (3) Both PES and SES seem to be safe and don’t 
increase severe cardiac complication, such as acute and late 
stent thrombosis.
Even in the DES era, small RVD is still an independent pre-
dictor of angiographic and clinical restenosis (Kastrati 2006). 
However, there are a very limited number of studies focusing 
on small vessel DES stenting. Therefore, large-sample size, 
double-blinded, randomized-controlled multicenter trials with 
long-term follow-up and a clinical primary endpoint are needed 
to establish the fact that both PES and SES are effective and 
safe in small vessel coronary disease.
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Abstract
Background: Percutaneous treatment of stenoses involving aorto-ostial lesions is technically demanding and has been associated with lower
procedural success and poorer clinical and angiographic outcomes when compared with non-ostial lesions. This study evaluated the
immediate and long-term (2-year) outcome of aorto-ostial stenoses treated with paclitaxel-eluting stents (PES).
Methods: From February 2003 to December 2004, a total of 76 consecutive patients with 76 lesions underwent percutaneous intervention
with PES for aorto-ostial lesions (right coronary artery, 37; left main, 26; saphenous vein graft, 13). All patients were clinically followed for
the occurrence of major adverse cardiac events (MACE), defined as cardiac death, non-fatal myocardial infarction (MI), target lesion
revascularization (TLR) or target vessel revascularization (TVR).
Results: All stents (1.7/lesion) were successfully deployed. Three lesions (3.9%) were pre-treated with debulking devices. Thirty-seven
lesions (48.7%) were post-dilated with non-compliant balloons (balloon/artery ratio, 1.2). Stents were positioned protruding into the aortic
lumen in 29 lesions (38.2%). Cumulative 2-year event-free survival was 68.4%. There was one angiographically-proven stent thrombosis
occurring 427 days after TLR for restenosis after the index procedure. The restenosis rate at 7 months (median) was 20.0% and in-stent late
lumen loss was 0.48 mm in 40 patients with angiographic follow-up.
Conclusions: Utilization of PES in this complex lesion subset is feasible and associated with favorable angiographic results at 7 months.
However, the gradual increase in later events up to 2 years suggests that aorto-ostial disease remains problematic even in the era of drug-
eluting stents.
© 2007 Elsevier Ireland Ltd. All rights reserved.
Keywords: Aorto-ostial lesion; Paclitaxel-eluting stent; Percutaneous coronary intervention; Aorto-ostial lesion; Paclitaxel-eluting stent
1. Introduction
Percutaneous treatment of stenoses involving aorto-ostial
lesion is a technically demanding procedure for interven-
tionalists and has been associated with lower procedural
success, and poorer clinical and angiographic outcomes
when compared with treatment of non-ostial lesion [1,2].
The extremely sclerotic and calcified nature of this lesion site
[3–5] has contributed to suboptimal immediate and long-
term results after balloon angioplasty as a stand-alone
strategy [6]. Debulking strategies with directional coronary
atherectomy (DCA) or rotational atherectomy (rotablator)
were assumed to alter outcomes for this particular lesion
subset, but their efficacies have not been determined. To
counter the ostial elasticity resulting in high restenosis rates
(enhanced recoil), stent implantation is a reasonable strategy
for lesion scaffolding, and bare metal stents have resulted
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in better outcomes than conventional balloon angioplasty
[7–9]. However, in addition to acute and chronic stent recoil,
excessive neointimal growth after stenting in this location
has been documented [10]. Although drug-eluting stents
(DES) have shown even better clinical and angiographic
results than bare metal stents, data on the efficacy of DES for
ostial lesions are still limited, mostly due to the exclusion of
these high risk lesions in the majority of the published
randomized trials [11–14]. Percutaneous treatment with
sirolimus-eluting stent (SES) for aorto-ostial lesions has
already been reported to improve short-term clinical and
angiographic outcomes [15]. Polymer-based paclicaxel-
eluting stent (PES, TAXUS™ Express2™, Boston Scientific
Corp., Natick, MA) is another FDA-approved drug-eluting
stent that has been shown to reduce clinical events in simpler
lesions [13]. To date, few reports are available on the
treatment of ostial stenoses using PES. In addition, little is
known about the long-term results of percutaneous treatment
of aorto-ostial lesions using DES. This study was made to
evaluate both the 7-month angiographic and 2-year clinical
outcomes of the use of PES for aorto-ostial narrowings.
2. Methods
From February 2003 to December 2004, a total of 93
consecutive patients underwent percutaneous intervention
for 93 aorto-ostial lesions in our institution. All the eligible
lesions were primary culprit lesions for each patient and
therefore stenting due to dissection, extended stenting from
non-ostial lesions, or spasm induced by catheter tip were
excluded. Seventeen patients were excluded from this study
because of deployment of SES (Cypher™, Cordis/Johnson
& Johnson, Warren, NJ) in 7, bare metal stents in 5,
angioplasty without stenting in 2, unsuccessful guidewire
crossing in 2 (chronic total occlusions), and PES with a
different type of platform (Infinium™, Sahajanand Medical
Technologies Pvt. Ltd., Gujarat, India) in 1. Thus, the study
population consisted of 76 consecutive patients treated with
TAXUS™ Express2™ stents. The study population is a
constitutive part of Taxus-Stent Evaluated at Rotterdam
Cardiology Hospital (T-SEARCH) registry of which the
design and goals have been described previously [16]. An
aorto-ostial lesions were defined as being located less than
3 mm (as measured by quantitative angiographic analysis) of
the orifice of the right coronary artery, left main coronary
artery, or saphenous venous graft when visualized in an
angiographic projection without foreshortening [6]. The
study protocol was approved by the local ethics committee
and is in accordance with the Declaration of Helsinki.
Written informed consent was obtained from all patients.
2.1. Medications and interventional procedures
Elective patients were all pre-treated with aspirin and
clopidogrel. A loading dose of 300 mg of clopidogrel was
adopted in emergency cases. Post-interventional prescription
of antiplatelet was life-long aspirin and 6-month clopidogrel
with daily dose of 75 mg. PESs were available in diameters
of 2.25, 2.5, 2.75, 3.0 and 3.5 mm. Usage of debulking
devices (DCA or rotablator), distal protection devices and
administration of glycoprotein IIb/IIIa inhibitors was left to
the discretion of each physician. Slight stent protrusion into
the aortic lumen was determined in the least foreshortened
angiographic projection. Angiographic success was defined
as residual diameter stenosis b30% in the presence of
Thrombolysis in Myocardial Infarction (TIMI) flow grade 3.
2.2. Clinical follow-up and definitions
Adverse events were assessed at 30 days, 1 and 2 years.
The primary endpoint was the occurrence of major adverse
cardiac events (MACE), defined as a composite of cardiac
death, non-fatal myocardial infarction (MI), target lesion
revascularization (TLR), and target vessel revascularization
(TVR). All deaths were regarded as those of cardiac origin
unless a noncardiac origin was proven either clinically or by
autopsy. Non-fatal MI was defined as the occurrence of an
elevated creatine kinase-MB fraction (CK-MB) N3 times the
upper limit of normal [16]. TLR was defined as either
surgical or percutaneous reintervention driven by significant
(≥50%) luminal narrowing either within the stent or the
borders 5 mm proximal and distal to the stent that was
undertaken in the presence of either anginal symptoms or
objective evidence of ischemia. TVR was defined as
reintervention in the treated vessel outside the target lesion.
Stent thrombosis was defined as angiographically-documen-
ted complete occlusion (TIMI flow grade 0 or 1) or flow-
limiting thrombus (TIMI flow grade 1 or 2) in a previously
treated artery. Stent thrombosis was categorized according to
its timing relative to the index procedure as early (within
30 days) or late (N30 days) thrombosis.
All patients were clinically followed for the occurrence of
MACE. Information about in-hospital outcomes was
obtained from an electronic clinical database maintained at
our institution and by review of patients' records. Post-
discharge survival status was examined from the Municipal
Civil Registries. Occurrence of MI or revascularization at
follow-up was collected by consulting our institutional
electronic patient database and by contacting referring
physicians and institutions.
2.3. Quantitative angiographic analysis
Quantitative angiographic analysis was performed using
the computer-based validated QCA system (CAAS II, Pie
Medical Imaging, Maastricht, the Netherlands). Quantitative
measurements included the diameter of the reference vessel,
the minimal luminal diameter, percentage (%) diameter
stenosis, and late luminal loss (the difference between the
minimal luminal diameter after the procedure and the
minimal luminal diameter at follow-up). Binary restenosis
was defined as a stenosis of at least 50% of the minimal
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luminal diameter in the target lesion at angiographic follow-
up. In most cases, reference vessel diameter was obtained
only from a point distal to the lesion. Angiographic patterns
of restenosis were also determined [17].
2.4. Statistical analysis
Values in the text and tables are presented as mean±SD,
or frequency (percentage) for descriptive purposes. The
cumulative incidence of adverse events was estimated
according to the Kaplan–Meier analysis. Statistical analyses
were performed with SPSS 12.0.1 for Windows (SPSS Inc.,
Chicago, IL). A p value b0.05 was considered statistically
significant.
3. Results
3.1. Baseline characteristics
Baseline patient, lesion, and procedural characteristics are
shown in Tables 1 and 2. Multivessel disease was observed
in 72.4% of the patients. More than half of the cases
underwent index PCI for an acute coronary syndrome
(unstable angina, 42.1%; acute myocardial infarction,
15.8%). There was no documentation of non-atherosclerotic
etiologies associated with aorto-ostial disease such as
syphilitic cardiovascular disease, Takayasu's arteritis, etc.
[18].
The seventy-six target vessels in the present study
consisted of 37 right coronary arteries, 26 left main coronary
arteries, and 13 venous grafts. These lesions included seven
restenotic lesions following bare metal stent implantation
(9.2%). Moderate to severe calcification was documented in
19 lesions, presence of thrombus in 13, restenosis of bare
metal stent in 7, chronic total occlusion (an occlusion period
more than 3 months) in 1.
3.2. Procedural results
Target lesions were treated using 1.69±0.97 stents (total
stent length per lesion, 32.11±26.58 mm) that were post-
dilated using balloons 3.6±0.44 mm diameter (mean
balloon–artery ratio, 1.24). Lesion modification by debulk-
ing devices or cutting balloon was made in 7 patients. Stent
placement with slight protrusion of the proximal edge into
the ascending aorta was performed in 38.2% of the cases.
Two patients were complicated by aorto-coronary dissection
involving in the sinus of Valsalva, which regressed
conservatively over a short period. Thirty-five patients
(46.1%) underwent concomitant treatment of non-ostial
lesions either in the same or different vessels.
3.3. Clinical outcome up to 2 years
Thirty-day, one-year as well as 2-year outcomes in terms
of clinical events are reported in Table 3.
Table 1
Baseline clinical and angiographic characteristics (n=76)
Age, years 66.0±10.9
Male gender, n (%) 51 (67.1)
Smoking:
current, n (%) 15 (19.7)
Former, n (%) 14 (18.4)
Diabetes:
type I, n (%) 13 (17.1)
Type II, n (%) 4 (5.3)
Hypertension, n (%) 31 (40.8)
Hypercholesterolemia, n (%) 44 (57.9)
Renal insufficiency, n (%) 9 (11.9)
Family history, n (%) 28 (36.8)
Prior myocardial infarction, n (%) 26 (34.2)
Previous intervention, n (%) 18 (23.7)
Previous bypass surgery, n (%) 17 (22.4)
Multivessel disease, n (%) 55 (72.4)
Stable angina pectoris, n (%) 31 (42.1)
Unstable angina pectoris, n (%) 32 (42.1)
Acute myocardial infarction, n (%) 13 (15.8)
Cardiogenic shock, n (%) 4 (5.3)
Table 2
Baseline lesion and procedural characteristics (n=76)
Lesion characteristics
Lesion location
Right coronary artery, n (%) 37 (48.7)
Left main coronary artery, n (%) 26 (34.2)
Venous graft, n (%) 13 (17.1)
In-stent restenosis of bare metal stent, n (%) 7 (9.2)
Chronic total occlusion, n (%) 1 (1.3)
Thrombus-containing lesion, n (%) 13 (17.1)
Moderate to severe calcification, n (%) 19 (25.0)
Eccentric lesion, n (%) 24 (31.6)
TIMI flow grade ≤2:
Baseline, n (%) 18 (23.7)
After procedure, n (%) 3 (3.9)
Procedural characteristics
Number of stents/lesion, n 1.69±0.97
Total stent length/lesion, mm 32.11±26.58
Maximal balloon size, mm 3.64±0.44
Balloon/artery ratio 1.24±0.23
Maximal inflation pressure, atm 20.18±2.65
Debulking, n (%) 3 (3.9)
Cutting balloon, n (%) 4 (5.3)
Direct stenting, n (%) 33 (43.4)
Post-dilatation, n (%) 37 (48.7)
Use of glycoprotein IIb/IIIa inhibitors, n (%) 10 (13.2)
Distal protection device, n (%) 12 (15.8)
Intra-aortic balloon pump, n (%) 4 (5.3)
Left ventricular assist device (LVAD), n (%) a 1 (1.3)
Periprocedural stent thrombosis, n (%) 0 (0.0)
Stent protrusion, n (%) 29 (38.2)
Aorto-coronary dissection after procedure, n (%) 2 (2.6)
Concomitantly treated lesion, n (%) 35 (46.1)
Angiographic success, n (%) 73 (96.1)
a The Impella LVAD Recover LP 2.5 (Impella Cardiotechnik, Aachen,
Germany).
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3.3.1. 30-day outcome
In the first month, 6 patients died, four of whom exhibited
fatal MI resulting in refractory cardiogenic shock as a
baseline clinical presentation, although stents were success-
fully deployed in each of the target lesions (1 right and 3 left
main coronary arteries). One patient with stable angina
underwent elective stenting for ostial left main disease, but
died due to a rapid hemodynamic collapse resulting from
compromised blood flow to the jailed left circumflex artery.
One patient died 21 days after concomitant stenting in 2
target lesions (ostial right coronary artery and left anterior
descending artery). This case was strongly suspected of
having early stent thrombosis either in the territory of the
right coronary artery or left anterior descending artery as the
cause of sudden death, which was not angiographically-
documented.
Out of the 4 MIs, 3 were MIs during the index procedures
and the other was a subacute stent thrombosis in a
concomitantly-treated different vessel (left anterior descend-
ing artery) 21 days after the index procedure. There were no
cases of TLR or TVR in the first 30 days.
3.3.2. 1-year outcome
Neither further death nor MI was documented after
30 days up to 1 year. TVR was required in 8 patients (TLR,
3/8), all of which were treated percutaneously.
3.3.3. 2-year outcome
There was a gradual increase in MACE throughout
2 years (Fig. 1). There were 3 more deaths identified between
1 and 2 years. One patient who died 465 days after stenting
was strongly suspected of having late stent thrombosis in the
territory of the right coronary artery as the cause of sudden
Table 3
Major adverse cardiac events
30-day outcome
Death 6 (7.9)
Non-fatal myocardial infarction 4 (5.3)
Target vessel revascularization 0
Target lesion revascularization 0
MACE 10 (13.2)
Stent thrombosis⁎ 1 (1.3)
1-year outcome
Death 6 (7.9)
Non-fatal myocardial infarction 4 (5.3)
Target vessel revascularization 8 (10.5)
Target lesion revascularization 3 (3.9)
MACE 18 (23.7)
Stent thrombosis⁎ 1 (1.3)
2-year outcome
Death 9 (11.8)
Non-fatal myocardial infarction 6 (7.9)
Target vessel revascularization 11 (14.5)
Target lesion revascularization 3 (3.9)
MACE 24 (31.6)
Stent thrombosis† 3 (3.9)
⁎Subacute stent thrombosis in a concomitantly-treated non-ostial target
vessel (left anterior descending) 21 days after the index PCI; †One is
subacute thrombosis in a non-ostial target vessel (left anterior descending)
2 days after stenting and the other is late thrombosis in the right coronary
ostial lesion 427 days after TLR. MACE = major adverse cardiac events.
Fig. 1. Kaplan–Meier event-free survival at 2 years for major adverse
cardiac events (MACE).
Table 4
Quantitative coronary angiography (n=76)
Baseline
Reference vessel diameter, mm 3.04±0.56
Minimum luminal diameter, mm 0.92±0.51
Diameter stenosis, % 69±16
Lesion length, mm 14.24±15.06
Post procedure
Reference vessel diameter, mm 3.30±0.51
Minimum luminal diameter, mm 2.73±0.52
Diameter stenosis, % 17±9
Follow-up (n=40) at 7 monthsa
Reference vessel diameter, mm 3.26±0.54
Minimum luminal diameter, mm 2.23±0.94
Diameter stenosis, % 34±26
In-stent late lumen loss, mm 0.48±0.88
Restenosis, n (%)b 8 (20%)
Focal — articulation 1
Focal — margin 1
Focal — body 2
Diffuse — intrastent 1
Diffuse — proliferative 1
Diffuse — total occlusion 2
aMedian of follow-up period.
bRestenosis patterns were adopted from the classification by Mehran et al.
(Ref. [17]).
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death, though this was not angiographically confirmed.
Additional 3 clinically-driven TVRs were performed. The 2-
year cumulative incidence of MACE was 31.6%. There were
two additional stent thromboses (early and late) identified.
One occurred 2 days after stenting a non-ostial lesion (left
anterior descending) and the other was a late thrombosis
427 days after the index PCI for the right coronary ostial
lesion.
3.4. Angiographic results
Quantitative coronary angiographic analysis is summa-
rized in Table 4. The mean reference vessel diameter was
3.04 mm. Angiographic follow-up data were obtained in 40
patients (52.6%) at the median timing of 7 months after the
index stenting. Binary in-stent restenosis rate was 20.0% (8/
40). Focal patterns of restenosis were found in 50% (4/8). In-
stent late lumen loss of PES in this lesion subset was
0.48 mm.
4. Discussion
The present study provides the 7-month angiographic and
2 year clinical outcomes of PES in aorto-ostial lesions in a
larger consecutive population than that of earlier studies
[1,9,15,19]. The results of the present study suggest the
following two main findings: 1) PES utilization is a feasible
treatment option in this complex lesion setting by keeping
the restenosis rate to 20.0% and thereby TLR rate to 5.3%; 2)
The long-term efficacy of PES, however, in overall clinical
outcome still remains to be determined due to the subsequent
increase in later events.
Aorto-ostial disease can be a critical cause of fatal
myocardial infarction or sudden cardiac death due to the
relatively large myocardial territory exposed to risk [3].
Lesions in this location are distinctive from branch ostial
lesions because of their specific histopathological character-
istics such as highly increased fibrous cellularity, calcifica-
tion and sclerosis [3–5]. Reflecting this lesion background,
Tsunoda et al. reported that excessive neointimal growth and
chronic stent recoil might be two important etiologic factors
for stent restenosis at this particular location [10]. With
regards to the former factor, stents coated with antiprolifera-
tive agents are reasonable devices of choice and PES
demonstrated successful reduction of neointimal growth
after stenting (late loss, 0.48 mm),. To overcome another
potential factor for restenosis, the combination of debulking
and DES may be a particularly optimal approach. Plaque
modification prior to stent implantation has been initially
embraced as a preferred treatment strategy for this lesion
subset [4]. However, since the role of debulking in the era of
DES has not been clarified, we performed adjunctive
debulking in only 3 patients. Instead of using atherectomy
devices, we aggressively post-dilated by adopting a
relatively large-sized non-compliant balloon (balloon–artery
ratio, 1.24) in order to achieve a satisfactory angiographic
result. Because of the delayed healing response of injured
vessel wall after implantation of DES [20], it might be
speculated that the relatively high mechanical injury
resulting from atherectomy further delayed healing process
following DES placement. Furthermore, atherectomy of
aorto-ostial lesions is technically demanding because of the
need to pull the guiding catheter from the coronary ostium
while leaving the atherectomy catheter in position for
debulking. Additionally, when performing DCA or rotabla-
tion for aorto-ostial lesions, great care should be taken to
avoid excision of guiding catheter material [21,22].
Slight stent protrusion into the aorta is usually associated
with a benign clinical course. However, unapposed protrud-
ing stent struts may theoretically promote platelet activation,
thrombosis, and/or distal embolization. In addition, protrud-
ing stent struts may not only pose an inability to easily re-
engage the ostium with either diagnostic or guiding
catheters, but also can complicate future interventional as
well as surgical procedures [23–26]. We encountered only
one angiographically-documented stent thrombosis related
to the target vessel and stent protrusion was not implicated in
this case. Of the 2 possible stent thrombosis cases, stent
placement with slight protrusion was performed in one
(465 days after stenting) and not in the other (21 days after
stenting). The 2 cases with very late stent thrombosis
occurring beyond 1 year suggest that current US Food and
Drug Administration-approved indications for 6-month
clopidogrel use following TAXUS implantation may not be
sufficient to prevent late stent thrombosis. Eisenstein et al.
showed that longer-term clopidogrel use may be associated
with more favorable clinical outcome for patients receiving
DES [27]. However, the small number of patients evaluated
in this analysis do not allow for any definitive statement with
respect to the safety profile of this stenting technique. So far,
it appears that positioning of PES with protrusion of only a
short segment of stent into the aorta might instead contribute
to lower restenosis by adequately covering the lesion.
Despite the low incidence of TLR at 2 years, the limited
role of PES on overall long-term outcome was also indicated
because of the gradual increase in TVR rate. Obstruction at
the origin of a coronary artery is most often associated with
more generalized coronary atherosclerosis and the presence
of multivessel coronary artery disease (72.4%). It may be
helpful for long-term favorable outcome to prevent and
adequately detect the progression of other non-ostial lesions
that are not significant at time of treatment of ostial lesions in
the same vessel. Long-term evaluation of non-ostial lesions
in the target vessels should be considered.
4.1. Study limitations
There were several limitations in this study. First, this was
a single-center's experience with implantation of PES in
aorto-ostial stenoses. Second, no control group was used to
compare the long-term efficacy of PES with other devices. In
this regard, direct comparison between PES and bare stent/
PES for aorto-ostial lesion
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SES would have been interesting to address whether a
different drug and different stent platform might influence
the incidence of restenosis. Third, the rate of follow-up
angiography was limited to 52.6% of 76 patients. Finally,
since each treatment strategy was not prespecified, the
results may reflect our bias toward our treatment technique.
However, this study more likely represents “real-life” prac-
tice of PES utilization.
5. Conclusions
In conclusion, our findings suggest that PES in aorto-
ostial lesions is safe and feasible in light of the low incidence
of restenosis at 7 months. However, the increase in later
events, especially the TVR rate, may attrite the long-term
benefit of PES in patients with this complex lesion subset.
References
[1] Huang HL, Hsieh IC, Chang SH, Chang HJ, Chen CC, Hung KC, et al.
Acute and long-term outcomes of intracoronary stenting in aorto-ostial,
left anterior descending artery-ostial and nonostial stenoses. Int
J Cardiol 2005;101:391–7.
[2] Mavromatis K, Ghazzal Z, Veledar E, Diamandopoulos L, Weintraub
WS, Douglas JS, et al. Comparison of outcomes of percutaneous
coronary intervention of ostial versus nonostial narrowing of the major
epicardial coronary arteries. Am J Cardiol 2004;94:583–7.
[3] Rissanen V. Occurrence of coronary ostial stenosis in a necropsy series
of myocardial infarction, sudden death, and violent death. Br Heart J
1975;37:182–91.
[4] Popma JJ, Dick RJ, Haudenschild CC, Topol EJ, Ellis SG.
Atherectomy of right coronary ostial stenoses: initial and long-term
results, technical features and histologic findings. Am J Cardiol
1991;67:431–3.
[5] Stewart JT, Ward DE, Davies MJ, Pepper JR. Isolated coronary ostial
stenosis: observations on the pathology. Eur Heart J 1987;8:917–20.
[6] Topol EJ, Ellis SG, Fishman J, Leimgruber P, Myler RK, Stertzer SH,
et al. Multicenter study of percutaneous transluminal angioplasty for right
coronary artery ostial stenosis. J Am Coll Cardiol 1987;9:1214–8.
[7] Rocha-Singh K,Morris N,Wong SC, Schatz RA, Teirstein PS. Coronary
stenting for treatment of ostial stenoses of native coronary arteries or
aortocoronary saphenous venous grafts. Am J Cardiol 1995;75:26–9.
[8] Rechavia E, Litvack F, Macko G, Eigler NL. Stent implantation of
saphenous vein graft aorto-ostial lesions in patients with unstable
ischemic syndromes: immediate angiographic results and long-term
clinical outcome. J Am Coll Cardiol 1995;25:866–70.
[9] Zampieri P, Colombo A, Almagor Y, Maiello L, Finci L. Results of
coronary stenting of ostial lesions. Am J Cardiol 1994;73:901–3.
[10] Tsunoda T, Nakamura M, Wada M, Ito N, Kitagawa Y, Shiba M, et al.
Chronic stent recoil plays an important role in restenosis of the right
coronary ostium. Coron Artery Dis 2004;15:39–44.
[11] Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M,
et al. A randomized comparison of a sirolimus-eluting stentwith a standard
stent for coronary revascularization. N Engl J Med 2002;346:1773–80.
[12] Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR,
O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard
stents in patients with stenosis in a native coronary artery. N Engl
J Med 2003;349:1315–23.
[13] Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann
JT, et al. A polymer-based, paclitaxel-eluting stent in patients with
coronary artery disease. N Engl J Med 2004;350:221–31.
[14] Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D,
et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare
metal stent in patients with complex coronary artery disease: a randomized
controlled trial. Jama 2005;294:1215–23.
[15] Iakovou I,GeL,Michev I, SangiorgiGM,MontorfanoM,Airoldi F, et al.
Clinical and angiographic outcome after sirolimus-eluting stent implan-
tation in aorto-ostial lesions. J Am Coll Cardiol 2004;44:967–71.
[16] Ong AT, Serruys PW, Aoki J, Hoye A, van Mieghem CA, Rodriguez-
Granillo GA, et al. The unrestricted use of paclitaxel-versus sirolimus-
eluting stents for coronary artery disease in an unselected population:
one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology
Hospital (T-SEARCH) registry. J Am Coll Cardiol 2005;45:1135–41.
[17] Mehran R,Dangas G, Abizaid AS,Mintz GS, Lansky AJ, Satler LF, et al.
Angiographic patterns of in-stent restenosis: classification and implica-
tions for long-term outcome. Circulation 1999;100:1872–8.
[18] Miller GA, Honey M, el-Sayed H. Isolated coronary ostial stenosis.
Catheter Cardiovasc Diagn 1986;12:30–4.
[19] Yamasaki M, Hara K, Masaki K, Kobayashi N, Nakajima H, Kouzuma
K, et al. Palmaz–Schatz stent implantation for aorto-ostial stenoses of
native coronary arteries and saphenous vein grafts. J Cardiol
1998;31:263–71.
[20] Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T,
et al. Localized hypersensitivity and late coronary thrombosis secondary
to a sirolimus-eluting stent: should we be cautious? Circulation
2004;109:701–5.
[21] Bauriedel G, Hofling B. Resection of guide catheter fragments during
coronary atherectomy in aorto-ostial lesions: a note of caution.
Catheter Cardiovasc Diagn 1994;31:202–5.
[22] Oda H, Tagawa M, Miida T, Takahashi K, Higuma N. Guide catheter
damage during rotational coronary atherectomy of aorto-ostial lesions.
Jpn Heart J 2000;41:649–57.
[23] Abhyankar A, Gai L, Bailey BP. Angioplasty through a stent side door.
Int J Cardiol 1996;55:107–10.
[24] Harb TS, Ling FS. Inadvertent stent extraction six months after
implantation by an entrapped cutting balloon. Catheter Cardiovasc
Interv 2001;53:415–9.
[25] Chetcuti SJ, Moscucci M. Double-wire technique for access into a
protruding aorto-ostial stent for treatment of in-stent restenosis.
Catheter Cardiovasc Interv 2004;62:214–7.
[26] Villa E, Pacini D, Di Bartolomeo R. Stenting an aorto-ostial stenosis of
the right coronary artery. Int J Cardiol 2006;106:413–4.
[27] Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB,
et al. Clopidogrel use and long-term clinical outcomes after drug-
eluting stent implantation. Jama 2007;297:159–68.
Chapter 6
66
 
 
 
 
 
 
 
 
 
Chapter 7 
 
 
Three-year clinical outcomes after coronary stenting of 
chronic total occlusion using sirolimus-eluting stents: 
insights from the rapamycin-eluting stent evaluated  
at Rotterdam cardiology hospital (RESEARCH) registry. 
 
García-García HM, Daemen J, Kukreja N, Tanimoto S, van Mieghem CA,  
van der Ent M, van Domburg RT, Serruys PW. 
 
Catheter Cardiovasc Interv. 2007;70:635-9 
 
Three-Year Clinical Outcomes After
Coronary Stenting of Chronic Total Occlusion
Using Sirolimus-Eluting Stents:
Insights From the Rapamycin-Eluting Stent
Evaluated at Rotterdam Cardiology
Hospital—(RESEARCH) Registry
He´ctor M. Garcı´a-Garcı´a, MD, MSC, Joost Daemen, MD, Neville Kukreja, MRCP,
Shuzou Tanimoto, MD, Carlos A.G. van Mieghem, MD, Martin van der Ent, MD, PhD,
Ron T. van Domburg, PhD, and Patrick W. Serruys,* MD, PhD
Background: We previously reported that the 1-year survival-free from target lesion re-
vascularization was 97.4% in patients with chronic total occlusion (CTO) treated with siro-
limus-eluting stents (SES). There are currently no long-term results of the efficacy of SES
in this subset of lesions. We assessed the 3-year clinical outcomes of 147 patients with
CTO treated with either SES or bare metal stents (BMS). Methods and Results: A total of
147 (BMS 5 71, SES 5 76) patients were included. Four patients died in the BMS group
while five patients died in the SES group, P 5 0.8; two myocardial infarctions occurred in
both groups, P 5 0.9; and target vessel revascularization was performed in nine patients
in the BMS and seven in the SES group, P 5 0.5. The cumulative event-free survival of
MACE was 81.7% in BMS group and 84.2% in SES group, P5 0.7. Two patients of the SES
group had a coronary aneurism at 3-year angiographic follow-up. Conclusions: The use
of SES was no longer associated with significantly lower rates of target vessel revascu-
larization and major adverse cardiac events in patients with CTOs after 3 years of follow-
up compared with BMSs. ' 2007 Wiley-Liss, Inc.
Key words: drug-eluting stents; angiography; coronary; total occlusions; percutaneous
coronary intervention; restenosis
INTRODUCTION
Drug-eluting stents (DES) are superior in terms of
clinical outcomes and restenosis rate to bare-metal
stents (BMS) in every angiographic and patient sub-
set [1–3]. In particular, in patients with chronic total
occlusion (CTO) DES have shown a significant
decrease in need for repeat revascularization and re-
stenosis rate [4–7], although this subset remains still
in the DES era a predictor of restenosis [8]. Our
group has previously reported the 6-month angio-
graphic and clinical outcomes of sirolimus-eluting
stent (SES) in patients with CTOs [9]. In this study,
we showed a marked reduction in restenosis rate and
major adverse cardiac events (MACE) compared with
BMS. This observation was confirmed in the PRISON
II study [10], a prospective, randomized trial that
included a total of 200 patients treated either with a
SES or BMS with both clinical and angiographical
follow-up at 6 months. However, among the interven-
tionalists, the clinical and angiographic long-term fol-
low-up of the DES is still a major concern, especially
in high-risk populations. We therefore investigated
the 3-year clinical and angiographic follow-up of
patients with CTO in a consecutive series of 147
patients, with comparison between the bare metal
stents and SESs.
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MATERIALS AND METHODS
From April 2002 to February 2003, 76 patients with
CTOs were treated solely with SES. In this period
SES (Cypher1; Cordis Corporation, Warren, NJ) was
the device of first choice for every PCI performed
in our institution as part of the rapamycin eluting
stent evaluated at rotterdam cardiology hospital
(RESEARCH) registry, a prospective single center
study set-up with the aim of evaluating the safety and
efficacy of SES in a ‘‘real world’’ scenario, following
the dynamic registry design described by Rothman and
coworkers [11,12]. Except for contraindications to clo-
pidogrel treatment, no exclusion criteria were made.
All consecutive patients treated successfully were en-
rolled irrespective of clinical presentation and CTO
lesion characteristics. Those patients treated with SES
implantation were compared with all those treated for
a CTO in the preceding 1 year with bare metal stents
(BMS), identified from the departments’ dedicated
database. The same operators utilizing standard techni-
ques treated all groups; the only difference being the
type of stent.
This protocol was approved by the hospital ethics
committee and is in accordance with the principles of
Good Clinical Practice for Trials of Medicinal Products
in the European Community and the Declaration of
Helsinki. Written informed consent was obtained from
every patient.
CTO Definition
CTO was defined as a complete occlusion on angi-
ography with no antegrade filling of the distal vessel
other than via collaterals. All the occlusions in a native
vessel with at least 3-month duration based on the
clinical history or a previous coronary angiogram were
included [9].
Angiographic Analysis
Quantitative coronary analysis in those patients with
angiographic follow-up was performed as previously
described [9]. Briefly, three segments were analyzed:
(1) stent segment; (2) the 5 mm proximal to the stent;
and (3) the 5 mm distal to the stent. The target lesion
comprised the in-stent plus the proximal and distal
edge segments. Binary restenosis was considered as
>50% diameter stenosis within the target lesion.
All patients were pretreated with 300 mg of clopi-
dogrel, which was then prescribed at a dose of 75 mg/
day for 6 months. All patients were advised to main-
tain aspirin (80 mg/day) lifelong.
Our primary endpoints were the 3-year incidence of
MACE, a compound endpoint of all-cause mortality,
nonfatal myocardial infarction and target-vessel revas-
cularization, in both groups. Secondary endpoints were
target vessel revascularization (TVR) and myocardial
infarction (MI). MI was defined by a rise in creatine
kinase-MB fraction (CK-MB) of three times the upper
limit of normal, according to American Heart Associa-
tion/American College of Cardiology guidelines [13].
TVR was defined as a percutaneous reintervention or
coronary artery bypass grafting (CABG) of a lesion in
the same epicardial vessel. Subacute angiographic stent
thrombosis was defined as an angiographically docu-
mented complete occlusion (TIMI grade 0 or 1 flow)
or a flow-limiting thrombus (TIMI grade 1 or 2 flow)
in the first 30 days after a successful procedure. Late
stent thrombosis was defined as angiographically
defined thrombosis with (TIMI grade 0 or 1 flow or
the presence of a flow limiting thrombus), occurring at
least 1 month after DES implantation accompanied by
acute symptoms. Angiographic follow-up was per-
formed in a subset of 30 patients in the SES group.
Three-Year Follow-Up Data
Patients were followed-up prospectively and eval-
uated for MACE-free survival of using both municipal
civil registries and health questionnaires inquiring
about postdischarge repeat coronary interventions (ei-
ther surgical or percutaneous) and MI. Since our hospi-
tal is a tertiary referral center for our region, with a
catchment area of 1.3 million people, most of the
repeat interventions were performed at our institution.
Follow-up information was prospectively entered into a
dedicated database. If a patient had an MI or a reinter-
vention at another center, medical records or discharge
letters were requested and systematically reviewed.
Local cardiologists or general practitioners were also
contacted as necessary. Patients lost to follow-up were
considered at risk until the date of last contact, at
which point they were censored.
Statistical Analysis
Continuous variables are presented as mean 6 SD
and were compared by the Student’s t test. Categorical
variables are presented as counts and percentages and
compared by Fisher’s exact test. The cumulative inci-
dence of adverse events was estimated according to
the Kaplan–Meier method and curves were compared
using the log-rank test. Separate Cox regression analy-
ses were performed to identify independent predictors
of adverse events. Preselected variables were: age, gen-
der, hypertension, diabetes, renal impairment, previous
intervention, old MI, smoking, treatment of the left
main coronary artery, and previous CABG. The final
results are presented as adjusted hazard ratios (HRs).
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RESULTS
Baseline and Procedural Characteristics
A total of 71 and 76 patients were included in the
BMS group and in the SES group, respectively. There
were no significant differences between the groups
with respect to baseline patient characteristics
(Table I). In the BMS group 76.1% and in the SES
group 65.8% were male (P ¼ 0.1) and the mean age
was 60.9 6 10.5 and 61.1 6 10.6 years, respectively
(P ¼ 0.9). Although not statistically significant, in the
SES group the number of diabetic patients and patients
treated in the LAD were higher. Glycoprotein IIb/IIIa
inhibitor use was low in both the BMS group (21.9%)
and SES group (18.4%) (P ¼ 0.08); as defined by pro-
tocol, clopidogrel prescription was longer in SES
group (6 months) as compared with the BMS group (1
month).
Three-Year Clinical Follow-Up
Both 6-month and 1-year outcomes have been
reported previously [9,14]. At 3 years, follow-up was
available in 87.3% of the patients in the BMS group
and in 96% of the SES group. Four patients died in
the BMS group, two of unknown cause, one of noncar-
diac cause, and one of cardiac death; while five
patients died in the SES group, P ¼ 0.8; in this group,
three deaths were of cardiac cause, one patient died of
cancer, and the cause of one patient was unknown.
Two MI’s occured in both groups, P ¼ 0.9; and
TVR was performed in nine patients in the BMS and
seven in the SES group, P ¼ 0.5. The cumulative sur-
vival-free of MACE was 81.7% in BMS group and
84.2% in SES group, P ¼ 0.7 (Table II and Fig. 1).
No cases of late stent thrombosis were identified in
these two groups.
In the multivariate analysis the only variable that
was an independent predictor of MACE was age, HR
1.04 (95%CI, 1.01, 1.07).
Three-Year Angiographic Follow-Up
Thirty patients underwent angiography at 3-year; the
in-stent minimum lumen diameter was 1.9 6 0.6 mm,
the in-stent diameter stenosis was 30.5%, and the late
loss 0.35 6 0.50; four patients had binary restenosis;
out of this four, two CTOs were found to be reoc-
cluded (Fig. 2). One of these patients with reocclusion
TABLE I. Baseline Patient Characteristics
BMS n ¼ 71 SES n ¼ 76 P value
Mean age (years) 60.9 6 10.5 61.1 6 10.6 0.9
Male sex (%) 76.7 65.8 0.1
Current smoker (%) 27.4 18.4 0.2
Diabetes mellitus (%) 5.5 14.5 0.07
Hypertension (%) 35.6 42.1 0.3
Hypercholesterolemia (%) 57.5 67.1 0.3
Previous myocardial
infarction (%)
50.7 51.3 0.8
Previous CABG (%) 0 3.9 0.2
Glycoprotein IIb/IIIa
inhibitor usage (%)
21.9 18.4 0.8
Target vessel 0.1
LAD (%) 27.5 46.1
LCX (%) 27.5 19.7
RCA (%) 44.9 36.8
Mean number of stents 1.9 6 0.8 2.2 6 1.2 0.9
Mean diameter of
the stent (mm)
3.1 6 0.58 2.8 6 0.3 <0.001
Mean length of stent (mm) 21.7 6 6.3 22.5 6 6.1 0.5
SES: sirolimus-eluting stents, PES: paclitaxel-eluting stents, CABG: cor-
onary artery bypass grafting, PCI: percutaneous coronary intervention,
LAD: left anterior descending artery, LCX: circumflex artery, RCA: right
coronary artery.
TABLE II. Clinical Events at Three-Year Follow-Up
BMS, n ¼ 71 SES, n ¼ 76 P value
Death, n(%) 4(5.6) 5(6.6) 0.8
MI, n(%) 2(2.8) 2(2.6) 0.9
TLR, n(%) 8(11.3) 6(7.9) 0.5
TVR, n(%) 9(12.7) 7(9.2) 0.5
TLR/Death, n(%) 12(16.9) 11(14.5) 0.7
TVR/Death, n(%) 13(18.3) 12(15.8) 0.7
MI/Death, n(%) 4(5.7) 6(8.1) 0.6
MACE, n(%) 13(18.3) 12(15.8) 0.7
MI, myocardial infarction; TLR, target lesion revascularization; MACE,
major adverse cardiac events.
Fig. 1. Three-year cumulative incidence of major adverse car-
diovascular events.
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was treated due to the presence of symptoms, while
the other patient was left untreated due to the absence
of symptoms and it is awaiting noninvasive ischemia
testing. Two patients had a coronary aneurism.
DISCUSSION
This report describes the 3-year clinical and angio-
graphic follow-up of patients with CTO treated with
either BMS or sirolimus stents.
There have been some publications comparing BMS
vs. DES treatment for CTOs with 6-month follow-up
[7,9,15], and recently the first randomized trial in the
DES era that included exclusively CTO patients was
published [10]; pooling these studies despite the differ-
ent nature of data (e.g. registries vs. randomized trial),
the analysis showed a decrease in TVR and MACE
with DES, OR 0.25 (95%CI, 0.16, 0.40) and OR 0.36
(95%CI, 0.24, 0.53), respectively. Three 1-year follow-
up studies have been published [5,6,14], (all registries),
which also showed a sustained benefit of DES in terms
of TVR and MACE, OR 0.1 (95%CI, 0.05, 0.20) and
OR 0.17 (95%CI, 0.07, 0.43), respectively. Clinical
reports including up to 1-year clinical follow-up, nei-
ther individually or globally, showed a decrease in
terms of all cause death or MI.
Although due to the study design some baseline
characteristics are different between the two groups
such the presence of diabetes, treatment of the LAD
(no statistically significant), and diameter of the stent,
in the 6-month [9] and 1-year [14] reports in patients
treated with SES a marked reduction in restenosis rate
and MACE was observed compared with BMS. In
turn, this 3-year follow-up report showed no difference
whatsoever in any of the MACE components. This is
in agreement with other two long-term follow-up sub-
studies of the RESEARCH registry, patients with dia-
betes mellitus and acute MI [16]. The former report
compared the 2-year clinical outcome of 708 consecu-
tive diabetic patients treated with either a BMS (n ¼
252), a SES (n ¼ 206), or a PES (n ¼ 250). TVR
rates were 19.5% in the BMS group, vs. 15.3% in the
SES group and 9.7% in the PES group. PES (21.2%)
but not SES (28.9%), were superior to BMS (29.7%)
in reducing MACEs. However, after propensity analy-
ses, none of the differences remained significant. The
second report where primary angioplasty was per-
formed in a consecutive group of 505 patients (BMS,
n ¼ 183; SES, n ¼ 186; PES, n ¼ 136), showed that
the cumulative incidence of death or MI was compara-
ble in the three groups: 16.6% in the BMS group,
14.6% in the SES group, and 16.9% in the PES group.
At 3 years, TVR was 12.0% in the BMS group, com-
pared with 8.0 and 7.7% in the SES and PES groups,
respectively. The cumulative incidence of death, MI or
TVR was 25.5% in the BMS group compared with
17.9 and 21.4% in the SES and PES groups, respec-
tively. In light of these results, it seems that a late
clinical restenotic phenomenon is observed in specific
subsets of patients, and that the beneficial effects in re-
stenosis rates of DES observed in the first year might
drop over the time.
The present study has all the intrinsic limitations of
a registry. Although in our center only in a limited pe-
riod of time all comers were treated with sirolimus
eluting stent and the number of CTO patients treated
was relatively small, all consecutively treated CTO
patients were included in this registry. A word of cau-
tion in interpreting the present findings as confirmative
must be given, since the sample size is small. However,
so far, in this subset of patients, this is the only registry
with clinical and angiographic long-term follow-up.
CONCLUSIONS
Despite clinical benefit after 1 year, the use of siro-
limus stent was no longer associated with significantly
lower rates of TVR and MACEs in patients with
Fig. 2. A patient with a chronic total occlusion in the distal
right coronary artery (panel A) was treated with four sirolimus
stent (SES), in panel B the final result. Seventeen months later
the patient underwent coronary angiogram due to stable an-
gina and focal stent restenosis was seen in the gap between
SES 3 and 4 (panel C). In addition, mild intimal hyperplasia
was observed in the body of the SES number 4. Patient was
treated with a PES (panel D). In the three-year angiographic
follow-up an increase was seen in the intimal hyperplasia
(panel E).
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CTOs after 3 years of follow-up compared with bare
metal stents.
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Chronic Total Occlusion Treatment in Post-CABG
Patients: Saphenous Vein Graft Versus Native
Vessel Recanalization—Long-term Follow-up
in the Drug-Eluting Stent Era
Emanuele Meliga, MD, He´ctor M. Garcı´a-Garcı´a, MD, MSc, Neville Kukreja, MRCP,
Joost Daemen, MD, Shuzou Tanimoto, MD, Steve Ramcharitar, MD, PhD,
Carlos A.G. van Mieghem, MD, Georgios Sianos, MD, Martin van der Ent, MD, PhD,
Willem J. van der Giessen, MD, PhD, Pim de Feyter, MD, PhD,
Ron van Domburg, PhD, and Patrick W. Serruys,* MD, PhD
Objective: To compare the postprocedural and long-term clinical outcomes of two
groups of patients, all presenting with chronic saphenous vein graft (SVG) occlu-
sion, who underwent either SVG or native vessel reopening. Background: Chronic
total occlusions (CTO) treatment in patients who underwent previous surgical
revascularization is a dilemma and the choice of performing native vessel or SVG
recanalization is not always easy. Methods: Between July 2002 and October 2004, a
total of 260 patients were successfully treated for a CTO. Of them, we selected all
patients (n = 24) who had previous bypass surgery with graft occlusion. Of this final
group, 13 patients underwent a percutaneous graft recanalization while 11 under-
went native vessel reopening. Results: Primary end points were in-hospital and
3-year rates of death, myocardial infarction, target lesion revascularization, and tar-
get vessel revascularization. No events occurred in either group during the in-hos-
pital period. Cumulative 3-year event-free survival in the native vessel and SVG
group was 81.8% and 83.9% respectively (P = NS). One death and one TVR
occurred in each group. Conclusion: In selected cases, SVG reopening instead of
the native vessel is feasible. In such a high-risk population, drug-eluting stent im-
plantation in both SVG and native CTO lesions is associated with good long-term
outcomes. ' 2007 Wiley-Liss, Inc.
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INTRODUCTION
Chronic total occlusions (CTOs) remain one of the
most challenging problems for interventionists as the
procedural success rate and acute outcome are still rel-
atively poor [1–6]. Percutaneous treatment of saphe-
nous vein grafts (SVGs) occlusions, notwithstanding
the use of drug-eluting stent (DES) and new protection
devices, remains exacting [7]; the atherosclerotic dis-
ease in SVGs is pathologically different from the
native vessel, showing soft and friable lesions usually
with a poorly developed fibrous cap and large and
bulky thrombi that tend to occupy the entire length of
the graft [8–12]. Which revascularization treatment
should we then recommend to patients with chronic
SVG occlusions? Is it worthwhile to treat the SVG
occlusions or should we avoid this approach and
always attempt to treat the native bypassed coronary
arteries?
To clarify this issue better we compared the clinical
outcomes of two groups of patients, all presenting
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chronic SVG occlusion, who underwent either SVG or
native vessel reopening.
METHODS
Population
Demographic and procedural data regarding all
patients undergoing PCI at our centre were prospectively
entered into a dedicated database. Between July 2002
and October 2004, a total of 351 patients had a CTO
treatment attempt in our center; 260 were successfully
treated (74.1%). Of them, we retrospectively selected
only those patients (n ¼ 24) who had undergone previous
saphenous vein bypass grafting and subsequently had
total occlusion of one or more grafts. Of this final group,
13 patients underwent a percutaneous reopening treat-
ment on the occluded graft while 11 underwent percuta-
neous reopening of the native vessel (Table I).
Exclusion criteria were unsuccessful attempt and
intolerance or contraindication to clopidogrel. No other
predefined clinical inclusion or exclusion criteria were
considered, and the indication for PCI was decided on
clinical and angiographic characteristics.
End Points
The primary outcome measures investigated were
the occurrences of death, myocardial infarction (MI),
target vessel revascularization (TVR), target lesion
revascularization (TLR), and major adverse cardiac
events (MACE) defined as a nonhierarchical composite
of all cause death, nonfatal MI, or repeat revasculariza-
tion during hospital stay and at 3 years.
Definitions
CTO was defined as a complete coronary obstruction
(TIMI flow grade 0) with an estimated duration of >3
months. Technical success was defined as the ability to
cross and open the occluded segment with no more
than 40% residual stenosis in all views; procedural
success was defined as a technical success with no in-
hospital MACE. MI was defined as a threefold CK-
MB increase; hemodynamic instability was defined as
the occurrence of sustained ventricular arrhythmias or
prolonged hypotension (BP < 90/60 mm Hg). TLR
was defined as any revascularization performed on the
treated segment; TVR was defined as any reinterven-
tion performed on the treated vessel.
Interventional Technique
The operators performed the procedure according to
standard techniques of the time via the femoral or
brachial approach. All procedural and technical details
and the choice of devices were left to the operator’s
judgment. In the cardiac catheterization laboratory,
patients received a bolus of 10,000 units of heparin
followed by repeated boluses per a weight-based proto-
col to achieve an activated clotting time >250 sec. All
the lesions were treated with DES implantation. Peri-
procedural abciximab was administered at the opera-
tor’s discretion. After the procedure, clopidogrel (75
mg daily) was prescribed to all patients for 6 months
after stent implantation; aspirin was given indefinitely.
Follow-up
A follow-up visit or telephone interview was sched-
uled at 30 days, 6 months, 1 year, and then yearly.
Civil registries were queried in case of death, to deter-
mine whether it was or not a cardiac death. A health
questionnaire was subsequently sent to all living
patients with specific questions on rehospitalization
and MACE [13,14]. All repeat interventions and reho-
spitalizations were prospectively collected during fol-
low-up and entered into a dedicated database. An exer-
cise tolerance test was recommended after 6 months in
event-free patients; angiographic follow-up was per-
formed only in those patients with recurrence of symp-
toms or with a positive stress test.
Statistical Analysis
Variables with normal distribution were analyzed
using parametric tests while variables with a non-normal
distribution were analyzed with nonparametric tests.
Continuous variables are expressed as mean 6 SD or
median 6 SD and differences were compared using
Student’s t test or Mann–Whitney test. Categorical varia-
bles are expressed as counts and percentages; differences
were assessed by Fisher’s exact test or v2 test, as appro-
priate. All statistical tests were two-tailed. When more
than one clinical event occurred in a patient, all the
events occurring were considered for survival analysis.
All analyses were performed using SPSS version 12
statistical software (SPSS Inc., Chicago, IL). A P value
< 0.05 was considered significant.
TABLE I. Baseline Clinical Characteristics
SVG group
(N ¼ 11)
Native group
(N ¼ 13) P value
Age (years) 67.8 6 12.4 60.8 6 10.9 NS
Women, n (%) 1 (7.6) 2 (18.1) NS
Diabetes mellitus, n (%) 5 (38.4) 3 (27.2) NS
Hypertension, n (%) 7 (53.8) 4 (36.6) NS
Current smoking, n (%) 2 (15.3) 2 (18.1) NS
Familiarity, n (%) 7 (53.8) 6 (54.5) NS
Dislipidemia, n (%) 10 (76.9) 9 (81.1) NS
Prior myocardial infarction, n (%) 7 (53.8) 6 (54.5) NS
Prior PCI, n (%) 5 (38.4) 7 (63.6) NS
Clinical presentation (ACS), n (%) 6 (46.1) 1 (9) <0.05
SVG, saphenous vein graft; PCI, percutaneous coronary intervention;
ACS, acute coronary syndrome.
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RESULTS
Baseline and Procedural Variables
Baseline clinical and angiographic characteristics are
shown in Tables I and II.
In our population, the median time from bypass sur-
gery to the index percutaneous was 10 years (range:
10 months to 20 years). In the SVG group, distal em-
bolic protection was used in 38.4%. There were no
significant differences in the two groups except that
patients with PCI for SVG versus native artery occlu-
sion presented more often with acute coronary syn-
drome (46.1% vs. 9.0%; P < 0.05), three vessel dis-
ease (100% vs. 63.6%; P < 0.05), received a slightly
higher number of stents (4 6 1.65 vs. 3 6 1.54; P <
0.05) and with a larger mean diameter (2.97 6 0.35
vs. 2.6 6 0.1 mm; P < 0.05).
Procedural and In-Hospital Outcomes
Procedural and In-Hospital Outcomes are summar-
ized in Table III.
Both technical and procedural success rates were
100%. No death, postprocedural infarction, or urgent
re-PCI occurred in either group. Two patients experi-
enced hemodynamic instability, both in the SVG
group. One patient needed an intra-aortic balloon pump
(none in native vessel group) and one patient needed
temporary pacing (none in native vessel group).
Follow-up Clinical Outcomes
Three-year follow up clinical outcomes are shown in
Table IV.
One patient dropped out after 9.2 months (276
days). One patient in the native vessel group died 11
months (335 days) after the procedure; one patient in
the SVG group died 24 months (720 days) after the
procedure. There was one TVR in the native vessel
group (13 months after the index procedure) and one
in the SVG group (5.2 months after the index proce-
dure). No MI or re-CABG occurred in the follow-up
period. The cumulative MACE free survival rate at 36
months was 81.8% in native vessel versus 83.9% in
the SVG group.
DISCUSSION
The main findings of this study are that SVG re-
opening instead of the native vessel is a feasible and
an interesting option in selected cases and that DES
use in this population is safe with good long-term out-
comes. Undoubtedly this can be considered one of the
most challenging and highest risk populations ever
treated in the DES era: patients with previous CABG,
treated with a PCI in SVGs or native vessels for a
CTO. What today can be considered ‘‘real world clini-
cal practice,’’ albeit still not so common, was discour-
aged a few years ago; in an editorial published by our
group in 1993 [1] it was suggested to avoid percutane-
ous treatment of SVG lesions and to opt for revascu-
larization of the native vessel if re-CABG, as a serious
alternative, was not feasible.
TABLE II. Angiographic and Procedural Characteristics
SVG group
(N ¼ 11)
Native group
(N ¼ 13) P value
Three vessel disease, n (%) 13 (100) 7 (63.6) <0.05
TL location, n (%)
LAD 2 (15.3) 0 (0) NS
LCX 4 (30.7) 7 (63.6) NS
RCA 7 (53.8) 4 (36.6) NS
Baseline RVD (mm) 3.04 6 0.36 2.71 6 0.31 <0.05
Postprocedure RVD (mm) 3.28 6 0.24 2.89 6 0.29 <0.05
Ostial location, n (%) 11 (84.6) 2 (18.1) <0.05
Calcified lesions, n (%) 3 (23) 5 (45.4) NS
Number of guiding
catheters/patient 1.07 6 0.2 1.7 6 0.9 <0.05
Number of guide wires/patient 2.15 6 1.34 2.17 6 1.1 NS
Number of balloons/patient 1.53 6 0.87 1.63 6 0.8 NS
TL number of placed
stents/patient 3.3 6 1.54 2.27 6 0.46 <0,05
TL average diameter stent (mm) 3 6 0.3 2.62 6 0.24 <0.05
TL average length stent (mm) 22.9 6 6.5 21.5 6 4.4 NS
Total number of treated lesions 1.76 6 0.92 1.72 6 0.78 NS
Total number of placed
stents/patient 4 6 1.65 3 6 1.54 <0.05
Total average diameter
stent (mm) 2.97 6 0.35 2.6 6 0.1 <0.05
Total average length stent (mm) 22.4 6 4.94 21.4 6 3.7 NS
Use of distal protection, n (%) 5 (38.4) 0 (0) NS
Procedural time (min) 148 6 39 135 6 36 NS
Contrast amount (ml) 360 6 112 399 6 133 NS
Periprocedural abciximab, n (%) 8 (61.5) 5 (45.4) NS
RVD, reference vessel diameter; LAD, left anterior descending; LCX,
left circumflex; RCA, right coronary artery; TL, target lesion; SVG, sa-
phenous vein graft.
TABLE III. Procedural and In-Hospital Outcomes
SVG group
(N ¼ 11)
Native group
(N ¼ 13) P value
Procedural success rate (%) 100 100 NS
Final TIMI flow grade 3, n (%) 11 (100) 13 (100) NS
Hemodynamic instability, n (%) 2 (15.3) 0 (0) NS
IABP, n (%) 1 (7.6) 0 (0) NS
Temporary pacing, n (%) 1 (7.6) 0 (0) NS
Perforation, n (%) 0 (0) 0 (0) NS
In-hospital death, n (%) 0 (0) 0 (0) NS
Postprocedural MI, n (%) 0 (0) 0 (0) NS
Urgent TVR, n (%) 0 (0) 0 (0) NS
Postprocedural CK levels (UI) 123 6 66 99 6 50 NS
IABP, intra aortic balloon pump; TVR, target vessel revascularization;
TIMI, thrombolysis in myocardial infarction; SVG, saphenous vein graft;
MI, myocardial infarction; CK, creatine-kinase.
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The 2005 ACC/AHA guidelines for PCI indicate
that the average technical success rate of recanalizing
CTO is 65%; advances in technical skills and introduc-
tion of new devices have enabled in some centers to
reach a 70% or greater technical success rate, which
anyway is still considerably lower compared with the
92% success rate of PCI for overall lesions [15–18].
Consistent with these data, technical success rate
between July 2002 and October 2004 in our centre
was 74.1%. It is well known that interventional
maneuvers on vein grafts are difficult and often associ-
ated with a high risk of complications; lesion crossing,
balloon inflation, and stent deployment can easily per-
forate the vein wall or dislodge friable atherosclerotic
and thrombotic material, causing distal embolization
and slow-flow or no-reflow phenomenon [1,19].
Which therefore were the elements that led the inter-
ventionist to attempt reopening a SVG instead of the
native vessel?
The decision was basically taken on angiographic
features: the presence of diffuse, complex, or ostial
blunt lesions in tortuous, calcified native vessels
deterred their recanalization while, on the other hand,
good graft conditions, short shaft or ostial tapered
SVG lesions or the presence of sequential grafts en-
couraged a reopening attempt.
DES, new protection devices, and antiplatelet drugs
make the attempt easier. Recent studies reported that
DES implantation (both sirolimus and paclitaxel elut-
ing stents) reduced in-stent restenosis and improved
both short- and long-term revascularization rates after
successful CTO recanalization in native vessels com-
pared with bare metal stents [20–22]. Moreover, distal
protection devices (e.g. FilterWire EX) and platelet
glycoprotein IIb/IIIa inhibitors have been shown to be
effective in elective PCI in SVGs by reducing distal
embolization and slow-flow or no-reflow phenomena
[23–25].
In this study, the use of DES for CTO recanaliza-
tion, associated with the use of antiplatelet drugs led
to excellent postprocedural and in-hospital outcomes.
No death, MI, urgent TVR, or distal embolization
occurred in either group. Additionally, only two
patients with PCI for SVG occlusion had in-hospital
hemodynamic instability (15.3%), one requiring an
IABP and one requiring temporary pacing.
Three-year follow-up outcomes are good especially
considering the high baseline risk profile of our popula-
tion: prior CABG, advanced age, prior infarction, three-
vessel and diffuse coronary disease, and diabetes melli-
tus were common characteristics of this population.
However, despite the encouraging outcomes of DES
use, up to 50% of late cardiac events in patients with
SVG lesions are due to disease progressions at different
sites rather than the initial target [26,27]; so a high
MACE rate should be expected in this population.
At 3 years, two patients died (one in each group) and
two underwent a re-PCI (one in each group). MACE-
free survival rate at 36 months in the native vessel and
SVG groups were 81.8% and 83.9% respectively, with-
out statistical difference between the groups.
This compares favorably with existing data on DES
use for native vessel CTO treatment, with reported
overall MACE-free survival rate at 6 and 12 months of
90–91% and 87–84% respectively [20,28,29], although
still few data are available on DES use for SVGs CTO
treatment. A recent report by Ge et al. showed an
overall MACE-free survival at 6 months of 88.5% in
SVG lesions [30], in line with the results of DES use
on native vessels. Though based on a very small,
highly selected population with peculiar angiographic
features and though should be interpreted with great
caution, these results show encouraging follow-up
results probably thanks to DES, new guide wires gen-
eration, and new specific devices introduction. In
selected cases, SVG recanalization instead of the
native vessel with DES can therefore be an interesting
option with a high procedural success rate; moreover,
DES implantation in both SVG and native CTO lesions
is associated with an equal effect on MACE-free sur-
vival at 3-year follow-up.
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Description
Kaneka’s coronary stent, MAHOROBA™, is a new drug eluting stent
(DES), which combines a thin, flexible cobalt-chromium (CoCr)
metal stent platform coated with a biodegradable polymer including
the pharmaceutical agent tacrolimus. The device has been
designed and developed to inhibit the growth of neointimal hyper-
plasia and avoid interference with the vascular healing response.
History
The advent of DES has revolutionised the practice of interventional 
cardiology by inhibiting the development of neointimal hyperplasia and
thereby reducing the rates of restenosis and repeat revascularisation
as compared to bare metal stents (BMS)1-4. After the first approval 
of DES in 2002, a large number of patients with coronary artery dis-
ease have undergone percutaneous revascularisation with DES.
Recently, however, certain potential safety concerns regarding their
widespread use have arisen. The most notable drawback of DES is that
they could increase the risk of thrombotic complications, especially
late stent thrombosis. In order to discuss this serious problem, the US
Food and Drug Administration held a medical device advisory panel
meeting on December 7-8, 20065. They concluded that DES are asso-
ciated with a numerical excess of late stent thrombosis (after 1-year
post implantation), although the magnitude of this excess is uncertain. 
The increased risk of thrombosis with the use of DES may be associ-
ated with altered endothelial function6 and/or delayed vascular heal-
ing7 induced by cytotoxic and cytostatic drug use. In addition, localised
hypersensitivity reactions to the polymer coating of the DES and drug
itself may also contribute to stent thrombosis8,9. To retain the positive
clinical aspects of DES and overcome their drawbacks, Kaneka
Corporation has developed a new DES, MAHOROBA™, which aims 
to inhibit excessive neointimal growth whilst avoiding the interruption
of the vascular healing process, including re-endothelialisation.
Stent characteristics
1. PLATFORM
Material: cobalt chromium (CoCr) alloy
Deployment: balloon expandable
Strut thickness: 75 μm (0.0030 inches)
Size available: 3.0 x 18 mm and 3.5 x 18 mm
Number of cells: both 8 cells and 10 cells are combined
Number of joints: 2
Radial force: 0.17 N/mm (for the 3.0 mm diameter stent)
Recoil/shortening: 3%/3%
Nominal/rated burst pressure: 9 atm/16 atm
2. DRUG
Used drug: tacrolimus
3. COATING
Characteristics: biodegradable polymer
Composition: poly DL-lactide-co-glycolide (PLGA: 3.58 μg/mm2)
+ tacrolimus (0.94 μg/mm2)
Coating methods: whole abluminal surface coating of the stent platform
Drug release kinetics: controlled with half the drug released over
more than 84 days
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4. DELIVERY SYSTEM
Guide compatibility: 6 Fr
Outer diameter:  2.7/2.1 Fr (in the distal/proximal shaft) 
Technical specifications
1. PLATFORM
The material of the stent platform is CoCr. The stent has an open-
cellular balloon-expandable design and consists of two helical coils
inter-crossed with two phase-different links on each turn, in which
each link deviates diagonally along the longitudinal axis (Figure 1).
This novel link configuration allows for low elastic recoil, sufficient
radial force and good scaffolding while featuring excellent flexibility
both mounted on the delivery balloon as well as after expansion. In
addition, the stent strut thickness (75 μm, 0.0030 inch) of the
MAHOROBA™ stent is thinner than most other DES (Table 1).
Randomised clinical trials have revealed that thin-strut BMS have
significantly reduced restenosis rates as compared to thick-strut
BMS10, probably because thin-strut stents cause less arterial injury
at deployment. Therefore, the MAHOROBA™ stent may reduce 
the growth of neointimal hyperplasia more than the other DES.
2. DRUG 
Tacrolimus (FK 506: Astellas Pharma Inc., Tokyo, Japan) is a water-
insoluble macrolide immunosuppressant indicated for the prophy-
laxis of organ rejection in patients receiving allogeneic liver or 
kidney transplantation. Tacrolimus binds to FK-binding protein12
(FKBP12), forming a compound (Tacrolimus-FKBP12 complex),
which inhibits the production of pro-inflammatory cytokines such as
interleukin 2 by preventing the activation of calcineurin and sup-
presses T-cell proliferation (immunosuppressive effect)11. This com-
plex also inhibits several steps of the cascade of events leading 
to neointimal formation12 and reduces the proliferation of smooth
muscle cells (SMC)13, which play an important role in the mecha-
nism of restenosis (antiproliferative effect). These two effects 
of tacrolimus contribute to the inhibition of neointimal growth.
Unlike drugs used in other DES, tacrolimus has a different mode 
of action for the cell cycle (Table 1). By reducing the expression 
of cell cycle proteins, tacrolimus holds cells in the G0 phase, 
in which cells are able to function, but unable to replicate.
Sirolimus, zotarolimus and everolimus arrest cell replication in the
G1 phase (cytostatic effect), whilst paclitaxel prevents mitosis and
then halts the metaphase (cytotoxic effect). Therefore, tacrolimus 
is a non-cytotoxic and non-cytostatic agent, which may be benefi-
cial in preventing excessive vessel injury. 
Additionally, tacrolimus is also expected to demonstrate less inhibition
of endothelial cell (EC) proliferation, which is an important process for
vascular healing. Matter et al reported in an in vitro study that the
inhibitory concentration50 (IC50) value of tacrolimus for EC is marked-
ly higher than that for SMC, while the IC50 value of sirolimus for EC is
remarkably lower than that for SMC14 (Figure 2). This result implies
that if equipotent concentrations for suppressing SMC proliferation are
used, tacrolimus may allow better re-endothelialisation than sirolimus.
Moreover, unlike sirolimus and paclitaxel, tacrolimus does not affect
tissue factor expression, which can lead to the initiation of coagulation
causing thrombus formation15,16. Tacrolimus may therefore reduce the
incidence rates of stent thrombosis as compared to the other drugs.
Considering these characteristics, if effective local drug concentra-
tions are achieved, tacrolimus can exert its antiproliferative and 
anti-inflammatory effects while being vascular protective with less
prothrombotic effects. Therefore, tacrolimus is a promising 
compound for the next generation of DES.
Figure 1. MAHOROBA™ Tacrolimus eluting coronary stent.
The upper part of this figure is a magnified image of the MAHOROBA™
tacrolimus eluting coronary stent. The lower is a schematic 
of the stent structure itself. Two helical coils inter-cross with two
phase-different links (red circle). Blue circles and arrows indicate that
each link deviates diagonally along the longitudinal axis. These novel
configurations of links achieve high flexibility and vessel scaffolding.
Figure 2. Inhibitory concentration50 (IC50) values of tacrolimus and
sirolimus for smooth muscle cells and endothelial cells.
The upper panel shows the inhibitory concentration50 (IC50) values of
tacrolimus for smooth muscle cells (SMC) and endothelial cells (EC).
The bottom panel shows the IC50 values of sirolimus for SMC and
EC. The IC50 value of tacrolimus for EC is markedly higher than that
for SMC, while the IC50 value of sirolimus for EC is remarkably lower
than that for SMC. Data are extracted from Matter et al14.
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3. COATING POLYMER AND DRUG RELEASE KINETICS
The whole abluminal surface of the stent platform is coated with 
a matrix containing bioabsorbable polymer and tacrolimus. The 
surface of the coating layer is generally smooth and no cracks 
or peeling are observed even when the stent expands (Figure 3).
Most other DES are coated with a durable polymer as a drug 
carrier (Table 1). A durable polymer may lead to hypersensitivity with
eosinophilic infiltration in surrounding tissues at the stent deployment
site17 since the polymer exists permanently. This hypersensitivity
reaction could be associated with stent thrombosis8. To minimise this
undesirable reaction, biodegradable materials can be an alternative
vehicle for drug delivery because they are fully metabolised into car-
bon dioxide and water18, and thus no chemical substances remain
permanently. Kaneka Corporation has developed a specially designed
fully biodegradable polymer composed of PLGA to achieve a long
degradation time. In a porcine model, the PLGA completely disap-
pears from the coronary artery in approximately 6 months (Figure 4).
As the drug is uniformly distributed in the polymer layer, tacrolimus
will be released continually for several months and completely disap-
pear concomitantly with PLGA degradation. Indeed, in an in vivo
porcine coronary model, the tacrolimus release kinetics of the
MAHOROBA™ stent are controlled with 26% and 45% of the drug
released in 28 days and 84 days, respectively, while the sirolimus-
eluting stents (Cypher®: Cordis Corporation, Warren, NJ, USA) are
designed such that 79% of the sirolimus has been released by
28 days19. This sustained drug release property results in subsequent
retention of a sufficient concentration of tacrolimus in target coronary
arterial tissues for several months (Figure 5).
The coating method of the MAHOROBA™ is completely different
from a previously investigated tacrolimus-eluting stent (Janus™,
Sorin Biomedica Cardio s.r.l., Saluggia, Italy)20. The Janus™ stent
does not have any polymer vehicle, but has deep reservoirs contain-
ing tacrolimus on the external abluminal stent surface, in which
controlled drug release is difficult. Consequently, the vessel wall
may acutely be exposed to extremely high concentration of the
drug, leading to excessive inflammation in vascular walls. An animal
study showed that the tacrolimus concentration in the arterial wall
peaked a few days after the Janus™ stent implantation and then
steeply fell to steady values12. These release kinetics may be a part
of the reason why the Janus™ stent had a neutral effect on resteno-
sis (in-stent late luminal loss of 0.65 mm) as shown in the Jupiter II
trial20. Although the same drug is used, the MAHOROBA™ stent
may prevent more neointimal hyperplasia than the Janus™ stent,
because the MAHOROBA™ stent features controlled drug release. 
4. DELIVERY SYSTEM
The delivery system is based on the rapid exchange type PTCA 
balloon catheter (Fortis™, developed by Kaneka Corporation) with
a semi-low-compliant balloon. This device is approved and has
been sold in Japan.
Technical report
Table 1. Different characteristics of DES.
MAHOROBA™ Cypher® Taxus® Endeavor™ Xience™
Company name Kaneka Cordis Boston Scientific Medtronic Abbott vascular
Platform
Material CoCr Stainless steel Stainless steel CoCr CoCr
Strut thickness, μm 75 140 132 91 81
Strut thickness, inch 0.0030 0.0055 0.0052 0.0036 0.0032
Number of cells 8 and 10 6 6 and 9 10 6
Number of joints 2 6 3 2 3
Coating Drug
Drug Tacrolimus Sirolimus Paclitaxel Zotarolimus Everolimus
Action point G0 G1 M G1 G1
Coating
Composition PLGA PEVA/PBMA SIBS PC
Characteristics Bioabsorbable Durable Durable Durable Durable
CoCr = cobalt chromium; PLGA = poly DL-lactide-co-glycolide; PEVA = polyethylene-co-vinyl acetate; PBMA = poly n-butyl methacrylate; 
SIBS = polystyrene-block-polyisobutylenebutadiene-block-polystyrene; PC = phosphorylcholine
Figure 4. Residual ratio of PLGA after stent implantation in a porcine
coronary artery.
The PLGA degrades gradually and completely disappears in approxi-
mately 6 months.
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Figure 3. Surface of MAHOROBA™ stent.
Scanning electron microscopy images show that the surface of the
expanded stent is smooth (left panel). Even in the magnified images
(right panel), no cracks or peeling are observed. 
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Preclinical experience
Preclinical testing started in 2005 and is ongoing into the second
quarter of 2007. The initial animal results were presented during
EuroPCR 200621. It showed that the MAHOROBA™ reduced neoin-
timal thickening and neointimal area at 1 and 3 months following
stent deployment as compared to BMS, while it allowed for vascu-
lar healing and endothelialisation. Kaneka in-house porcine data
also showed that well endothelialised neointima was visible as early
as 14 days (Figure 6) after stenting without visible qualitative differ-
ences between MAHOROBA™ and BMS. The biodegradable PLGA
polymer did not cause obvious luminal inflammation. 
Future directions
In summary, the principal characteristics of MAHOROBA™ are the
following. First, the coating drug, tacrolimus, is a non-cytotoxic and
non-cytostatic drug. Tacrolimus prevents the growth of neointimal
hyperplasia and allows for better re-endothelialisation. Second, the
coating polymer is fully absorbable and minimises adverse effects
caused by the permanent presence of polymer. Third, the specially
designed biodegradable polymer can sustain longer drug release,
which allows a sufficient concentration of tacrolimus in coronary
arterial tissues for several months. Lastly, the stent strut thickness is
small, which may also contribute to reducing neointimal growth. 
The primary goal of the next generation of DES is no longer the 
complete inhibition of neointimal hyperplasia but the restitution of a
healthy, functionally active endothelial lining capable of modulating
the healing process, in order to prevent potential drawbacks of DES,
such as stent thrombosis. The MAHOROBA™ is a second genera-
tion of DES, which aims to address these issues. To evaluate the
safety and efficacy of the MAHOROBA™ stent in humans, the first-
in-man study, which is a prospective, single-armed, multicentre,
core lab analysis study, will be launched in May 2007. 
Study name: MAHOROBA I
Study P.I.: Patrick W. Serruys
Enrolment: 45 patients
Primary endpoint: In-stent late luminal loss at 4 and 12 months
Clinical site: 3 clinical sites in The Netherlands
Thoraxcenter/ Rotterdam (P.W. Serruys, P.I.)
Medisch centrum Rijnmond-Zuid/Rotterdam (P. Smits, P.I.);
Amphia Ziekenhuis/ Breda (P. den Heijer, P.I.)
Core Lab: Cardialysis/ Rotterdam, The Netherlands (Angio/ IVUS/
OCT/ MSCT)
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Figure 6. Representative scanning electron microscopy images from
MAHOROBA™ at low and high power magnification. 
MAHOROBA™ shows almost complete re-endothelialisation 14 days
after deployment (upper panel: low magnification). Stent struts are
almost completely covered by the endothelial cells and embedded in
the arterial wall. Black arrowheads indicate stent struts. Bottom panel
is a magnified image of the white box in the upper panel. Endothelial
junctions (white arrow head) are clearly visible.
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MAHOROBA, first-in-man study: 6-month
results of a biodegradable polymer sustained
release tacrolimus-eluting stent in de novo
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Aims To report the 4-month angiographic and 6-month clinical follow-up in first-in-man study using the tacrolimus-eluting
bioabsorbable polymer-coated cobalt–chromium MAHOROBATM stent.
Methods
and results
A total of 47 patients with either stable angina or unstable angina, or silent myocardial ischaemia, based on a de novo
coronary stenosis that could be covered by a single 18 mm stent in a native coronary artery with a diameter between
3.0 and 3.5 mm were enrolled at three sites. The primary endpoint was in-stent late loss at 4 months. The secondary
endpoints include %volume obstruction of the stents assessed by intravascular ultrasound (IVUS) at 4 months and
major adverse cardiac events (MACE) at 6 months. Forty-seven patients were enrolled. Procedural success was
achieved in 97.9%. At 4-month follow-up, in-stent late loss was 0.99+0.46 mm, whereas in-stent %volume obstruc-
tion in IVUS was 34.8+15.8%. At 6 months, there were no deaths, but 2 patients suffered from a myocardial infarc-
tion and 11 patients required ischaemia-driven repeat revascularization. The composite MACE rate was 23.4%.
Conclusion This tacrolimus-eluting stent failed to prevent neointimal hyperplasia, despite the theoretical advantages of the tacro-
limus, which has less inhibitory effects on endothelial cells than smooth muscle cells.
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Keywords Tacrolimus-eluting stent † First-in-man study † Drug-eluting stent † Coronary artery disease
Introduction
Sirolimus-eluting stents (SESs) and paclitaxel-eluting stents (PESs)
have markedly reduced the rate of in-stent restenosis and late
lumen loss compared with bare-metal stents (BMSs),1 resulting in
a significant reduction in repeat revascularizations. Accordingly,
percutaneous coronary intervention (PCI) using drug-eluting
stents (DESs) has been accepted as the most effective treatment
option for de novo coronary artery disease.
However, enthusiasm for this technology has recently been
dampened by concerns about late stent thrombosis, an
event often associated with lethal consequences. Delayed
re-endothelialization after DES has been suggested as one of the
plausible causes of late stent thrombosis.2–4 Pathological autopsy
studies also support the hypothesis of delayed endothelialization,
showing an association between lack of neointimal strut coverage
after DES implantation and stent thrombosis. Localized hypersen-
sitivity reactions to the durable polymer coating and/or to the drug
† This article has not been published and is not under consideration elsewhere.
* Corresponding author. Tel: þ31 10 4635260, Fax: þ31 10 4369154, Email: p.w.j.c.serruys@erasmusmc.nl
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org.
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itself may also theoretically add to stent thrombosis.5 Furthermore,
endothelial dysfunction after DES has lately attracted considerable
attention. Recent reports suggest that DES may impair endothelial
responses to acetylcholine or exercise-mediated vasodilation in
humans.6,7
Tacrolimus is a macrolide immunosuppressant drug licensed for
prophylaxis of rejection in recipients of organ transplantation.8 The
intracellular receptors are the FK binding proteins (FKBP, including
FKBP12): the tacrolimus–FKBP complex binds to inhibit the calci-
neurin–calmodulin complex,8 which suppresses proliferation of
T-cells, smooth muscle cells (SMCs), and endothelial cells (ECs).
Tacrolimus has a much less inhibitory effect on SMC and EC
than sirolimus, but tacrolimus depresses EC less than SMC.9–11
These results suggest that tacrolimus may allow better
re-endothelialization than sirolimus if proper concentrations for
suppressing SMC proliferation are used. Furthermore, unlike siro-
limus or paclitaxel, tacrolimus does not affect the tissue factor and
e-NOS expression, which might attenuate the risk of stent
thrombosis.12,13
A poly D, L-lactide-co-glycolide (PLGA) polymer with sustained
drug release for several months was employed to maintain high
tissue concentration of tacrolimus. This polymer coating is fully
absorbable and theoretically minimizes adverse effect, such as
possible hypersensitivity reactions, caused by the permanent
presence of a durable polymer. In a porcine model, the
MAHOROBA stent (Kaneka, Osaka, Japan) demonstrated early
re-endothelialization and reduction of neointimal thickening up
to 90 days after the implantation.14 Conversely, it has yet to be
demonstrated that the biodegradation of the polymer in human
atherosclerotic vessels does not in itself induce an inflammatory
and proliferative response.
The objective of the MAHOROBA I, first-in-man (FIM) study
was to test the safety and feasibility of the MAHOROBATM stent
to treat de novo coronary lesions.
Methods
Study design and patient selection
The study enrolled 47 patients at three participating sites in The
Netherlands. The local Ethics Committee approved the protocol for
each study site, and all patients gave written informed consent before
the procedure. Patients over 18 years of age were eligible, provided
they had stable angina, unstable angina, or silent myocardial ischaemia
with a de novo coronary artery lesion with .50 and 100% stenosis of
a length that could be covered by a single 18 mm stent with a diameter
between 3.0 and 3.5 mm in one or two major epicardial arteries. The
second lesion should fit with inclusion/exclusion criteria and be
treated with the same study stent. Patients were not eligible for enrol-
ments if they had an evolving acute myocardial infarction (MI) within
72 h, renal dysfunction (serum creatinine.2.0 mg/dL), a total occlusion
with a TIMI flow of 0 or 1, low left ventricular ejection fraction (,30%),
a platelet count of ,100 000 cells/mm3 or .700 000 cells/mm3, a
white blood cell count of ,3000 cells/mm3, previous drug-eluting or
BMS implantation in the target vessel, a target lesion supplied by an
arterial or venous bypass graft, a heavily calcified lesion, a bifurcation
lesion involving a side branch .2.0 mm in diameter with an ostial
disease, unprotected left-main disease, planned PCI within 60 days
after trial stent implantation, planned surgery within 6 months after
stent implantation, stroke or transient ischaemic attack within the
prior 6 months, a known allergy to aspirin, clopidogrel, cobalt–chro-
mium alloy, heparin, tacrolimus (or similar drugs), or contrast agents
that cannot be adequately premedicated.
The MAHOROBA stent
The MAHOROBA tacrolimus-eluting stent (TES) comprises a
drug-eluting PLGA coating and a cobalt–chromium (CoCr) stent
with a strut thickness of 75 mm, as previously described.15 The stent
has an open-cellular balloon-expandable design and consists of two
helical coils inter-crossed with two phase-different links on each
turn, in which each link deviates diagonally along the longitudinal axis
(Figure 1). The entire abluminal surface of the stent is coated with a
fully biodegradable PLGA polymer matrix. The molecular weight of
the PLGA polymer was 84 000 Da. The mass ratio of the drug and
polymer was 20.6 and 79.4 wt%, respectively. The dose density of
tacrolimus and the polymer was 0.94 and 3.58 mg/mm2, respectively.
The purity of the polymer was over 99.9%. The PLGA polymer was
proven by compliance with the ISO 10093s. In the porcine artery
model, the PLGA degrades and disappears completely in 6
months.16 Tacrolimus is released continually for several months and
completely resolves with PLGA degradation.
Study procedure
Lesions were treated using standard interventional techniques with
mandatory pre-dilatation prior to stent implantation. The following
sizes of MAHOROBA stent were used in the study: 18 mm length
and either 3.0 or 3.5 mm diameter. Intravascular ultrasound (IVUS)
was performed after angiographically optimal stent placement and
was repeated if additional post-dilatation was required. Treatment
Figure 1 (A) A photograph of MAHOROBA tacrolimus-eluting
stent. (B) A schematic view of the stent structure. Two helical
coils inter-cross with two phase-different links. Blue circles and
arrows indicate that each link deviates diagonally along the longi-
tudinal axis.
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with aspirin, at a minimal dose of 100 mg per day, was started prior to
procedure and continued indefinitely. A loading dose of 300 mg of clo-
pidogrel was administered at least 6 h before the procedure, followed
by 75 mg daily for at least 13 months.
Follow-up
Patients were evaluated clinically at 30 days and 4 months with further
evaluation scheduled at 9 and 12 months followed by annual evaluation
out to 5 years: patients were asked specific questions about major
cardiac adverse events and the interim development of angina accord-
ing to the Canadian Cardiovascular Society classification of stable
angina. Angiographic and IVUS evaluations were performed at
4 months.
Quantitative coronary angiography
Quantitative coronary angiography (QCA) analyses were performed
by a corelab (Cardialysis B.V., Rotterdam, The Netherlands) with
the CAAS II analysis software (Pie Medical B.V., Maastricht, The
Netherlands). In each patient, the stented segment and the peri-stent
segments defined by a length of 5 mm proximal and distal to the
stent edge were analysed. The following QCA parameters were com-
puted: minimal luminal diameter (MLD), reference diameter obtained
by an interpolated method, and percentage diameter stenosis. Binary
restenosis was defined in every segment (proximal, distal, and stent)
as diameter stenosis 50% at follow-up. Stent-to-artery ratio was
calculated as a mean diameter of the last balloon at the highest
pressure divided by the baseline reference vessel diameter. Late
loss was defined as the difference between MLD post-procedure
and MLD at follow-up. Results are presented as means using
matched pair of angiographic views using multiple X-ray views.
For the assessment of acute stent recoil, two sequential angio-
graphic images were analysed: first an image of the complete expansion
of the largest balloon at the highest pressure, whereas the second was
an image immediately after the final balloon deflation. These two
images were analysed in the same angiographic projection. When
the stent delivery balloon was used for stent expansion, QCA
measurements were performed between the markers of the stent
delivery balloon and within the deployed stent markers. Acute stent
recoil was calculated as previously described.17–19
Intravascular ultrasound
All cases were imaged with a 2.5 F Atlantis SR pro imaging 40 MHz
catheter (Boston Scientific, Santa Clara, CA, USA). Post-procedure
and at follow-up, stented culprit vessel segments were examined
with mechanical IVUS using automated pullback at 0.5 mm per
second. The coronary segment was examined by IVUS beginning
5 mm distal to and extending 5 mm proximal to the stented
segment. A validated offline quantitative computer-based IVUS soft-
ware was used for semi-automated three-dimensional reconstruction
and analysis (CURAD Vessel analysis, Wijk bij Duurstede, The
Netherlands).20 The lumen, stent boundaries, and the external
elastic membrane were detected in longitudinal reconstructed views.
In order to obtain a smooth appearance of the vessel wall structures
in the longitudinal views, a retrospective image-based gating method
was applied (e.g. IntelligateTM).21
The volumetric parameters of the stent, lumen, and obstruction
[e.g. neointima hyperplasia (NIH)] volume and percentages were
calculated as:
Stent Volume ¼
Xn
i¼1
ðStent AreaðiÞÞ  H;
where Stent_Area(i) is the stent area in one of the cross-sections of
the stent, n the number of cross-sections, and H the distance
between two consecutive cross-sections.
Lumen Volume ¼
Xn
i¼1
ðLumen AreaðiÞÞ  H;
where Lumen_Area(i) is the lumen area in one of the cross-sections of
the stent. The other parameters are similar as described in the above
formula.
NIH Volume ¼
Xn
i¼1
ðStent AreaðiÞ  Lumen AreaðiÞÞ  H;
where Stent_Area(i) is the stent area in one of the cross-sections of
the stent, Lumen_Area(i) the lumen area in the same, and the other
parameters are similar as described in the above formula.
%NIH Obstruction ¼ NIH Volume
Stent Volume
 100%:
Incomplete apposition was defined as one or more stent struts separ-
ated from the vessel wall with evidence of blood speckles behind the
strut by ultrasound, whereas late acquired incomplete apposition was
defined as incomplete apposition of the stent at 4-month follow-up
which was not present at post-procedure.
Clinical endoint definitions
Target vessel (or lesion) revascularization was considered to be
ischaemia-driven if the target vessel (or lesion) diameter stenosis
50% by core laboratory quantitative analysis with ischaemic symp-
toms or with objective signs of ischaemia at rest or during exercise
test, or a target vessel (or lesion) diameter stenosis 70% with or
without documented ischaemia. Major adverse cardiac events
(MACE) was defined as the composite of cardiac death, any MI, or
ischaemia-driven target lesion revascularization (TLR). Spontaneous
MI was defined as either a typical rise and gradual fall (Troponin) or
more rapid rise and fall (CK-MB) of biochemical markers of myocardial
necrosis with ischaemic symptoms, development of new pathological
Q-waves on the ECG or ECG changes indicative of ischaemia, or
pathological findings of an acute MI, or development of new pathologi-
cal Q-waves on follow-up ECG in the absence of cardiac biomarker
assessment during the acute event.22 Stent thrombosis was prospec-
tively adjudicated using the Academic Research Consortium defi-
nitions.23 Definite stent thrombosis is considered to have occurred
by either angiographic or pathological confirmation of thrombosis.
Study endpoints
The primary study endpoint was in-stent late loss at 4 months as
measured by QCA. Angiographic secondary endpoints include
in-segment late loss, binary restenosis rate, percentage diameter steno-
sis, and proximal and distal late loss at 4 months. Secondary IVUS end-
points at 4 months include minimal lumen area, stent volume, luminal
volume, intrastent neointimal volume, %volume obstruction, incomplete
stent apposition, and plaque volume behind the stent struts. Secondary
clinical endpoints at 6 months included all-cause death, MI, coronary
artery bypass surgery, TLR, definite stent thrombosis, and MACE.23
Statistical analysis
Continuous variables are presented as means+ standard deviation,
and categorical variables are presented as counts and percentages.
Paired comparisons between post-procedure and 4-month follow-up
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were done by a Wilcoxon’s signed rank test. All statistical tests were
two-tailed and a P-value of ,0.05 was considered as statistically signifi-
cant. The current study is a FIM and single-arm study, and was designed
to provide preliminary hypothesis-generating observations for further
studies. The sample size was not defined on the basis of an endpoint
hypothesis but rather to provide some information about the device
efficacy and safety. The sample size requirement was established by
the assessment of the minimum number of patients needed to
provide reliable and non-trivial results, but is in range of the test
group of the FIM trials of the SES (n ¼ 45).24,25 Statistical analysis
was performed with SAS 8.2 (SAS Institute Inc., NC, USA).
The role of funding source
The study was sponsored by Kaneka (Osaka, Japan). In collaboration
with the investigators, the sponsor designed the study. Data collection
and data analysis were done by an independent clinical research organ-
ization (Cardialysis B.V.). The sponsor had no role in data interpret-
ation or writing of the report. The corresponding author had full
access to all the data in the study and had final responsibility for the
decision to submit for publication.
Results
Patient characteristics
Forty-seven patients were included between May 2007 and
November 2007. The baseline clinical characteristics are presented
in Table 1. The average age of the patients was 61.1+9.4 years,
whereas 19.1% were diabetic and 66.0% were male. Procedure
success was 97.9% since, in one patient, the MAHOROBA stent
did not cross the lesion due to severe calcification. Since the
follow-up is planned up to 5 years, the follow-up will be accom-
plished in November 2012.
Quantitative coronary angiography
analysis
Angiographic follow-up at 4 months was achieved in 41 patients
(Figure 2). The angiographic parameters with matched pair analysis
for phase and projection at baseline, post-procedural, and
follow-up angiography (n ¼ 37) are presented in Table 2. Table 3
presents the results of QCA parameters related to acute stent
recoil assessment. Acute absolute recoil was 0.22+ 0.20 mm. At
4 months, the mean in-stent late loss, in-stent percentage diameter
stenosis, and the rate of binary angiographic restenosis were
0.99+0.46 mm, 38.66+20.79%, and 26.7%, respectively.
Figure 3 demonstrates the cumulative frequency of in-stent MLD
immediately after the index procedure and after 4 months.
Intravascular ultrasound evaluation
At 4 months, IVUS evaluation was performed in 40 patients. The
results are tabulated in Table 4. A significant reduction of luminal
volume was observed (187.4+93.4 mm3 at post-procedure vs.
123.5+67.2 mm3 at follow-up, P, 0.0001) with %volumetric
obstruction of 34.78+15.76%.
Incomplete stent strut apposition at baseline was reported in 16
of 46 (34.8%) patients, and this was resolved in 10 and persisted in
7 patients at 4-month. There were three cases of late acquired
incomplete apposition based on the IVUS definition of
malapposition of at least one stent strut separated from the
vessel wall. According to a methodology, previously reported by
our group, the malapposed volume at follow-up was 3.99 mm3 in
median (inter-quartile range 1.88–7.39).26
Major adverse cardiac events
Major adverse cardiac events are listed in Table 5. There were two
cases of MI: one patient suffered a non-Q-wave MI at 64 days after
the implantation of one MAHOROBA stent in the proximal left
anterior descending artery, whereas the other experienced a
non-Q-wave MI at 4 days after the procedure with angiographically
proven definite stent thrombosis in the proximal left circumflex.
Both patients were taking dual antiplatelet therapy at the time of
MI. The latter patient experienced second TLR at 124 days due to
restenosis of the MAHOROBA stent. There were other nine
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Table 1 Baseline clinical, lesion, and procedural
characteristics
Patient (n) 47
Male [n (%)] 31 (66)
Age (years+ SD) 61.1+9.4
BMI (kg/m2+ SD) 28.2+3.5
Cardiovascular risk
Diabetes mellitus [n (%)] 9 (19.1)
Current smoker [n (%)] 14 (29.8)
Hypercholesterolaemia [n (%)] 34 (72.3)
Family history of CAD [n (%)] 27 (57.4)
Hypertensive [n (%)] 24 (51.1)
Previous MI [n (%)] 12 (25.5)
Previous CABG [n (%)] 2 (4.3)
Prior PCI [n (%)] 5 (10.6)
Anginal status [n (%)]
Silent ischaemia 3 (6.4)
Stable angina 38 (80.9)
Unstable angina 6 (12.8)
Target vessel [n (%)]
Left anterior descending artery 20 (40.8)
Left circumflex artery 12 (24.5)
Right coronary artery 16 (32.7)
AHA/ACC lesion classification [n (%)]
A 1 (2.1)
B1 23 (48.9)
B2 22 (46.8)
C 1 (2.1)
Reference vessel diameter (mm+ SD) 2.76+0.46
Lesion length (mm+ SD) 11.69+5.36
Minimal lumen diameter (mm+ SD) 1.09+0.36
Stent/artery ratio (mean+ SD) 1.17+0.15
Maximal inflation pressure (atm+ SD) 16.3+3.00
SD, standard deviation; BMI, body mass index; CAD, coronary artery disease; MI,
myocardial infarction; CABG, coronary artery bypass graft; PCI, percutaneous
coronary intervention.
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cases of ischaemia-driven TLR (ID-TLR). In total, MACE rate
(cardiac death, target-vessel MI, or ID-TLR) at 6 months is 23.4%
(11/47).
Discussion
The efficacy of tacrolimus in inhibiting neointimal proliferation has
been demonstrated in preclinical studies. Wieneke et al.27 in an
in vivo study using rabbit iliac artery model demonstrated that
TESs coated with a nanoporous layer of aluminium oxide resulted
in a significant reduction of neointimal thickness (NIT) by 50% with
a total dose of 60 mg of tacrolimus and 56% for a dose of 120 mg of
tacrolimus, when compared with BMS. In the in vivo study by
Kollum et al.28 using a swine model of restenosis, TES (JOMED,
Rangendingen, Germany) with a nanoporous ceramic aluminium
Figure 2 Study profile.
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Table 2 Results of quantitative coronary angiographic
analysis in matched pairs (n 5 37)
Variables In-stent In-segment
Reference vessel diameter (mm)
After procedure 2.94+0.41 2.90+0.43
At 4 months 2.57+0.48 2.57+0.48
Minimal luminal diameter (mm)
After procedure 2.57+0.36 2.27+0.46
At 4 months 1.58+0.63 1.55+0.62
P-value ,0.0001 ,0.0001
Late loss (mm) 0.99+0.46 0.72+0.51
Diameter stenosis (%)
After procedure 12.50+5.73 21.54+8.75
At 4 months 38.66+20.79 40.00+20.29
P-value ,0.0001 ,0.0001
Binary restenosis rate at 4
monthsa (%)
26.7 26.7
aBinary restenosis was calculated based on the unmatched data.
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Table 3 Angiographic parameters related to acute
stent recoil assessment (n 5 40)
Variables
Mean diameter of balloon at the highest pressure (mm) 3.17+0.32
Mean diameter of stent immediately after balloon
inflation (mm)
2.95+0.37
Acute absolute recoil (mm) 0.22+0.20
Acute per cent recoil (%) 7.11+6.18
Figure 3 Cumulative frequency distribution curves of %
minimal luminal diameter at pre-procedure, post-procedure,
and follow-up.
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oxide coating at a dose of 180 mg demonstrated a significant inhibi-
tory effect on neointimal proliferation. However, the inhibitory
effect on restenosis was counteracted by inflammatory reaction
due to major particle debris as a result of cracking of the
ceramic coating.
After these preclinical studies, two clinical trials were performed
using a TES with a biocompatible and non-thrombogenic
carbofilmTM coating (Janus; Sorin Biomedica Cardio, Italy). In the
‘FIM’ study using the Janus stent loaded with a 1.5 mg/mm2 of tacro-
limus, TES was associated with a 3.8% binary restenosis rate at the
6-month follow-up in non-diabetics and 16.9% in diabetics.29 After
increasing the dose of TES from 1.5 to 2.3 mg/mm2, the investigators
performed a randomized trial including 332 patients to compare the
performance of the TES with that of the BMS. The free drug—not
incorporated in polymer or excipient—was released from wells
carved in the abluminal side of the stent. No differences in angio-
graphic results were observed at 6-month (in-stent late luminal
loss; TES 0.65+0.47 vs. BMS 0.66+0.53 mm), and the 12-month
MACE rates of TES were not lower than BMS (19.5 vs. 16.1%).30
The MAHOROBA strut has its own design with no previous clini-
cal use and its mechanical performances were evaluated in this FIM
study. Acute recoil analysis by QCA suggests that the MAHOROBA
stent may have a relatively weaker radial strength than contempor-
ary metallic DESs; the absolute recoil of MAHOROBA was 0.22+
0.20 mm, whereas % relative recoil was 7.11+6.18%. Different
methodologies of recoil assessment render comparison between
different stents difficult. However, recent analysis by an independent
clinical research organization (Cardialysis B.V.) provides us with
comparative recoil analysis of a CoCr everolimus-eluting stent and
the MAHOROBA stent employing the same methodology. Accord-
ing to the results, the acute recoil of the MAHOROBA seems to be
higher, although stent oversizing can affect the results.15
The MAHOROBA stent is characterized by a biodegradable
polylactic-co-glycolic acid coating with a bioabsorption time of
about 6 months, resulting in a long-term sustained release of the
drug. Although the MAHOROBA stent was used in patients with
favourable characteristics and simple lesion, angiographic follow-up
at 4 months demonstrated a mean in-stent late loss of 0.99 mm,
which is equivalent or even slightly higher than the late loss
observed in historical series with BMSs.
The reason for the absence of neointimal inhibition in MAHOR-
OBA may be multifactorial: first of all, contrary to the mode of
action of sirolimus and its analogues that inhibit mTOR and sub-
sequently up-regulate p27, tacrolimus acts through different
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 4 Intravascular ultrasound measurements in matched pairs at post-procedural and 4 months follow-up (n5 42)
Post Follow-up P-value
Vessel volume (mm3) (mean+ SD) 350.1+170.7 377.2+175.9 0.0002
Stent volume (mm3) (mean+ SD) 188.6+98.7 190.7+100.7 0.316
Luminal volume (mm3) (mean+ SD) 187.4+93.4 123.5+67.2 ,0.0001
Plaque volume behind stents (mm3) (mean+ SD) 165.1+75.9 186.48+81.87 ,0.0001
Intimal hyperplasia volume (mm3) (mean+ SD) 67.23+48.36
In-stent volume obstruction (%) (mean+ SD) 34.78+15.76
Frequency of ISA (%)a 34.8 21.4
Resolved ISA at follow-up [n (%)] 10 (50)
Persisting ISA at follow-up [n (%)] 7 (35)
Late acquired ISA at follow-up [n (%)] 3 (15)
ISA volume (mm3) [median (inter-quartile range)] 2.69 (2.12–7.03) 3.99 (1.88–7.39)
SD, standard deviation; ISA, incomplete stent apposition.
aFrequency of ISA was calculated as number of patients with at least one strut with incomplete stent apposition divided by the total number of patients.
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Table 5 Adverse cardiac events at 6 months
(per-patient analysis)
Event n %
All-cause death 0 0
Cardiac death 0 0
Stroke 0 0
Myocardial infarction 2 4.3
Target vessel 2 4.3
Non-target vessel 0 0
Cardiac death, stroke, or myocardial infarction 2 4.3
Repeat PCI–ID-TLRa 11 23.4
Repeat PCI–non-ID-TLRb 1 1
Repeat PCI–TVR 0 0
CABG 0 0
MACE (cardiac death, target-vessel myocardial infarction,
or ID-TLR)
11 23.4
Definite stent thrombosis 1 2.1
MACE, major adverse cardiac events; ID-TLR, ischaemia-driven target lesion
revascularization; Non-ID-TLR, non-ischaemia-driven target lesion
revascularization; TVR, target vessel revascularization; PCI, percutaneous
coronary intervention; CABG, coronary artery bypass graft.
aOne patient experienced ID-TLR twice, but counted as one.
bOne patient experienced both ID-TLR and non-ID-TLR.
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pathways and involves the calcineurin–calmodulin complex.
Therefore, its mode of inhibition of SMC proliferation is fundamen-
tally different from sirolimus, and redundancy of signalling pathways
for cell growth may supersede the specific inhibitory effect of
tacrolimus. Pimecrolimus, a tacrolimus analogue might not only
fail to inhibit but might also even promote further neointimal
hyperplasia. In the recent prospective, three-arm, GENESIS study
randomizing patients with de novo coronary artery disease either
to paclitaxel-eluting (10 mg) or pimecrolimus/paclitaxel
dual-eluting (162.5/10 mg) or pimecrolimus-eluting stent
(325 mg), the pimecrolimus-eluting stent demonstrated the
highest in-stent late loss (paclitaxel 0.58+ 0.58 vs. paclitaxel/pime-
crolimus 0.96+0.73 vs. pimecrolimus 1.40+ 0.67 mm) with the
highest target vessel revascularization rate (2.0 vs. 14.4 vs.
35.0%) at 6-month.31 Therefore, the GENESIS study was sus-
pended before complete enrolment was achieved. Taking these
results into consideration, tacrolimus and its analogue might not
be a suitable drug to prevent the restenosis even though efficacy
in neointimal inhibition of neointima had been demonstrated in
the animal studies. Secondly, the relatively low intra-parietal con-
centration during elution may be insufficient to effectively inhibit
neointimal hyperplasia. Matter et al.11 demonstrated that in
human saphenous vein cells, the IC50 of sirolimus to inhibit pro-
liferation of vascular SMC was 4.1  1029 mol/L, whereas the IC
of tacrolimus was 0.38  1026 mol/L. In the study by Mohacsi
et al.10 using human thoracic aorta, IC50 of sirolimus and tacroli-
mus was 1–10  1029 and 1  1026, respectively. These results
suggest that a100- to 1000-fold higher tissue concentration of
tacrolimus is necessary to exert the same neointimal inhibition
as a SES. The MAHOROBA stent has a tissue concentration
with a peak value of around 130 ng/mg artery (Figure 4), whereas
Cypher is around 6 ng/mg artery32 in animal models. The concen-
tration of tacrolimus may therefore still be too low to achieve suf-
ficient neointimal inhibition, although it is about 20 times higher
than the SES. Recently, in a porcine coronary study, van Beusekom
et al. assessed neointimal thickening after the implantation of a
BMS, polymer-coated stent (Pol) without drug, a slow degrading
low dose (1 mg/mm2) TES, and a fast degrading high-dose (2 mg/
mm2) TES. The low-dose TES is similar to the MAHOROBA
stent. Morphometry indicated that NIT in both TES was signifi-
cantly reduced when compared with BMS and Pol up to 90 days
(BMS: 335+148; pol: 381+ 186; low-dose TES: 226+ 52; and
high-dose TES: 262+80 mm). However, at 180 days, only the
high-dose TES showed significantly lower NIT when compared
with BMS or Pol stent because the slow degrading low-dose TES
demonstrated catch-up of NIT between 90 and 180 days. There-
fore, the inhibitory effect of low-dose TES (equal to MAHOROBA
stent) on neointimal hyperplasia was somewhat suboptimal in the
animal study, and high-dose TES might be optimal for DES. Thirdly,
remnant polymer after complete elution of the drug could to some
extent continue to stimulate neointimal growth in the stent. In a
porcine model, the polymer of the MAHOROBA stent continues
to be degraded up to 110 days but possibly without sufficient
tacrolimus beyond 90 days to dampen the tissue response.30
Fourthly, the rate of incomplete stent apposition appears high at
35% in this study, although it is still in the range of previous
study.33 The lack of proper elution of the drug at the abluminal
side might be a potential explanation for the large presence of
neointimal hyperplasia observed in this study.
Modification in the dose and release of tacrolimus might be
mandatory to create an effective TES. Figure 4 shows the tissue
concentration of tacrolimus in TES with different doses. Conver-
sely, the MAHOROBA demonstrates the ability to maintain
tissue concentrations for longer periods, but in the first 2 weeks
is unable to attain sufficient concentration that are considered ade-
quate for neointimal inhibition after stenting. Theoretically, a
biphasic-release TES with a burst phase in the first 2 weeks fol-
lowed by sustained release could have the ability to inhibit neoin-
timal proliferation. A dual polymeric coating with rapid and slow
drug-eluting profiles might be necessary to achieve biphasic
release. An increased amount of polymer is indispensable to
contain higher dose of drug than current, which could result in a
thicker profile of the stent struts and a longer duration of absorp-
tion. It will be a technological challenge to develop a dual-coated
stent with thin struts and an improved polymer degradation
profile synchronized with drug release.
Intravascular ultrasound analysis in the current study demon-
strated a significant increase in the plaque behind the stent (PBS)
4 months after the procedure. In the PISCES study using PESs
with a durable PGLA polymer coating, specially designed for
drug delivery with programmable pharmacokinetics, a significant
increase in PBS at 4-month was reported in paclitaxel-loaded
stents with equal or longer elution than 10 days, but not in-stents
with a short elution of 5 days.34 These results suggest that the
long-term presence of either drugs or PGLA polymer might
cause extensive remodelling after stent implantation, presumably
resulting from vessel inflammation. Also in the study using
PESs,35 a significantly increased peri-stent area was observed at 6
months. However, sirolimus36 or everolimus-eluting stents26 with
durable polymers, this effect on positive vascular remodelling has
not been reported.
The current study has several limitations. The angiographic and
IVUS follow-up were only performed at 4 months, which might be
Figure 4 Comparison of release curves in MAHOROBA stent
(1 mg/mm2, orange), high-dose tacrolimus-eluting stent (2 mg/
mm2, pink), and ideal curve (light blue).
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too short to assess the full extent of neointimal hyperplasia after
DES implantation. At the time of the study design, further invasive
imaging with angiography and IVUS was planned in the protocol at
12 months to assess the full process of neointimal hyperplasia.
However, after evidencing high amounts of neointimal hyperplasia
with high rates of ischaemic TLR events at 4 months, the protocol
was amended by the data safety monitoring board for safety
reasons. It was decided to monitor patients more carefully with
non-invasive stress ECG testing at 6 months and 9 months. Since
the scientific goal had not been achieved, the invasive angiography
originally planned at 12 months for scientific purposes was aban-
doned, and angiographic follow-up after 4 months was only per-
formed for clinical reasons. Frequency of incomplete stent
apposition was as high as 34.5%. The rate of malapposition,
however, was calculated as the number of patients with at least
one strut with incomplete stent apposition divided by the total
number of patients and does not reflect the number of malap-
posed strut or the malapposed volume. This study did not
mandate IVUS-guided stenting, so that post-dilation was comple-
tely left to the operators’ discretion. In addition, given the relatively
high stent malapposition rate and % acute recoil, it is difficult to
know how much each component of the stent (i.e. polymer,
stent platform and drug) could contribute to the failure of
this DES.
Despite the conceptual advantages of using tacrolimus with a
biodegradable polymer, this FIM study has failed to establish the
effectiveness of this stent. Taking the multifactorial reasons of
failure into consideration, tacrolimus formulation of the current
stent seems unsuitable to prevent restenosis. Technical improve-
ments enable us to construct TES with a higher drug content
and improved polymer degradation profile in synchronization
with drug release.
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Comparison of In Vivo Acute Stent Recoil Between
the Bioabsorbable Everolimus-Eluting Coronary
Stent and the Everolimus-Eluting Cobalt
Chromium Coronary Stent: Insights From
the ABSORB and SPIRIT Trials
Shuzou Tanimoto,1 MD, Patrick W. Serruys,1* MD, PhD, Leif Thuesen,2 MD,
Dariusz Dudek,3 MD, Bernard de Bruyne,4 MD, PhD,
Bernard Chevalier,5 MD, and John A. Ormiston,6 MBChB
Objectives: This study sought to evaluate and compare in vivo acute stent recoil of a
novel bioabsorbable stent and a metallic stent. Background: The bioabsorbable ever-
olimus-eluting coronary stent (BVS) is composed of a poly-L-lactic acid backbone,
coated with a bioabsorbable polymer containing the antiproliferative drug, everolimus,
and expected to be totally metabolized and absorbed in the human body. Because
the BVS is made from polymer, it may have more acute recoil than metallic stents in
vivo. Methods: A total of 54 patients, who underwent elective stent implantation for sin-
gle de novo native coronary artery lesions, were enrolled: 27 patients treated with the BVS
and 27 patients treated with the everolimus-eluting cobalt chromium stent (EES). Acute abso-
lute recoil, assessed by quantitative coronary angiography, was defined as the difference
between mean diameter of the last inflated balloon at the highest pressure (X) and mean
lumen diameter of the stent immediately after the last balloon deflation (Y). Acute percent
recoil was defined as (X – Y)/X and expressed as a percentage. Results: Acute absolute
recoil of the BVS and EES was 0.20 6 0.21 mm and 0.13 6 0.21 mm, respectively (P =
0.32). Acute percent recoil was 6.9% 6 7.0% in the BVS group and 4.3% 6 7.1% in the
EES group (P = 0.25). Conclusions: In vivo acute stent recoil of the BVS is slightly larger
but insignificantly different from that of the EES, implying that the BVS may have good ra-
dial strength similar to the metallic stent. ' 2007 Wiley-Liss, Inc.
Key words: bioabsorbable; coronary artery disease; recoil; stents
INTRODUCTION
Coronary stents have been used as standard mechan-
ical devices for percutaneous coronary intervention
(PCI) in the treatment of patients with coronary artery
disease (CAD) [1]. They provide vessel wall scaffold-
ing and prevent early elastic recoil and restenosis,
which are major limitations of balloon angioplasty.
Consequently, the use of coronary stents achieves high
success rates of PCI and improves the outcome of
CAD patients. However, because of the permanent na-
ture of metallic stents, their presence on the intimal
surface of a coronary artery poses risks associated with
a continuous interaction between the metal and the sur-
rounding tissue [2]. This can lead to long-term endo-
thelial dysfunction or chronic inflammation, and may
result in many potential concerns, such as in-stent neo-
intimal hyperplasia and thrombogenesis. The clinical
requirement of stents for vessel scaffolding is tempo-
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rary and limited to the time of the revascularization
and, shortly thereafter, until vascular healing and re-
endothelialization within the stented coronary segment
have taken place. Beyond this period, the advantage of
metallic stents diminishes. Indeed, when compared
with bare metal stents (BMS), drug-eluting stents
(DES) significantly reduce coronary restenosis by
applying an antiproliferative drug to inhibit the intimal
hyperplastic response [3,4]. However, once the drug is
eluted from DES, they behave like metallic stents. In
addition, as the drug itself inhibits endothelial function
[5] or normal vascular healing [6] or both, prolonged
antiplatelet therapy is required to prevent stent throm-
bosis in patients treated with DES [7,8].
In terms of the short-term need for vessel scaffold-
ing and avoidance of the potential long-term complica-
tions of metallic stents, bioabsorbable polymer stents
appear to be an ideal alternative candidate material.
Further, they can also be used as a vehicle for drug
delivery to target lesions. Conceptually, once they are
fully absorbed, only the healed vessels are left behind
with no residual prosthesis and, therefore, no potential
interactions with the coronary artery. Accordingly,
long-term antiplatelet therapy may not be warranted.
However, in quest for preventing acute vessel recoil,
there has been concern that polymer stents may not be
efficacious due to their intrinsic characteristics when
compared with metallic stents.
The bioabsorbable everolimus-eluting coronary stent
(BVS: developed by Bioabsorbable Vascular Solutions,
Mountain View, CA) is composed of a poly-L-lactic
acid (PLLA) backbone, coated with a bioabsorbable
polymer containing the antiproliferative drug everoli-
mus (Certican1, Novartis Pharmaceuticals Corpora-
tion, Basel, Switzerland). The ongoing first-in-
man trial (the ABSORB trial) assesses its safety and
feasibility in patients with CAD. In the present
study, we evaluated acute stent recoil of the BVS in
the ABSORB trial. In addition, using the SPIRIT clin-
ical trials as a control group, we compared the acute
stent recoil of the BVS and the XIENCE V everoli-
mus-eluting cobalt chromium stent (EES: manufac-
tured by Advanced Cardiovascular Systems, Santa
Clara, CA).
METHODS
Study Population
The ABSORB trial is a prospective, open-labeled,
multicenter (six clinical sites), first-in-man clinical
investigation of the BVS in patients with single de
novo native coronary artery lesions. It was approved
by the ethics committee at each participating institu-
tion, and all patients gave written informed consent.
Patients were eligible for the study if they were aged
above 18 years, with a diagnosis of stable or unstable
angina, or silent ischemia. Target lesions were selected
that could be covered with a single stent of 3.0 3
12 mm2 or 3.0 3 18 mm (i.e. 3.0 mm in diameter by
visual estimation, less than 8 mm or 14 mm in length)
and a stenosis of between 50% and 99% of luminal di-
ameter with a Thrombolysis in Myocardial Infarction
flow grade of 1 or more. Patients were ineligible if
they had any of the following: evolving myocardial in-
farction; left main coronary artery stenosis; an ostial
lesion; lesion located within 2 mm of a bifurcation;
lesion with moderate-to-heavy calcification by visual
assessment; angiographically visible thrombus within
the target lesion; a left ventricular ejection fraction of
less than 30%; candidate for heart transplant; known
hypersensitivity or contraindication to aspirin, heparin,
clopidogrel, everolimus, PLLA, or contrast sensitivity
that could not be adequately premedicated.
In order to compare the acute stent recoil of BVS and
metallic stents, we chose patients enrolled in the recently
completed SPIRIT trials as the control group. The SPIRIT
trials are planned to assess the safety and efficacy of the
EES in patients with CAD. To date, short-term follow-up
results of the SPIRIT FIRST trial [9,10] and the SPIRIT II
trial [11] have been reported. Both trials were prospective,
multicenter, single-blinded, randomized-controlled clinical
investigations in patients with the diagnosis of stable or
unstable angina, or silent ischemia and compared EES
with BMS (SPIRIT FIRST trial) or paclitaxel-eluting
stents (SPIRIT II trial). The study protocol of these two tri-
als has been reported previously [9,11]. Briefly, the
patients of the SPIRIT FIRST trial had a single de novo
native coronary stenosis of less than 12 mm lesion length,
covered by a single stent of 3.0 3 18 mm, more than
50% diameter stenosis, and a vessel reference diameter of
3.0 mm, as assessed by online quantitative coronary angi-
ography (QCA). In the SPIRIT II trial, eligibility criteria
were the presence of maximum two de novo native coro-
nary lesions, each located in a different major epicardial
coronary vessel. Stent sizes available were 2.5, 3.0, 3.5, or
4.0 mm in diameter and 8, 18, or 28 mm in length. Target
lesions were less than 28 mm length, covered by a single
stent or two overlapping stents, more than 50% diameter
stenosis, with the vessel reference diameter ranging from
2.5 to 4.25 mm as assessed by visual estimation. Exclusion
criteria of these two SPIRIT trials were similar to those of
the ABSORB trial.
Careful considerations were taken to select the control
group to adjust for target lesion characteristics, since sev-
eral differences in inclusion criteria existed and different
stent sizes were available among these three trials. Finally,
as the control group, we selected consecutive patients who
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received a single 3.0 3 18 mm EES for a single de novo
lesion from the SPIRIT FIRST and II trials.
Description of the Stent
The BVS is comprised of four main components:
the polymer stent backbone, the polymer drug reser-
voir, the antiproliferative drug everolimus, and the
delivery system. The polymer stent is balloon-expanda-
ble and is composed of a high-molecular-weight PLLA
backbone, with serpentine rings connected by links
(Fig. 1A and B). The stent body is coated with a ma-
trix of everolimus and poly-D,L-lactic acid (PDLLA) in
a 1:1 ratio. PLLA and PDLLA are fully metabolized
and totally absorbed in the human body. The BVS is
laser-cut from an extruded tube of the PLLA and has
two radio-opaque platinum markers on both ends of its
surface, to facilitate the identification of the prosthesis
(Fig. 1C). Two stent sizes are available: 3.0 3 12 mm
or 3.0 3 18 mm. The thickness of the stent struts is
0.150 mm (Fig. 1D). The stent itself is mounted on the
VISION RX balloon catheter, which has two radio-
opaque balloon markers, reflecting the expanded stent
length. These markers aid in positioning the stent fluo-
roscopically.
The EES has been described in detail previously [9].
Briefly, the EES is composed of the MULTI-LINK
VISION1 Stent (Abbott Vascular, Santa Clara, CA),
which is a balloon-expandable stent with serpentine
rings connected by links fabricated from a single piece
of medical grade L-605 cobalt chromium alloy, coated
with a durable polymer containing everolimus. The
morphological design of the EES is similar to that of
the BVS. The thickness of the strut is 0.081 mm. The
stent is mounted on the MULTILINK VISION1 bal-
loon catheter, which is identical to the BVS delivery
balloon catheter.
Study Procedure
All procedures were performed electively. Target
lesions were treated using standard interventional tech-
niques, with mandatory predilatation and stent deploy-
ment at a pressure not exceeding the rated burst pres-
sure (16 atm). Postdilatation with a balloon shorter
than the implanted stent was allowed at operator dis-
cretion if an optimal angiographic result was not
Fig. 1. Bioabsorbable everolimus-eluting coronary stent
(BVS). Panel A shows an overview of the stent. The black
arrow indicates a radio-opaque platinum marker on the sur-
face of the stent. Panel B is the magnified image of the stent.
The stent body is transparent. Two radio-opaque markers
(white arrows) on both ends of the stent are easily detected
by the fluoroscopy (Panel C), although the stent body is radio-
lucent. Optical coherence tomography can clearly indicate
stent struts as a unique box appearance (Panel D). The stent
strut thickness is 0.150 mm. In Panel E and F, multislice com-
puted tomography demonstrates that two radio-opaque
markers (white arrows) are clearly visible and the stent body
is invisible. [Color figure can be viewed in the online issue,
which is available at www.interscience.wiley.com.]
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obtained immediately after stent deployment. Bailout
stenting for edge dissection was permitted. During
PCI, intravenous boluses of heparin were administered
according to local practice. Treatment with aspirin was
started at least 24 hr before the procedure, and contin-
ued throughout the length of clinical investigation
in the ABSORB trial and for at least 1 year in the
SPIRIT trials. A loading dose of 300 mg of clopidog-
rel was administered before the procedure, followed by
75 mg daily for a minimum of 6 months in the
ABSORB and SPIRIT II trials and for 3 months in the
SPIRIT FIRST trial.
Quantitative Coronary Angiography Analysis
QCA was performed using the CAAS II analysis
system (Pie Medical BV, Maastricht, the Netherlands).
For each patient, the stented segment and the peri-stent
segment (defined by a length of 5 mm proximal and
distal to the stent edge) were analyzed. The following
QCA parameters were computed: minimal luminal di-
ameter (MLD), reference vessel diameter, and percent
diameter stenosis. In addition to the baseline and post-
PCI images, two images were analyzed for acute stent
recoil assessment in this study. One was an image of
complete expansion of the last balloon (either the stent
delivery balloon or the postdilatation balloon) at the
highest pressure (Image A, Figs. 2A and 3A). The
other was an image immediately after the last balloon
deflation (Image B, Figs. 2B and 3B). These two
images were analyzed in the same angiographic projec-
tion. The time interval between Images A and B was
usually less than 1 min. When the stent delivery bal-
loon was used for stent expansion, QCA measurement
was performed between the markers of the stent deliv-
ery balloon (Segment A) in Image A and within
the deployed stent markers (Segment B) in Image B.
In case a postdilatation balloon was used during the
procedure, the measurement was performed between
markers of the postdilatation balloon in Image A (Seg-
ment C) and within the segment area in Image B, where
the postdilatation balloon was placed and inflated (Seg-
ment D). When bailout stenting was performed and a
nonstudy stent overlapped with the study stent, only the
study stent segment was analyzed.
Acute Stent Recoil Assessment
Acute stent recoil was calculated as follows [12,13]:
(1) When the stent delivery balloon was used for stent
expansion, acute absolute stent recoil was defined as
the difference between mean diameter of the stent
delivery balloon at the highest pressure in the Segment
A (X) and mean luminal diameter in the Segment B (Y).
Acute percent stent recoil was defined as (X  Y)/X and
expressed as a percentage. (2) In case a postdilatation
balloon was used in the procedure, acute absolute recoil
was defined as the difference between mean diameter of
the postdilatation balloon at the highest pressure in Seg-
ment C (X0) and mean luminal diameter in Segment D
(Y0). Acute percent recoil was defined as (X0  Y0)/X0
and expressed as a percentage.
Fig. 2. Methodology of acute stent recoil assessment when
only the stent delivery balloon was used for stent expansion.
Image A is of complete expansion of the stent delivery bal-
loon. Image B is immediately after balloon deflation. In Image
A, analysis is performed between balloon markers (between
dotted lines; Segment A). In Image B, analysis is performed
within the stent markers (between dotted lines; Segment B).
These two images are analyzed in the same angiographic pro-
jection, so that segments A and B are well-matched. In this
case, the mean diameter of segments A and B are 3.10 and
2.83 mm, respectively. This corresponds to acute recoil of 0.27
mm or 8.7%. White solid lines indicate the minimum diameter
of the balloon or minimum lumen diameter within the analyzed
segment.
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Statistical Analysis
The analysis was performed on patients with analyz-
able angiographic images. Categorical variables were
presented as counts and percentages, and compared by
means of the Fisher’s exact test. Continuous variables
were presented as mean 6 standard deviation and
were compared using the Mann–Whitney U-test. A
value of P < 0.05 was considered statistically signifi-
cant. Statistical analysis was performed with SPSS
12.0.1 for Windows (SPSS, Chicago IL).
RESULTS
Patient Demographic and Lesion Characteristics
A total of 30 patients were enrolled in the ABSORB
trial between March 2006 and July 2006. Three of the
30 were excluded. In one patient, the stent did not
pass through the target lesion. This was a clinical de-
vice failure. In another patient, angiographic images
were not analyzable because there was no matched
view for acute stent recoil assessment. In the other
patient, catheter calibration was impossible. Hence, the
BVS group included 27 patients with 27 lesions. As
the 3.0 3 18 mm BVS was launched at the end of
enrollment, this stent size was deployed in only one
patient, with the other 26 patients receiving the 3.0 3
12 mm BVS.
In the SPIRIT FIRST and II trials, 89 patients (27
from the SPIRIT FIRST trial and 62 from the SPIRIT II
trial) were treated with a single EES of 3.0 3 18 mm
for a single de novo lesion. From this population, in
order to match the number of the patients in the BVS
group with that in the control group, we selected the
first 27 consecutive patients with successful EES im-
plantation and analyzable angiography for acute stent
recoil assessment. This control group consisted of 19
patients with 19 lesions from the SPIRIT FIRST trial
and 8 patients with 8 lesions from the SPIRIT II trial.
Clinical, angiographic, and procedural data are
shown in Table I. Both groups shared similar patient
demographics. Although neither American College of
Cardiology/American Heart Association lesion com-
plexity class type A nor C lesion was observed, lesion
complexity was greater in the EES group than in the
BVS group, but this difference did not reach the statis-
tical significance (P ¼ 0.10). Calcified lesions, identi-
fied by core laboratory and classified as moderate or
severe grade, tended to be more frequent in the BVS
group (30% vs. 15%, P ¼ 0.33). Stent-to-artery ratio
(defined as mean diameter of the last balloon at the
highest pressure divided by baseline reference vessel
diameter) and maximum balloon pressure during the
entire procedure showed no significant differences
between the groups.
QCA and Acute Stent Recoil Results
QCA assessments of pre- and post-PCI are shown in
Table II. Baseline results were similar between the
groups, except for the lesion length, which was rela-
Fig. 3. Methodology of acute stent recoil assessment when a
postdilatation balloon was used during the procedure. Image
A is of complete expansion of the postdilatation balloon.
Image B is immediately after balloon deflation. In the Image A,
analysis is performed between balloon markers (between
black dotted lines; Segment C). In the Image B, analysis is
performed within the stent in the same segment where the
postdilatation balloon was placed and inflated (between black
dotted lines; Segment D). These two images are analyzed in
the same angiographic projection, so that segments C and D
are well-matched. In this case, the mean diameter of seg-
ments C and D are 3.33 and 3.15 mm, respectively. This corre-
sponds to acute recoil of 0.18 mm or 5.4%. White solid lines
indicate the minimum diameter of the balloon or minimum
lumen diameter within the analyzed segment. White dotted
lines indicate the stented segment.
Acute recoil of bioabsorbable DES
111
tively longer in the EES group than in the BVS group
(10.5 6 2.7 mm vs. 9.1 6 3.9 mm, P ¼ 0.06). After
PCI, as compared to the EES group, the BVS group
had significantly smaller MLD (2.30 6 0.32 mm vs.
2.43 6 0.30 mm, P ¼ 0.03) and significantly larger
diameter stenosis (17.0% 6 7.4% vs. 11.3% 6 4.2%,
P ¼ 0.0003).
Table III presents the results of QCA parameters
related to acute stent recoil assessment. Acute absolute
and percent recoil of the BVS were higher than those
of the EES, but the differences did not reach statistical
significance (0.20 6 0.21 mm [95% CI: 0.11–0.28] vs.
0.13 6 0.21 mm [95% CI: 0.05–0.22], P ¼ 0.32;
6.9% 6 7.0% [95 % CI: 4.1–9.6] vs. 4.3% 6 7.1%
[95% CI: 1.5–7.1], P ¼ 0.25, respectively).
Relationship of Angiographic and Procedural
Variables With Acute Percent Stent Recoil
Table IV shows the relationship of angiographic and
procedural variables with the acute percent stent recoil.
For both groups, smaller reference vessel diameter
(<3.0 mm) and lower maximum balloon pressure
(16 atm) led to higher percent recoil, although no
statistical relationship was found. Stent oversizing
(stent-to-artery ratio  1.1) induced significantly
higher percent recoil of the EES (8.2% 6 4.1% vs.
0.3% 6 7.3%, P ¼ 0.0003), while this factor was
not correlated with acute stent recoil of the BVS (8.4%
6 5.7% vs. 5.9 6 7.6%, P ¼ 0.25). There was a trend
toward more recoil of the BVS in calcified lesions than
in noncalcified lesions (11.8% 6 4.3% vs. 6.0% 6
7.0%, P ¼ 0.06). However, this trend was equivocal in
the EES group (5.8% 6 7.2% in calcified lesions and
3.6% 6 7.5% in noncalcified lesions, P ¼ 0.52).
DISCUSSION
The principal finding from the present study is that
in selected patients, in vivo acute stent recoil of the
BVS is slightly larger, but not significantly different
from that of the EES.
TABLE I. Clinical, Angiographic, and Procedural
Characteristics
BVS
(N ¼ 27)
EES
(N ¼ 27) P value
Age (years) 62.5 6 9.2 63.7 6 9.6 0.53
Male, n (%) 15 (56) 16 (59) 1.0
Diabetes, n (%) 1 (4) 2 (7) 1.0
Hypertension, n (%) 19 (70) 20 (74) 1.0
Hypercholesterolemia, n (%) 21 (78) 17 (63) 0.37
Current smoking, n (%) 6 (22) 5 (19) 1.0
Prior myocardial infarction, n (%) 2 (7) 7 (26) 0.14
Lesion location, n (%)
Right coronary artery 6 (22) 9 (33) 0.54
Left anterior descending 13 (48) 12 (44) 1.0
Left circumflex artery 8 (30) 6 (22) 0.76
ACC/AHA lesion type, n (%)
Type A 0 (0) 0 (0) NA
Type B1 17 (63) 10 (37) 0.10
Type B2 10 (37) 17 (63) 0.10
Type C 0 (0) 0 (0) NA
Lesion calcification, n (%) 4 (15) 8 (30) 0.33
Stent/artery ratio 1.06 6 0.11 1.11 6 0.17 0.19
Maximum pressure (atm) 16.3 6 3.07 15.4 6 3.00 0.24
ACC/AHA, American College of Cardiology/American Heart Associa-
tion; NA, not applicable.
TABLE II. Angiographic Results at Pre- and Post-PCI
BVS
(N ¼ 27)
EES
(N ¼ 27) P value
Pre-PCI
Lesion length (mm) 9.1 6 3.9 10.5 6 2.7 0.06
Reference vessel
diameter (mm) 2.72 6 0.48 2.67 6 0.42 0.90
Minimum lumen
diameter (mm) 1.08 6 0.24 0.99 6 0.27 0.37
Diameter stenosis (%)
59.3 6 11.5 62.7 6 9.6 0.36Post-PCI
Minimum lumen
diameter (mm) 2.30 6 0.32 2.43 6 0.30 0.03
Diameter stenosis (%) 17.0 6 7.4 11.3 6 4.2 0.0003
TABLE III. Angiographic Parameters Related With
Acute Stent Recoil Assessment
BVS
(N ¼ 27)
EES
(N ¼ 27) P value
Mean diameter of balloon
at the highest pressure (mm) 2.86 6 0.34 2.92 6 0.32 0.55
Mean diameter of stent
immediately after balloon
inflation (mm) 2.67 6 0.40 2.78 6 0.30 0.18
Acute absolute recoil (mm) 0.20 6 0.21 0.13 6 0.21 0.32
Acute percent recoil (%) 6.9 6 7.0 4.3 6 7.1 0.25
TABLE IV. Relationship of Angiographic and Procedural
Variables With Acute Percent Stent Recoil
BVS EES
Number % Recoil P value Number % Recoil P value
Reference vessel diameter
3.0 mm 8 3.1 6 6.4 0.14 6 0.7 6 9.1 0.18
<3.0 mm 19 8.4 6 6.7 21 5.3 6 6.3
Stent/artery ratio (stent oversizing)
1.1 10 8.4 6 5.7 0.25 14 8.2 6 4.1 0.003
<1.1 17 5.9 6 7.6 13 0.3 6 7.3
Maximum balloon pressure
>16 atm 7 5.9 6 5.4 0.62 8 2.7 6 6.1 0.24
16 atm 20 7.2 6 7.5 19 4.9 6 7.5
Lesion calcification
Yes 4 11.8 6 4.3 0.06 8 5.8 6 6.2 0.52
No 23 6.0 6 7.0 19 3.6 6 7.5
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The main function of metallic stents is to scaffold
the vessel wall and prevent early elastic recoil and
acute vessel closure. The need for this property is lim-
ited to the period ranging from the time of PCI to sev-
eral months, thereafter, when the stented segment is
fully endothelialized and vascular damage has healed.
Beyond this period, the scaffolding properties of the
stent are probably unnecessary. Their permanent pres-
ence induces chronic inflammation between the metal
and surrounding tissue [2], which causes in-stent neo-
intimal hyperplasia and thrombogenesis. Further, me-
tallic stents prevent the lumen expansion associated
with late favorable remodeling sometimes seen follow-
ing balloon angioplasty [14,15], impair the vessel ge-
ometry, and interfere with surgical reintervention [16]
and with recently developed coronary imaging modal-
ities such as multislice computed tomography and
magnetic resonance imaging. These imaging modalities
may become the default noninvasive diagnostic tool
for CAD patients in the near future [17]. To fulfill the
short-term need for scaffolding vessel walls and over-
come the aforementioned drawbacks of metallic stents,
the concept of bioabsorbable polymer stents is attrac-
tive. From preclinical studies, the BVS is predicted to
be fully metabolized to carbon dioxide and water and
to be fully absorbed between 2 and 3 years after im-
plantation. Therefore, the healed natural vessels are
left behind, which may no longer require antiplatelet
therapy and will no longer restrict potential surgical re-
vascularization of the stented segment. In addition, the
absence of metallic stents is amenable to noninvasive
imaging modalities (Fig. 1E and F) and may be adapt-
ive to late positive remodeling. However, as polymers
are more flexible than metals, there is potential that
the radial strength of bioabsorbable polymer stents
may be lower than that of metallic stents. Conse-
quently, there has been concern that more acute stent
recoil might occur after bioabsorbable polymer stent
deployment than after metallic stent deployment. The
present study is the first report of a comparison of in
vivo acute stent recoil between a bioabsorbable poly-
mer stent and a metallic stent.
In previous human clinical trials, acute stent recoil
varied between 3% and 15% following Wiktor or Pal-
maz-Schatz stent implantation [12,13,18–21]. The wide
range of BMS recoil was related in part to differences
in stent material and design and in part to the differ-
ence in definitions of recoil. Stent recoil was usually
defined as the difference between the minimum bal-
loon diameter and the MLD poststent implantation.
However, usage of minimum variables, proposed by
previous investigators, has the potential for assessing
only a part of the stented segment, because the balloon
does not expand uniformly, causing asymmetric stent
expansion. To reflect the behavior of the vessel wall of
the entire stented segment, we used mean variables
and defined acute stent recoil as the difference between
the mean diameter of the last inflated balloon and the
mean luminal diameter immediately after the last bal-
loon deflation. Our study demonstrated that the acute
percent stent recoil of the BVS was 6.9%, which is
slightly more than the EES recoil (4.3%), but in line
with previously reported in vivo conventional metallic
stent recoil [12,13,18–21]. It is noteworthy that, if we
adopted the definition using minimum variables to this
study, the acute percent stent recoil of the BVS and
EES would be calculated as 8.0% 6 10.1% and
6.8% 6 9.7%, respectively (P ¼ 0.72), which are also
in accordance with previously reported in vivo BMS
recoil [20,21]. Taking these results into consideration,
the BVS has no less detectable acute stent recoil than
the metallic stents in diseased human coronary arteries.
The idea of bioabsorbable stents is not new. Since
metallic stents were introduced, several types of poly-
meric stents have been tested in experimental studies.
The Igaki-Tamai stent was the first polymeric stent
examined in diseased human coronary arteries [22].
This was a self-expanding coil stent, composed of a
high-molecular-weight PLLA monofilament (321 kDa)
with a zigzag helical design. Its acute stent recoil
assessed by QCA was 22%, which is numerically
higher than that of the BVS in our study. Again, this
is partly because the definition of stent recoil was dif-
ferent. Acute recoil of the Igaki-Tamai stent was
defined as the difference between the maximum bal-
loon diameter and the MLD post stent implantation. If
this definition was applied to our study, acute stent
recoil of the BVS would be 25.5%, which is similar to
the recoil after the Igaki-Tamai stent implantation.
Although the stent body of the BVS resembles the
Igaki-Tamai stent, one difference between both stents
is that the BVS is coated with the antiproliferative
drug, everolimus. Considering the fact that angio-
graphic and clinical follow-up results of patients
treated with the Igaki-Tamai stent were comparable to
those of BMS, the BVS may lead to better short- and
intermediate-term angiographic and clinical outcomes
than does BMS, because of suppression of the intimal
hyperplastic response by everolimus.
Since stent recoil is the resultant of the balance
between the elastic recoil and radial strength of the
stent, along with the elastic properties of the arterial
wall, it can be affected by several lesion or procedural
characteristics, such as reference vessel diameter, stent
oversizing, maximum balloon pressure, and the pres-
ence of lesion calcification. In the EES group, only
stent oversizing correlated with acute stent recoil in ac-
cordance with previous reports [13]. Conversely, no
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relationship was found in the BVS group between
these lesion or procedural characteristics, although
there was a trend toward higher recoil in patients with
calcified lesions. This discrepancy between the BVS
and EES may be based on the difference in their
composition and design. However, these findings were
derived from only a small number of patients, and the
technical and clinical relevance remains unclear.
Larger studies are needed to assess the association
between lesion and procedure-related variables and
acute stent recoil of the BVS.
Limitations
Limitations of the present study include the small
number of patients. The lack of statistically significant
differences in acute percent stent recoil between the
BVS and EES may be due to the small sample size.
To detect the difference of acute percent stent recoil
between both stents at a 5% significance level with
80% power in a prospective analysis according to the
result of this study, 117 patients would be needed in
each group. Our study population consisted of patients
enrolled in three different trials, in which inclusion/
exclusion criteria varied. This may have introduced
some bias, although we carefully selected the control
patients to adjust baseline and lesion characteristics.
Target lesions treated with the BVS were relatively
simple, and acute stent recoil of the BVS may increase
in more complex lesions. In addition, detailed lesion
characteristics, such as plaque composition and lesion
eccentricity, were unknown, because we evaluated
acute stent recoil only by QCA, and not by intravascu-
lar ultrasound or optical coherence tomography. Lastly,
the present study evaluated BVS recoil immediately
after its implantation. Further investigations are war-
ranted to determine the recoil properties of the BVS
beyond this period.
CONCLUSIONS
In vivo acute stent recoil of the BVS is slightly
larger but insignificantly different from that of the
EES. This implies that the BVS may have good radial
strength similar to the metallic stent. The BVS may
result in angiographic and clinical outcomes compara-
ble to the drug-eluting metallic stents at short- and in-
termediate-term follow-up.
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Late Stent Recoil of the Bioabsorbable
Everolimus-Eluting Coronary Stent and
its Relationship With Plaque Morphology
Shuzou Tanimoto, MD,* Nico Bruining, PHD,* Ron T. van Domburg, PHD,* David Rotger, BSC,†
Petia Radeva, PHD,† Jurgen M. Ligthart, BSC,* Patrick W. Serruys, MD, PHD, FACC*
Rotterdam, the Netherlands; and Bellaterra, Spain
Objectives This study sought to evaluate late recoil of a novel bioabsorbable everolimus-eluting coronary stent (BVS), which
is composed of a poly-L-lactic acid backbone, coated with a bioabsorbable polymer containing everolimus.
Background Little is known about the mechanical behavior of bioabsorbable polymer stents after deployment in diseased
human coronary arteries.
Methods The study population consisted of 16 patients, who were treated with elective BVS implantation for single de
novo native coronary artery lesions and were followed at 6 months. All patients underwent an intravascular ultra-
sound examination at post-procedure and follow-up. A total of 484 paired cross-sectional areas (CSAs) were ac-
quired and analyzed. Late absolute stent recoil was defined as stent area at post-procedure (X)  stent area at
follow-up (Y). Late percent stent recoil was defined as (X  Y)/X  100. In each CSA, plaque morphology was
assessed qualitatively and classified as calcific, fibronecrotic, or fibrocellular plaque.
Results Late absolute and percent recoil of the BVS was 0.65  1.71 mm2 (95% confidence interval [CI]: 0.49 to 0.80
mm2) and 7.60  23.3% (95% CI: 5.52% to 9.68%). Calcified plaques resulted in significantly less late recoil
(0.20  1.54 mm2 and 1.97  22.2%) than fibronecrotic plaques (1.03  2.12 mm2 and 12.4  28.0%, p 
0.001 and p  0.001, respectively) or fibrocellular plaque (0.74  1.48 mm2 and 8.90  19.8%, p  0.001
and p  0.001, respectively).
Conclusions The BVS shrank in size during the follow-up period. The lesion morphology of stented segments might affect the
degree of late recoil of the BVS. (ABSORB Everolimus Eluting Coronary Stent System First in Man Clinical Investi-
gation; NCT00300131) (J Am Coll Cardiol 2008;52:1616–20) © 2008 by the American College of Cardiology
Foundation
Compared with metallic stents, bioabsorbable polymer
stents could have a lower radial strength, resulting in more
stent recoil after implantation, because polymers are more
flexible than metals. The bioabsorbable everolimus-eluting
coronary stent (BVS) (Abbott Vascular, Santa Clara, Cali-
fornia) is composed of a high-molecular-weight poly-L-
lactic acid (PLLA) backbone, coated with a matrix of
bioabsorbable polymer and everolimus. All components of
the BVS, except for 2 radio-opaque platinum markers on
both ends of its surface, are expected to be fully metabolized
and absorbed in the human body between 2 and 3 years
(1,2). Although acute recoil of the BVS as assessed by
quantitative coronary angiography (QCA) was slightly but
not significantly higher than that of the everolimus-eluting
metallic stent (2), little is known about late mechanical
behavior of the BVS. In the present study, we evaluated late
recoil of the BVS and assessed its relationship with lesion
morphology of the stented segments.
Methods
Study population. Of the 30 patients included in the
ABSORB (ABSORB Everolimus Eluting Coronary Stent
System First in Man Clinical Investigation) trial, 16 were
enrolled at the Thoraxcenter, Erasmus Medical Center,
Rotterdam, the Netherlands. The trial has been described in
detail previously (1,2). It was approved by the local ethics
committee, and all patients gave written informed consent.
In brief, patients were eligible for the study if they had
single de novo native coronary artery lesions that could be
covered with a single BVS. Patients were ineligible if they
had evolving myocardial infarction, left main coronary
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artery stenosis, an ostial lesion, a bifurcation lesion, a totally
occluded lesion, a lesion with moderate-to-heavy calcifica-
tion, angiographically visible thrombus within the target lesion,
or a left ventricular ejection fraction 30%.
Study procedure. Target lesions were electively treated
with standard interventional techniques with mandatory
pre-dilation and stent deployment at a pressure not exceed-
ing the rated burst pressure (16 atm). Post-dilation with a
balloon shorter than the implanted stent was allowed at
operator discretion. Bailout stenting for edge dissection was
permitted with metallic stents. At the end of the procedure,
intravascular ultrasound (IVUS) procedures were performed
with a 40-MHz IVUS catheter (Atlantis SR Pro, Boston
Scientific Corporation, Natick, Massachusetts) with an
automated pullback system at 0.5 mm/s. After IVUS
examinations, no other stent-related procedures were added.
All patients were planned to undergo both a coronary
angiography and an IVUS examination 6 months after the
initial procedure.
QCA and quantitative IVUS analysis. The QCA was
performed with the CAAS II analysis system (Pie Medical
BV, Maastricht, the Netherlands) by an independent ob-
server blinded to the clinical and IVUS findings. The
following QCA parameters were computed: minimal lumen
diameter, reference vessel diameter, percent diameter steno-
sis, and lesion length. The accuracy of this method has been
reported in detail previously (3).
To analyze and compare the IVUS data consistently, all
IVUS examinations were retrospectively electrocardiogram
(ECG)-gated with the validated Intelligate method, which
automatically selects near end-diastolic frames from pre-
recorded non–ECG-gated IVUS data (4). The IVUS im-
ages of both post-procedure and follow-up studies were
analyzed by side-by-side viewing, comparing for matched
segments. Only the stented segments were analyzed and
were identified by the first and the last cross section
containing visible stent struts. The lumen, stent, and exter-
nal elastic membrane contours were detected with the
validated software (CURAD QCU Analysis Software,
Curad B.V., Wijk bij Duurstede, the Netherlands), which
allows semi-automated detection of the lumen–intima in-
terface and the external elastic membrane in longitudinal
reconstructed views of coronary vessels (5,6).
Late stent recoil assessment. Stent recoil was computed
from measurements of IVUS cross-sectional areas (CSAs),
obtained every 0.5 mm. Late absolute stent recoil was
defined as stent area at post-procedure (X)  stent area
at follow-up (Y). Late percent stent recoil was defined as
(X  Y)/X  100.
Image-based plaque characterization. The IVUS appear-
ance of the BVS struts is unique and differs from that of
metallic stents. The polymer struts are visible as 2 parallel
lines of echoes without acoustic shadowing (AS), due to the
fact that the ultrasound is mainly backscattered at the
interfaces (blood/polymer interface and polymer/tissue in-
terface) of the struts with the surrounding environment.
Therefore, plaque characteriza-
tion of BVS implanted segments
can be assessed without the im-
age artifacts as seen in IVUS of
metallic stents.
To investigate the possible re-
lationship between the degree of
late stent recoil and plaque mor-
phology in stented segments,
plaque characterization of BVS
implanted segments was qualita-
tively assessed by IVUS appear-
ance. All acquired CSAs were
classified into 3 different plaque
types: calcific, fibronecrotic, or
fibrocellular plaque. Each plaque
type was defined as follows (7–11): calcific plaque: highly
echogenic areas having a density greater than that of the
adventitia and causing AS, possibly combined with rever-
berations; fibronecrotic plaque: plaque components causing
echolucent areas within the plaque combined with AS or
plaque having AS without reverberations; and fibrocellular
plaque: plaque components other than calcific and fibrone-
crotic plaques. In case several plaque types were identified in
1 CSA, the predominant plaque type was selected.
Statistical analysis. Statistical analysis was performed with
SAS software (SAS Institute Inc., Cary, North Carolina).
Categorical variables were expressed as counts and percent-
ages. Continuous variables were presented as mean values
with SDs. The Student t test was performed for testing
differences of late BVS recoil among 3 different plaque types
of stented segments. To adjust for multiple observations/
patient, with possible correlations of adjacent cross sections,
the t statistic was divided by C  (1  [m  1]), where m
is the number of observations/patient and  is the intraclus-
ter correlations (12). The intracluster correlation  is de-
fined as: variance (between patients)/(variance [between
patients]  variance [within patients]). A value of p  0.05
was considered statistically significant.
Results
All patients were successfully treated and underwent
follow-up coronary angiography and IVUS procedures at
6.0  1.2 months. Only 1 patient received bailout stenting.
A total of 484 paired (post-procedure and follow-up) CSAs
were acquired. Baseline and follow-up results are shown in
Table 1. According to the protocol, lesion complexity was
relatively simple: no type C lesion, short lesion length (9.83
4.02 mm), large reference vessel diameter (2.96  0.48 mm),
and mild degree of diameter stenosis (62  13%). Late
absolute stent recoil was 0.65  1.71 mm2 (95% confidence
interval [CI]: 0.49 to 0.80 mm2), and late percent stent
recoil was 7.60  23.3% (95% CI: 5.52% to 9.68%). All
acquired CSAs were qualitatively assessable in terms of
lesion morphology of stented segments. The fibrocellular,
Abbreviations
and Acronyms
AS  acoustic shadowing
BVS  bioabsorbable
everolimus-eluting coronary
stent
CI  confidence interval
CSA  cross-sectional area
ECG  electrocardiogram
IVUS  intravascular
ultrasound
PLLA  poly-L-lactic acid
QCA  quantitative
coronary angiography
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fibronecrotic, and calcific group consisted of 204, 126, and
154 CSAs, respectively. The relationship between late stent
recoil and lesion morphology is shown in Figure 1. Late
absolute and percent stent recoil were significantly less in
calcified lesions (0.20  1.54 mm2 and 1.97  22.2%,
respectively) than in fibrofatty lesions (0.74  1.48 mm2
and 8.90  19.8%, p  0.001 and p  0.001, respectively)
or in fibronecrotic lesions (1.03  2.12 mm2 and 12.4 
28.0%, p  0.001 and p  0.001, respectively). Although
there was a trend toward more recoil in fibronecrotic lesions
than in fibrocellular lesions, no significant differences in late
absolute and percent stent recoil were observed between
these 2 lesion types (p  0.18 and p  0.1, respectively).
Discussion
The present study indicated that the BVS shrank in size
during the follow-up period. This observation was at vari-
ance with the observed 6 months’ late recoil of the Igaki-
Tamai stent, which was the first polymeric stent examined
in diseased human coronary arteries (13). Although the
Igaki-Tamai stent was composed of the same material
(PLLA) as the BVS, it became larger in size (0.71 mm2 at
6 months according to IVUS analysis). This discrepancy
could have been caused by the differences in study protocols
and/or baseline characteristics of the target lesions between
2 studies. However, the main reason might be associated
with differences in stent design. Because the Igaki-Tamai
stent was self-expandable, whereas the BVS was balloon-
expandable, the Igaki-Tamai stent tends to expand gradu-
ally in time until it reaches fully unconstrained dimensions.
The current results also differed from reported late recoil
of metallic stents as assessed by IVUS. The Palmaz-Schatz
stent exhibited only a little recoil (0.1 mm2 and 0.6%) at 4
months (14). Late recoil of the XIENCE V everolimus-
eluting stent (Abbott Vascular), which is a metallic stent
coated with the same antiproliferative drug as in the BVS,
was computed as 0.02 mm2 and 0.3% at 6 months (1,15).
These changes are in the range of reproducibility measure-
ments. However, it is obvious that the vessel scaffolding
properties of the BVS have not been maintained for a long
period compared with metallic stents, even if the BVS shows a
good radial strength, similar to metallic stents, immediately
after deployment (2). This might be due to differences in
material components between both stent types. Because poly-
mers are more flexible than metals, there is a potential that
polymer stents are affected by the elastic properties of the
arterial wall more directly and have been compressed steadily.
In addition, because the BVS is designed to be gradually
metabolized, the polymer backbone will lose its structural
integrity over time, which could diminish its radial strength
and lead the stent to shrink. However, no clear image of such
a degradation process of the BVS was documented, even when
using a 40-MHz IVUS catheter, probably due to an insuffi-
cient resolution of IVUS to clarify this phenomenon.
Because the extent of stent recoil is the result of the
balance between the elastic recoil and radial strength of the
stent, along with the elastic properties of the arterial wall, it
can be affected by the plaque characteristics of the stented
segments. The elastic property of the arterial wall is deter-
mined by atherosclerotic plaque constituents. Previous stud-
ies revealed the following: 1) calcific plaques had stiffer
mechanical properties than other types of plaques and thus
Clinical, Lesion, and Procedural Characteristics
Table 1 Clinical, Lesion, and Procedural Characteristics
Patient demographic data (n  16 patients)
Age, yrs 60.9 8.6
Male 11 (69%)
Hypertension 10 (63%)
Hypercholesterolemia 12 (75%)
Diabetes 1 (6%)
Current smoking 4 (25%)
Prior myocardial infarction 2 (13%)
Lesion characteristics (n  16 lesions)
Treated vessel
Right coronary artery 4 (25%)
Left anterior descending 5 (31%)
Left circumflex artery 7 (44%)
ACC/AHA lesion type
Type A 0 (0%)
Type B1 8 (50%)
Type B2 8 (50%)
Type C 0 (0%)
Procedural characteristics
Pre-dilation before stenting 16 (100%)
Post-dilation 12 (75%)
Maximal pressure during entire procedure, atm 16.1 0.89
Stent/artery ratio 0.98 0.16
Clinical success 16 (100%)
QCA results
Pre-procedure
Lesion length, mm 9.83 4.02
Reference vessel diameter, mm 2.96 0.48
Minimal lumen diameter, mm 1.09 0.31
Diameter stenosis, % 62 13
Post-procedure
Minimal lumen diameter, mm 2.45 0.33
Diameter stenosis, % 19 8
Acute gain, mm 1.36 0.46
Follow-up
Minimal lumen diameter, mm 2.00 0.27
Diameter stenosis, % 29 14
Late loss, mm 0.45 0.39
IVUS results (n  484 CSAs)
Post-procedure
Stent area, mm2 6.94 1.47
Follow-up
Stent area, mm2 6.29 1.70
Lumen area, mm2 5.83 1.51
Neointimal area, mm2 0.47 0.58
Late absolute stent recoil, mm2 0.65 1.71
Late percent stent recoil, % 7.60 23.3
Values are mean  SD or n (%).
ACC/AHA American College of Cardiology/American Heart Association; CSA cross-sectional
area; IVUS  intravascular ultrasound; QCA  quantitative coronary angiography.
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exhibited less elasticity; and 2) fibrofatty or fibronecrotic
plaques had more elasticity than calcific plaques, but no
significant difference was observed between these 2 plaque
types (10,11). In concurrence with these statements, the
present study demonstrated that calcified plaques resulted in
significantly less late recoil than the other plaque types and
that fibrocellular or fibronecrotic plaques induced more late
recoil than calcified plaques, although no significant differ-
ences in late recoil were observed between these 2 plaque
types (Fig. 1). These findings suggest that an IVUS exam-
ination of the target lesion before stenting could be useful to
predict the extent of stent recoil in case of BVS implantation.
Study limitations. Limitations are the small number of
enrolled patients and that the clinical implication of the
BVS shrinkage remains unclear. Target lesions were rela-
tively simple, and late recoil of the BVS might increase in
more complex lesions. Further investigations are warranted
to determine the recoil properties of the BVS at the time of
its complete degradation.
Conclusions
A certain degree of late stent recoil was observed 6 months
after BVS implantation, indicating that the BVS shrank in size
during the follow-up period. The lesion morphology of stented
segments might affect the extent of late recoil of the BVS.
Reprint requests and correspondence: Dr. Nico Bruining, Eras-
mus Medical Center, P.O. Box 1738, 3000 DR, Rotterdam, the
Netherlands. E-mail: n.Bruining@erasmusmc.nl.
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Abstract
A 71-year-old man was admitted with stable angina pectoris. The coronary lesion in the obtuse marginal branch was successfully treated
with a BVS bioabsorbable poly-L-lactic acid everolimus-eluting coronary stent and a Cypher stent. On multislice computed tomography
(MSCT) coronary angiography performed after stenting, the in-stent lumen within radio-lucent polymer struts of the BVS stent was clearly
depicted. In contrast, the metallic struts of the Cypher stent hampered precise in-stent luminal evaluation due to blooming artifact.
Non-metallic coronary stents composed of radio-lucent polymers might have potential advantages compared to metallic stents with
respect to non-invasive MSCT imaging.
© 2007 Elsevier Ireland Ltd. All rights reserved.
Keywords: Multislice computed tomography; Stents; Imaging; Angiography; Coronary disease
1. Case report
A 71-year-old male ex-smoker with hypercholesterolemia,
was admitted with stable angina pectoris. Conventional
coronary angiography revealed a high grade stenosis at the
proximal segment of the obtuse marginal branch (Fig. 1A).
The patient was enrolled in the ABSORB trial, a first-in-man
clinical investigation of the bioabsorbable poly-L-lactic acid
everolimus-eluting coronary stent (BVS: Bioabsorbable
Vascular Solutions, Inc., Abbott Laboratories, Mountain
View, CA) in patients with single de novo native coronary
artery lesions [1,2]. After predilation, a 3.0×12 mm BVS
stent was implanted at the target lesion. Due to distal stent-
edge dissection, and according to the study protocol, a
3.0×13 mm bailout Cypher stent (Cordis, Miami Lakes, FL)
was successfully implanted with minimal overlap with the
BVS stent (Fig. 1B).
Multislice computed tomography (MSCT) coronary
angiography performed 4 days later with a dual-source 64-
slice CT scanner (Somatom Definition, Siemens, Forhheim,
Germanny) demonstrated these two stents with contrasting
characteristics (Fig. 2). The radio-lucent polymer struts of
the BVS stent were invisible, therefore the in-stent lumen
was clearly depicted on MSCT. The 2 radio-opaque platinum
markers indicated both ends of BVS stent. In contrast, the
metallic struts of the Cypher stent hampered clear depiction
of the in-stent lumen due to the “blooming” effect.
2. Discussion
MSCT coronary angiography has emerged as a non-
invasive diagnostic modality to evaluate coronary artery
disease. Rapid progress of MSCT technology with the
⁎ Corresponding author. Department of Cardiology, Toin Heart Center,
Yokohama General Hospital 2201, Kurogane-cho, Aoba-ku, Yokohama
225-0025, Japan. Tel.: +81 45 902 0001; fax: +81 45 904 3434.
E-mail address: amiuap@nifty.com (M. Otsuka).
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Fig. 1. Conventional coronary angiograms of the left coronary artery before (A) and after (B) percutaneous coronary intervention. The lesion in the proximal
obtuse marginal branch (OM) (arrow) was successfully treated with a BVS bioabsorbable poly-L-lactic acid everolimus-eluting coronary stent (white arrow head)
and a Cypher stent (black arrow head). LAD, left anterior descending coronary artery. LCX, left circumflex coronary artery.
Fig. 2. Three-dimensional volume-rendered images (A, B) and curved multiplanar reconstructions of the obtuse marginal branch (C) by multislice computed
tomography coronary angiography after stenting. The polymer struts of the BVS stent are invisible, and only 2 radio-opaque platinummarkers at either end of the
stent can be seen (arrows). In contrast, the metallic struts of Cypher stent (⁎) are brightly visible with blooming, hampering precise in-stent luminal evaluation.
LM, left main coronary artery.
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number of detectors increased to 16–64 and faster speed of
gantry rotation promises more accurate coronary images
with improved spatial and temporal resolution and has
resulted in progressively its high ability for detection of
coronary stenoses, as compared to catheter-based conven-
tional angiography [3]. However, visualization or evaluation
of the in-stent lumen by MSCT is still challenging owing to
blooming artifact caused by metallic stent struts. Some
reports have shown the limited assessability or the impact of
blooming artifact on the in-stent evaluation [4,5]. In terms of
evaluating the stented segment noninvasively and visualiz-
ing these segments accurately using MSCT, the polymer
stents might have potential advantages when compared to
metallic stents [2,6].
The MSCT images of the present case contrastively
demonstrate both the “radio-lucent” non-metallic BVS stent
composed of bioabsorbable polymers and the “radio-opaque”
metallic stent implanted in the same coronary vessel.
Although the nominal diameters of both stents were same,
the in-stent lumen of the BVS stent was clearly depicted on
MSCT compared to the metallic stent.
The BVS stent is expected to be fully absorbed in a few
years after implantation. Therefore, the stent may not require
long lasting antiplatelet therapy and the stented segment may
allow for future surgical revascularization [1,2]. In addition,
the polymer stent could be amenable to MSCT that will play
an increased role in the future for evaluating of neointimal
growth and arterial remodeling of the stented segment.
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Abstract
Aims: To investigate if three-dimensional (3D) based quantitative techniques are comparable to each other
and to explore possible differences with respect to the reference method of 2D-QCA in the acute phase and
to study whether non-invasive MSCT could potentially be applied to quantify luminal dimensions of
a stented coronary segment with a novel bioabsorable drug-eluting stent made of poly-l-lactic-acid (PLLA).
Methods and results: Quantitative imaging data derived from 16 patients enrolled at our institution in a first-
in-man trial (ABSORB) receiving a biodegradable stent and who were imaged with standard coronary
angiography and intravascular ultrasound were compared. Shortly, after stenting the patients also
underwent a MSCT procedure. Standard 2D-QCA showed significant smaller stent lengths (p<0.01).
Although, the absolute measured stent diameters and areas by 2D-QCA tend to be smaller, the differences
failed to be statistically different when compared to the 3D based quantitative modalities. Measurements
made by non-invasive QMSCT-CA of implanted PLLA stents appeared to be comparable to the other 3D
modalities without significant differences.
Conclusions: Three-dimensional based quantitative analyses showed similar results quantifying luminal
dimensions as compared to 2D-QCA during an evaluation of a new bioabsorbable coronary stent design in
the acute phase. Furthermore, in biodegradable stents made of PLLA, non-invasive QMSCT-CA can be
used to quantify luminal dimensions.
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Quantitative multi-modality imaging of a new stent
Introduction
Coronary stenting has resolved the problem of acute recoil and late
remodelling after a coronary balloon dilatation procedure1. The
introduction of drug-eluting stents (DES), not so long ago, solved
partially the problem of in-stent restenosis occurring in patients
treated with bare metal stents1. However, the combination of an
implanted metallic device into the coronary vessel wall and the
elution of antiproliferative drugs from durable polymer coated stent
struts for long-lasting inhibition of neointima hyperplasia (NIH)
proliferation2, potentially delayed the healing process2,3. The non-
endothelialised polymer coated stent struts may stay in direct
contact with the bloodstream, even after a period of two years,
which may possibly lead to late stent thrombosis after
discontinuation of the antiplatelet therapy4,5. A possible solution to
overcome this problem could be a fully bioabsorbable DES stent
which will maintain the benefits of a mechanical scaffold post-
balloon procedure while eluting temporarily the local
pharmaceutical treatment6,7.
To investigate the effectiveness of a bioabsorbable stent made from
poly-L-lactic acid (PLLA)8, coated with the proven effective NIH
inhibiting drug everolimus9, a multi-modality quantitative imaging
study was implemented as a sub-study of the ABSORB trial10. The
ABSORB trial is the first-in-man study of the implantation of the
Abbott Vascular BVS bioabsorbable stent (Bioabsorbable Vascular
Solutions, Santa Clara, CA, USA).
Besides the usually applied imaging techniques to evaluate the
results of new stent designs in these kind of studies (e.g., two-
dimensional (2D) quantitative coronary angiography (QCA)11 and
quantitative intravascular ultrasound (QCU)12, also the newly
available imaging techniques of three-dimensional (3D) QCA13 and
quantitative non-invasive imaging by multi-slice computed
tomography coronary angiography (QMSCT-CA)14 were applied
during the acute phase to evaluate their respective imaging values
and future application. Metallic stents, with their inherent
radiopacity hampers the luminal assessment of these devices with
MSCT-CA15. PLLA does not cause MSCT-CA related image artefacts
and thus could provide an improved visualisation of the lumen in
BVS stented coronary segments. MSCT-CA was applied for
evaluation since most patients might prefer its friendly non-invasive
nature in case they participate in a longitudinal study evaluating
these new stent modalities.
This study compared these imaging methodologies for the
quantitative assessment of BVS stented coronary arteries.
Methods
Patients and study design
Sixteen patients (11 men and five woman, 60.9±8.6 years) were
included in this sub-analysis, which was part of the multicentre
ABSORB trial10. The study design has been described in detail
elsewhere10, however in brief: It is a first-in-man prospective, open-
labelled multicentre trial of patients with a single de novo coronary
artery lesion treated with the BVS stent. The local ethical committee
approved the study and each patient gave a written informed
consent. Target lesions that could be covered by a 3.0 mm±12 mm
or a 3.0 mm±18 mm (diameter, length) stent were selected.
Locations of the BVS stent in the 16 patients were: five left anterior
descending (LAD), four right coronary arteries (RCA) and seven left
circumflex arteries (LCX).
BVS stent design
The laser-cut PLLA stent design consists of four major components:
a high crystalline polymer backbone, a low crystalline polymer
coating impregnated with everolimus and a delivery system6,10
(Figure 1). The stent struts are 150 μm thick and at the distal and
proximal edges of the stent two platinum radiopaque markers, each
135 μm, are embedded into the stent struts to facilitate accurate
fluoroscopic positioning of the stent.
Figure 1. This figure presents the BVS stent design. At the proximal and
distal side the two golden coloured platinum markers can be
appreciated.
Coronary Arteriography including Two- and
Three-dimensional (2D and 3D) QCA
Coronary arteriography was performed according to standard
procedures16. Each angiogram was preceded by the injection of 1-3 mg
isosorbide dinitrate. Two-dimensional QCA was performed with the
CAAS II system11 (Pie Medical BV, Maastricht, The Netherlands).
Three-dimensional QCA was performed with CAAS QCA-3D (CAAS
5.0, Pie Medical BV, Maastricht, The Netherlands ). This latter system
uses the detected contours in the frontal and lateral images in
combination with the projection data available in the DICOM format
to make a reconstruction of the coronary artery segment in 3D. In
this study two simultaneously acquired orthogonal views by a bi-
plane system were used. The QCA measurements were performed
off-line.
Intravascular ultrasound (IVUS) procedure and
Quantitative IVUS (QCU)
IVUS was performed after successful implantation and additional
balloon dilatation if necessary. The IVUS catheter used was a 40 MHz
Atlantis™ catheter (Boston Scientific, Santa Clara, CA, USA)
connected to a Galaxy™ ultrasound console (Boston Scientific,
Santa Clara, CA, USA). The catheter was pulled back by
a continuous speed mechanical device at 0.5 mm/s17. IVUS data
were acquired after intracoronary injection of isosorbide dinitrate.
All image data were digitally stored on CD-ROM and transferred
later to an IVUS Picture Archiving and Communications System
(IVUS-PACS).
Quantitative IVUS analysis was performed using validated QCU
software (CURAD BV, Wijk bij Duurstede, The Netherlands),
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allowing semi-automatic detection of the intima- or stent-
boundaries in longitudinal reconstructed views of the stented
segment18. To overcome possible inaccuracies in quantitative
analysis and problems using automatic contour detectors, which
are common in non-ECG-gated acquired IVUS studies due to
longitudinal catheter motion and rotation of the coronary artery
around the IVUS catheter during the cardiac cycle19,20, the validated
retrospective image-based pre-processing gating algorithm
Intelligate® was applied21. This algorithm filters near-end-diastolic
frames from a non-gated IVUS study and creates a new
retrospective gated IVUS study resulting in smooth longitudinal
views in which automatic contour detectors can be applied
(Figure 2).
MSCT-CA procedure and Quantitative MSCT-CA
(QMSCT-CA)
The MSCT-CA procedure, in a 64-slice spiral CT scanner (Sensation
64®, Siemens, Forchheim, Germany), was performed within three
days after implantation of the BVS stent according to a standardised
protocol22. The x-ray tube rotation time was 330 ms, resulting in
a temporal resolution of 165 ms. Detector collimation was 32 x 0.6 mm
with a pitch of 0.2 (table advancement was 3.8 mm per rotation).
By rapid alternation of the longitudinal position of the focal spot 
(Z-Sharp® Technology, Siemens, Forchheim, Germany), 64 slices
could be acquired simultaneously. A tube voltage of 120 kV with
tube currents between 800 and 900 mAs were applied.
Clinical research
Figure 2. This figure shows examples of all applied quantitative modalities. In panel A, standard 2D quantitative coronary angiography (QCA) and
in panel B, a reconstruction made by the new 3D-QCA technique. Panel C shows a cross-sectional measurement of quantitative intravascular
ultrasound (QCU) from which a reconstructed longitudinal view (L-views) is presented in panel D. The blue line indicates the stent contour and
the green line the external elastic membrane contour. Panel E, shows a cross-sectional measurement of the multi-slice computed tomography
coronary angiography imaging (QMSCT-CA). Panel F, the reconstructed L-view, with as red contour the lumen/stent contour and the green contour
the outer vessel border. The two bright spots at either side of the contour lines are the metal markers of the stent, which are causing a blooming
artefact on the MSCT-CA image.
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Patients with a heart rate >60 BPM were given a β-blocker (up to
100 mg of metroprolol) and/or anxiolytic medication (1 mg of
lorazepam) 45 min before the procedure. To enhance the coronary
arteries a bolus of 100 mL of iomeprol 400 mgl/mL (Iomeron®, Bracco,
Milan, Italy) was intravenously administered at a rate of 3.5-5 mL/s,
depending on the size of the patient.
After the procedure, the image data was retrospective gated and
reconstructed using images acquired during the middle- and late
phase of diastole by software of the manufacturer (Siemens). The
B30f convolution kernel was applied. All image datasets were
uploaded to a local MSCT-PACS for later quantitative analysis. The
coronary arteries in which the BVS stent was implanted were
extracted using dedicated semi-automated MSCT-CA vessel
extraction software14 (CURAD BV). This software allows the creation
a new image dataset from the original MSCT-CA image data as if an
intravascular imaging procedure like IVUS has been performed.
After vessel extraction, quantitative analysis can be performed
similar as QCU (Figure 2). Although, the contour detection is of
course rather different for QMSCT-CA, the calculated parameters
are similar allowing an optimal environment for comparisons
between the different imaging modalities. Validation of this software
has been described elsewhere14.
Measured parameters
Although the applied quantitative software packages are producing
many different parameters of the coronary vessel- and stent
dimensions, only a few can be used for comparison. In this study
we used the mean values of the measured implanted stent lengths,
-diameters and -areas to compare.
To calculate diameters from the original cross-sectional area
measurements as being performed by QMSCT-CA and QCU a
circular model was assumed and the following formula was
applied23:
Diameter = 2 × , Formula 1
To calculate areas from the original diameter measurements by 2D-
QCA again a circular model was assumed and the following formula
applied:
Area = π ×
2
, Formula 2
Statistical analysis
Quantitative data are presented as mean±standard deviation.
Analysis of variance with the Bonferroni post hoc test was used to
compare the mean values among groups. In these analyses a p-
value of <0.05 was considered to be significant. The results were
further analysed by the method proposed by Bland and Altman24,
and for this study 2D QCA was selected to be the “golden standard”.
Results
All quantitative measurements for each modality were performed by
a different observer, and they were blinded for the other results. In
fact the measurements were also performed at different locations to
prevent possible crossover bias.
d
2
Area
π
Two-dimensional QCA and QCU were available in all 16 patients.
Three-dimensional QCA was not assessable in five patients due to
an insufficient reading of the geometry settings of the x-ray
equipment. MSCT-CA could not be performed in two patients due to
contrast allergies. In two of the remaining 14 patients, quantitative
analysis was not possible due to poor image quality (e.g. excess of
motion during the scan).
Stent lengths
Stents were identified by their metal markers on the coronary
angiography images for the QCA techniques and on MSCT-CA; and
by their first and last visible strut appearance in a given cross-
section in the IVUS images (Table 1, Figure 2 and 3). Two patients
Figure 3. This graph shows all individual implanted measured stent
lengths, diameters and areas as measured by the different modalities.
It can be clearly appreciated that two-dimensional quantitative
angiography (2D-QCA) shows significantly shorter measured lengths.
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were not taken into account for comparison of the length
measurements, because they received an 18 mm long stent and
the 14 others were all 12 mm in length. The metallic markers resulted
in a blooming artefact on the MSCT-CA images and therefore the
region of interest (ROI) for QMSCT-CA was selected by clipping a
small amount off the far ends of these markers (Figure 2H).
The length of the stents as determined by two-dimensional QCA was
significantly shorter compared to the other modalities (p<0.001
with all modalities), with an 18% relative difference to the expected
nominal stent length (e.g. 12 mm, Table 1). The Bland-Altman
analysis shows the differences with the 3D based quantitative
methods (Figure 4, Table 2).
In this study three different imaging modalities were applied with
four different quantitative analyses techniques to evaluate the
clinical benefits of a new bioabsorbable coronary stent design
during the acute phase. In the past two decades only 2D-QCA and
QCU were available to study the success or failure of new
interventional techniques and new pharmaceutical treatments.
Recently, 3D-QCA13, an upgrade from 2D-QCA, and non-invasive
MSCT-CA14 imaging became clinically available. Both having their
specific advantages and disadvantages. At this point in time the
imaging modalities are more complementary to each other, rather
than being competitors. However, the question ought to be raised if
they are comparable in simple quantitative parametric measurements
as stent -length, -diameters and -areas? This study evaluated the
quantitative outcome of these imaging techniques in the acute
phase, directly after implantation of a new bioabsorbable stent
design and the simple straightforward message is that the 3D based
techniques are more in-line with each other and closer to the
expected nominal stent dimensions than 2D-QCA measurements.
The measured implanted stent lengths in the 3D based-modalities
were comparable but significantly different compared to 2D-QCA.
The problem of foreshortening of stenoses and stent lengths by 2D-
QCA has been described before11. However, 2D-QCA also showed
absolute smaller stent diameters and derived areas as compared to
the other modalities (Table 1)25. Although, it must be underscored
that QCA diameters were converted into areas assuming a circular
model (Formula 2). In this particular study, e.g. measuring a stent,
the assumption of a circular model seems appropriate, although,
a non-eccentric appearance after implantation of a PLLA stent is
not inconceivable.
The reported smaller stent dimensions as measured by 2D-QCA as
compared to QCU, are in-line with previous reports13,23. The relative
concordance between the measurements obtained by the 3D-QCA,
QCU and QMSCT-CA raises the question whether there is a
systematic error measurement deviation by 2D-QCA, which should
be corrected. A recent study to validate the 3D-QCA software also
showed a 10% smaller measured diameter for a phantom
introduced into a coronary artery to act as a stenosis with precisely
known dimensions13.
The three selected parameters for this comparison study may seem
basic, however, they are the ones most used in new stent design
studies and have acted as endpoints in many multicentre trials.
Furthermore, they are the most directly measured being not derived
by complicated mathematical computations.
The observation made in this study is that quantitative non-invasive
MSCT-CA showed results similar to the currently used reference
method, e.g. QCU. Previous reports showed both under- as well as
overestimation of coronary lumen dimensions as measured by
QMSCT-CA when compared to the de facto reference method use
of QCU14,26. However, it is difficult to compare the results of these
studies with the present one, since most of them were not
performed in stented segments, which immediately after stenting
most likely have a circular shape (which is more easily analysable
by most contouring systems). This could have enhanced 
the concordance between the various quantitative modalities 
of our study.
Clinical research
Table 1. Measured stent dimensions.
2D-QCA 3D-QCA QCU QMSCT-CA Stent
Length [mm] 9.89±0.93 12.24±0.55 12.51±0.85 11.89±0.20 12
Diameter [mm] 2.86±0.31 3.03±0.25 2.98±0.29 3.05±0.36 3
Area [mm2] 6.50±1.47 7.23±1.17 7.10±1.39 7.41±1.78 7.07
Stent dimensional measurements by all applied imaging modalities (presented
as mean±SD). The stent column presents the optimal stent implantation
dimensions
Table 2. 2D-QCA vs. 3D modalities.
3D-QCA QCU QMSCT-CA
Length [mm] –2.57±1.23 –2.63±1.51 –1.85±1.00
Diameter [mm] –0.21±0.20 –0.12±0.32 –0.21±0.34
Area [mm2] –0.96±0.93 –0.60±1.45 –0.99±1.55
The mean±SD differences of the Bland-Altman analysis for all 3D quantitative
analysis vs. the reference method of 2D QCA. In the corresponding Bland-
Altman figures (e.g. Fig. 4, 6 and 8) the average of these mean values is
presented, this to prevent making the graphs too busy.
Stent diameters
Comparison of the stent diameter results showed no statistical
differences between the quantitative modalities (Table 1). However,
2D-QCA showed smaller absolute diameters (approximately 5%) as
compared to the 3D oriented modalities and the nominal stent
diameter, respectively. For the stent diameters the Bland-Altman
analysis shows that in the majority of cases smaller stent diameters
are measured by 2D QCA (Figure 4, Table 2).
Stent areas
Similar results were also found for the stent area measurements
(Table 1). Standard 2D-QCA showed smaller absolute areas as
compared to the 3D modalities, although statistically not significant,
but with a relative difference of 7% as compared to the nominal stent
area. For the stent areas the Bland-Altman analysis showed similar
results as for the diameter measurements (Figure 4, Table 2).
Discussion
This report shows that of the applied 3D oriented quantitative
coronary imaging techniques (e.g. 3D-QCA, QCU and QMSCT-CA),
luminal measurements in a bioabsorbable stented coronary
segment are comparable, but are showing deviation with 2D
oriented QCA.
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The metal markers render the selection of ROI with QCA and
QMSCT-CA, although they resulted in a slight underestimation of the
implanted stent lengths with MSCT-CA due to the blooming artefact.
Leaving the metal markers out seems not to be an option in the
research phase, because without them it is impossible to locate the
stent using angiography and/or MSCT-CA. Furthermore, the
expected bioabsorption of the struts between 2-3 years, may on the
other hand make it difficult to retrieve the ROI on IVUS, if the struts
are no longer visually detectable. The tiny metal markers (135 μm),
may by then be embedded into the coronary vessel wall, were
already not identifiable at baseline with IVUS.
Study limitations
Unfortunately, the number of patients of this first-in-man BVS stent
study was limited and not every imaging modality could be applied
in all patients. While showing a deviation with the 3D techniques,
still 2D-QCA was applicable in all patients together with IVUS. Both
MSCT-CA and 3D-QCA showed lower success rates, which should
be taken into account when planning longitudinal studies. However,
this is a unique patient population in which for the first time four
different imaging methodologies and one new derived imaging
method could be applied and used for quantitative analysis. Of course,
it will be more interesting to see how the applied 3D imaging
techniques perform during the long-term follow-up.
Conclusion
Three-dimensional based quantitative analyses showed similar
results quantifying luminal dimensions as compared to 2D-QCA
during an evaluation of a new bioabsorbable stent design in the acute
phase. Furthermore, in biodegradable stents made of PLLA, non-
invasive QMSCT-CA can be used to quantify luminal dimensions.
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Paclitaxel-eluting stent restenosis shows three-layer
appearance by optical coherence tomography
Shuzou Tanimoto, MD; Jiro Aoki, MD; Patrick W. Serruys, MD, PhD; Evelyn Regar*, MD, PhD
Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands.
All authors contributed to coronary angiography and OCT data acquisition. All authors also contributed to writing and reviewing this manuscript.
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A 73-year-old woman with hypertension, hyperlipidemia and posi-
tive familial history of coronary artery disease presented with
Canadian Cardiovascular Society class III angina and underwent
coronary angiography, which showed a chronic occluded right
coronary artery (Panel A). The vessel was recanalized and treated
with three paclitaxel-eluting stents (TAXUS®, Boston Scientific:
3.5 x 32 mm distally, 3.5 x 28 mm in the middle part, 3.5 x 12 mm
proximally). Postintervention coronary angiography showed a good
result (Panel B). Twelve-month follow-up angiography revealed
focal in-stent restenosis (Panel C).  Intracoronary optical coherence
tomography (OCT: LightLabImaging™, Boston, MA, USA) pullback
displayed well-expanded stents covered with a thin, homogenous,
highly reflective neointimal layer (Panel D, E). In contrast, the nar-
rowest lesion site (minimal lumen area 1.1 mm2; stent area
9.0 mm2) showed a three-layer appearance of the neointima
(Panel F). The inner luminal layer appeared concentric, homoge-
nous and signal-rich (maximal thickness 0.27 mm). A second layer
consisting of a low-reflective area with poorly delineated borders fol-
lowed. The third layer was in direct contact with the stent struts and
revealed only minimal signal intensity. These signal-poor areas
(maximal thickness 1.18 mm) might represent acellular fibrinoid
deposition that has been well described in experimental studies. The
patient was re-treated with repeat paclitaxel-eluting stent implantation.
OCT is an analogue of intravascular ultrasound with an ultra-high
resolution (10 μm) superior to any current available imaging modal-
ities. This imaging device may be useful in visualizing neointimal
growth in drug-eluting stents and improve our understanding of its
underlying physiopathology in the future.
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Abstract
Aims: To validate a novel 3-D QCA system (CardiOp-B™) and compare the 2-D (CAAS II™) and 3-D sys-
tems in in vivo experimental settings. The phantom lumen diameters were also assessed ex vivo by optical
coherence tomography (OCT). The accuracy of the 3-D system has not been appreciated.
Methods and results: Precision-drilled plexiglass phantoms with 5 different luminal diameters that ranged
from 0.5 to 1.9 mm were percutaneously inserted into the coronary arteries in four Yorkshire pigs. Twenty-
two angiographic images of the artificial phantom coronary artery stenoses in the pigs were acquired as an
in vivo validation test. Quantitative assessments of the minimum and mean lumen diameters were per-
formed using both QCA systems. Ex vivo images of the same phantom lumens were also taken and meas-
ured using OCT.
Both of the 2-D and 3-D QCA systems significantly underestimated the actual phantom lumen diameters
with the exception of measurements taken in the lateral projection at isocenter using the 2-D QCA systems.
This underestimation was more significant in the 3-D system (accuracy of 0.19 at isocenter; 0.23 by
catheter calibration). There was good agreement between the two QCA systems. OCT measured the ex vivo
lumen diameter of plexiglass phantoms precisely.
Conclusions: The accuracy of the luminal diameter measurements with the current 2-D system was still
superior to the 3-D system. Further development and validation studies under various conditions are war-
ranted. The excellent results achieved by OCT with the ex vivo images indicate its potential as an intravas-
cular quantitative imaging tool for future clinical practice.
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Introduction
The field of quantitative coronary angiography (QCA) has under-
gone substantial improvement since the first automated QCA devel-
opments took place 1980’s1. Two major clinical applications have
stimulated this improvement: 1) the on-line use during coronary
intervention procedures in catheterisation laboratories; 2) the use 
as an angiographic endpoint for the assessment of stent or pharma-
cological treatments in experimental and clinical trials. On the other
hand, the use of two-dimensional (2-D) interpretation of lesion 
or vessel anatomy and the lack of information about the vessel wall
(other than for calcification) are well known limitations of current
angiography and are situations where intravascular ultrasound
(IVUS) can provide supplemental information. Development of
online three-dimensional (3-D) vessel reconstruction systems based
on angiography may be a solution to the former limitation. The con-
cept of 3-D reconstruction of coronary tree was postulated as early
as the 1980’s2. The routine use of a 3-D quantitative angiography
system in the catheterisation laboratory could be a major improve-
ment in interventional cardiology. 
Recently, a novel 3-D visualisation and quantitative analysis software
system (CardiOp-B™, Paieon Medical Inc., Rosh Ha’ayin, Israel) has
been introduced. This newly developed software system uses the
detected vessel contours in two projections during coronary angiog-
raphy to visualise a 3-D reconstruction of an arterial segment.
Quantitative results are presented based on the reconstruction. 
Its utility and potential advantage over 2-D QCA systems has been
reported3,4. However, to date there have been no studies determin-
ing the accuracy of the 3-D quantitative angiographic technique 
by the in vivo measurement of precisely known vessel lumens. 
Our group has implemented in vivo validation techniques using
radiolucent cylindrical plexiglass or polyamide stenosis phantoms
with precision-drilled eccentric lumens in the field of quantitative
angiographic analysis5-7. The aim of this study was to validate 
a novel 3-D QCA system (CardiOp-B™) and compare the 2-D and 
3-D systems in in vivo experimental settings that simulated a diag-
nostic coronary angiogram.
Aside from the primary objective, we also tested the accuracy 
of optical coherence tomography (OCT), a light-based imaging
modality with a high resolution (10 μm), in the ex vivo measurement
of lumen diameter using the same plexiglass phantoms. This addi-
tional examination was performed in order to investigate its poten-
tial as a quantitative intravascular imaging modality in the future. 
Methods
This study was conducted according to the guidelines of the
American Heart Association on animal use in research and was
approved by the ethics committee on animal experimentation of the
Erasmus Medical Center.
Plexiglas stenosis phantoms
The stenosis phantoms were manufactured at the workshop of the
Erasmus Medical Center. The phantom stenoses that were used con-
sist of radiolucent plexiglass (acrylate) and polyamide cylinders that
have had precision-drilled circular lumens of 499 (aimed to be
0.5mm), 707 (0.7 mm), 982 (1.0 mm), 1,367 (1.4 mm) and
1,921 μm (1.9 mm) in diameter (Figure 1). The outer diameters of
the cylinders are 3.0 or 3.5 mm; the mean lengths of phantoms are
8.28, 7.96, 7.85, 8.01, and 7.38 mm in 0.5, 0.7, 1.0, 1.4, 1.9 mm
diameter phantoms, respectively. Optical calibration of the stenosis
channels using 40 fold magnification gives a tolerance of 0.003 mm.
A second 1.3 mm diameter lumen, parallel to the stenosis lumen, has
been drilled in the cylinders to enable their attachment to the tip of
4 Fr Fogarty catheters (Vermed, Neuilly en Thelle, France). The
lumens of the Fogarty catheters contained a removable metallic stylet
that aided the intracoronary insertion of the phantoms as well as their
positioning in the radiographic isocenter. Details of our experimental
approach to QCA validation have been previously described5-7.
Animal preparation
Four Yorkshire pigs (average weight, 40 to 45 kg) were pretreated with
intramuscular ketamine (20 mg/kg) and intravenous etomidate
(5 mg/kg). The animals were then intubated and ventilated with 
a mixture of oxygen and isoflurane. Anaesthesia was maintained with
a continuous intravenous infusion of pentobarbital (5-20 mg/kg/hour).
12 Fr introducer sheaths were inserted into both carotid arteries 
to allow the sequential insertion of the guiding catheter and phan-
toms. Jugular access was used for the administration of medication
and fluid. An intravenous bolus (10,000 IU/l) followed by a continu-
ous infusion of heparin was given.
In vivo image acquisition of stenosis phantoms
by fluoroscopy
The digital angiograms were obtained with a biplane cine angio-
graphic system (Axiom Artis™, Siemens, Forchheim, Germany) that
employs a matrix size of 1,024 x 1,024 pixels. The radiographic sys-
Figure 1. A: The magnified tip of one of the Fogarty catheters used
for mounting the phantom. Note the transparent radiolucent cylinder
connected to the tip of the catheter with a channel of 1.9 mm diam-
eter (white arrow) and the catheter lumen used for insertion of remov-
able metallic stylet (black arrow). B: The catheter tip photographed
perpendicularly to the long axis of the phantom lumen. Note the
almost perfect circular aspect of the precision-drilled lumen (diame-
ter 1.9 mm, white arrow). The catheter lumen used for insertion of
metallic stylet is indicated with a black arrow.
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tem settings used were the same (kVp, mA, ms) in all projections.
All phantoms were imaged in two projections simultaneously. After
engaging the 6 Fr guiding catheter (Mach 1™, Boston Scientific
Corp., Natick, MA, USA) in either the left or right coronary artery,
intracoronary isosorbide-dinitrate (1 mg) was administered. The first
angiogram was then performed for orientation purposes. The phan-
toms were wedged in the coronary arteries and positioned in the X-
ray isocenter using the tip of the metal wire as a marker. The wire
was removed prior to angiography. Coronary angiography was per-
formed by manual injection of contrast medium (Visipaque™
320 mg I/ml, Amersham Health B.V., Eindhoven, The Netherlands).
The ventilator was disconnected transiently during contrast injection
to minimise the effect of diaphragmatic movement on angiographic
images. 
Calibration 
Two different calibration methods were used during off-line analysis.
1) Calibration at the isocenter: this method was performed using an
automatic isocentric calibration - this is one of the calibration options
of the biplane angiographic system. The calculated calibration factor
is used for 2-D and 3-D QCA analyses by entering the number in 
millimetres in the manual calibration mode; 2) Conventional catheter
calibration: the non-tapering part of the tip of each 6 Fr guiding
catheter filled with contrast was used as a reference. 
Quantitative angiographic analysis of ex vivo
and in vivo phantom images
The off-line measurement of the minimum lumen diameter (MLD)
and the mean lumen diameter (mean LD) were performed by 2-D
QCA (CAAS IITM version V2.0.1, Pie Medical Imaging, Maastricht,
The Netherlands) as well as by 3-D QCA system (CardiOp-BTM ver-
sion 1671017, Paieon Medical Inc.). For in vivo analysis, an end-
diastolic cine frame was selected. 
Manual edge correction is an option available in both systems, 
but this was intentionally never allowed in the present analyses. 
In the 2-D system, a restriction option was applied in order to cor-
rect for an unsatisfactorily detected contour in one image. This
option is not technically a manual correction, but offers users the
possibility of excluding parts of the image of the detection by
restricting the area of interest. For the one measurement with the 
3-D system, the automatically determined stenotic segment was
manually corrected to avoid the measurement of the MLD at the site
of a discrete intraluminal filling defect. Minimum values as well 
as mean values were determined as the diameters of the stenosis
phantom lumens. Each angiographic image that was analysed 
or calibrated (for catheter calibration) was designated specifically 
by the number of the frame count so that all of the analyses using
both QCA systems were performed upon identical images.
2-D QCA system
The diameter of the stenosis phantoms was calculated with an auto-
matic contour detection technique. The user is able to define a
number of centreline points within the vessel segment. The frontal
and the lateral images are analysed separately. The mean LD of the
phantom lumen is obtained with the CAAS II™ system from a user-
defined region of interest (ROI) where the two vessel contours are
considered to be parallel (Figure 2). 
3-D QCA system
This system uses the contours detected in the frontal and lateral
images in combination with the projection data in the DICOM format
into a 3-D reconstruction of an arterial segment. The two acquired
images that are used for reconstruction must differ by an angle 
of at least 30 degrees. In this study, two orthogonal views, simultane-
ously acquired by the biplane system, were used for reconstructing
a 3-D vessel image. If calibration was performed in one view, further
calibration was not requested in the second corresponding view. 
To perform quantitative analysis, the user is requested to mark three
points: proximal and distal reference points and point within the
A
B
C
Figure 2. Angiographic visualisation of the artificial coronary obstruc-
tion produced by a 1.0 mm stenosis phantom in the left anterior
descending artery (A) with subsequent quantitative measurement 
of luminal diameter by 2-D QCA system (CAAS II™) (B, C). The 
bidirectional arrow indicates the region of interest for mean luminal
diameter (C).
mm
C A
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3,40
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stenosis. The severity of the stenosis is indicated by the colour given
by the computer to the reconstructed segment that varies from
white (healthy vessel) to dark red (99% cross-sectional area steno-
sis) (Figure 3). The minimum luminal diameter values are automat-
ically given as one of the default quantitative data. As mean LD with-
in the user-defined ROI is not automatically supplied in this system,
we obtained the values using a text import wizard of MS Excel 2003.
The current version of 3-D QCA system does not provide quantita-
tive degree of vessel curvature and bifurcation angle between main
and side branch.
Ex vivo image acquisition of stenosis 
phantoms by OCT
We prepared a fluid mixture containing 90% degassed water and
10% ethanol as an ex vivo replacement for blood. The room tem-
perature was kept at 22 °C. These conditions are similar to those
required for the preparation for an ex vivo validation of intravascu-
lar ultrasound8,9. The OCT wire was inserted into the five differently
sized phantom lumens. Images were obtained with the M2 OCT
imaging system (Lightlab Imaging, inc.). The M2 OCT system uses
a 1,310-nm broadband light source to produce images with an axial
resolution of 15 μm and a lateral resolution of 25 μm by the princi-
ple of interferometry. The M2 uses the ImageWire™ imaging probe
to deliver light to the tissue and collect the returning signals. The
ImageWire™ consists of 0.006-inch (0.15 mm) fiberoptic core,
inside a sheath with a maximum o.d. of 0.019 inch (0.48 mm). 
OCT image analysis
The images were stored for off-line analysis in the OCT system com-
puter. The analysis was performed using proprietary software from
Lightlab Imaging, Inc. with a mouse based interface. The system
was calibrated to the reflection of the OCT imaging wire that is the
standard calibration technique for this system. Lumen diameter and
lumen area in each of the 5 phantoms were measured.
Intra- and inter-observer variability assessment
Two independent observers, who were blinded to the real phantom
diameters, assessed reproducibility by measuring the minimum
and mean luminal diameter using each of the two QCA systems. 
In the ex vivo cases imaged by OCT, only the cross sectional diam-
eter was analysed and used for evaluation of reproducibility. These
examinations by two observers were performed on different days.
One of the two observers performed second measurements on dif-
ferent days for assessment of individual reproducibility. 
Statistical analysis
The individual values for minimum and mean luminal diameter
obtained by both QCA systems were compared with the corresponding
values of the phantom by paired t test (two-tailed). Additionally, the data
were plotted against the actual phantom diameter values and a linear
regression analysis was applied. The mean differences between meas-
ured luminal diameters and the corresponding phantom dimensions
Figure 3. Illustration of the 3-D reconstruction process by CardiOp-BTM. Color-coded 3-D reconstruction of coronary artery with artificial stenot-
ic segment (3-D Reconstruction view) is derived from 2 orthogonal views (Frontal and Lateral). The 3-D colour varies according to the severity
of stenosis ranging from white (healthy vessel) to dark red (99% cross-sectional area stenosis). The squares in pale blue, yellow and green denote
proximal reference point (P), most stenotic point (S) and distal reference point (D) of the target lesion, respectively. The region of interest (ROI)
for calculation of mean luminal diameter can be manually defined by moving the proximal (P) and distal (D) points (Definition of ROI for mean
LD; Graph view).
Frontal
Lateral
3-D Reconstruction view
Defining of ROI 
for mean LD
Graph view
P
S
D
P
P S D
S
D
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were computed and considered to be an index of the accuracy of 
the measurements, while the standard deviation of the differences 
was defined as an index of precision. The relative standard deviation
was calculated (precision / mean of measured diameter value x 100) 
to assess the degree to which the sets of diameter data points varied.
In order to determine the agreement between 2-D and 3-D QCA 
systems, Bland-Altman analysis was performed10. Statistical analyses
were performed with SPSS 12.0.1 for Windows (SPSS Inc., Chicago, IL,
USA). A p value < 0.05 was considered statistically significant.
Results
Thirty coronary angiographic images were acquired after intracoro-
nary insertion of the stenosis phantoms. Three images were
excluded from the QCA analysis because of extreme foreshorten-
ing of the stenosis segment in frontal views. Five images that had
insufficient arterial filling using the 0.5 or 0.7 mm phantoms were
also excluded. The remaining 22 images were used for the diame-
ter measurements using both QCA systems. 
In vivo intra- and inter-observer variability of the 2 QCA systems and
ex vivo OCT was calculated in all the 22 analysable images (Table 1).
Satisfactory reproducibility was noted in all of the two QCA systems
and OCT.
In vivo assessment of luminal diameter 
by 2-D and 3-D QCA
The comparative results of the actual phantom lumen diameter and
the dimensional values derived from both QCA systems are shown in
Table 2 along with Figures 4 and 5. In both systems, accuracy was
better with isocentric calibration compared to catheter calibration.
Mean luminal diameter measurements yielded better accuracy 
than minimum values in any of the dimensional measurements.
Among the 8 methods of diameter measurements in the 2-D QCA,
mean luminal diameter by isocentric calibration in lateral view proved
to have the best accuracy (0.01 mm). Both systems significantly under-
estimated the actual phantom diameter values, except for minimum
and mean diameters in the lateral view with isocentric calibration. 
There was again good correlation between luminal diameter meas-
urements and phantom actual diameter values with both QCA 
systems (r=0.961 ~ 0.987). However, the 2-D QCA system demon-
strated better values of accuracy than the 3-D system in diameter
measurements regardless of the calibration option.
Agreement between 2-D and 3-D QCA systems
A direct comparison between the 2-D (frontal views) and the 3-D
QCA systems is shown in Figure 6. The two systems demonstrate
good correlations in diameter measurements (r=0.947 isocenter,
minimum; r=0.982, isocenter, mean; r=0.940, catheter, minimum; 
r=0.976, catheter, mean). The plot of differences between both 
systems demonstrates satisfactory agreement over the entire range
of phantom sizes. This proved to be true for calibration at the isocen-
ter as well as for catheter calibration (Figure 6). 
Ex vivo assessment of luminal diameter by OCT
Figure 7A depicts the linear regression analysis of comparison
between actual phantom luminal diameter versus ex vivo diameter
values derived from OCT. OCT-based dimensional values proved 
to correlate extremely well with the real luminal diameter (accura-
cy= – 0.03, precision=0.02, relative standard deviation=1.8%, 
r=1.000, intercept=0.01, slope=1.02). OCT clearly visualised the
circular lumen of plexiglass phantom (Figure 7B). 
Table 1. Intra- and inter-observer variability of lumen diameter.
Intra-observer Inter-observer
Diff. r Intercept Slope Diff. r Intercept Slope
Ex vivo analysis
OCT lumen diameter 0.03±0.02 1.000 –0.01 0.99 0.00±0.05 0.996 0.04 0.97
In vivo analysis
2-D QCA system
Isocentric 
Frontal MLD –0.01±0.03 0.997 –0.01 1.01 0.02±0.11 0.969 -0.02 1.00
Lateral MLD 0.00±0.03 0.998 0.00 1.00 0.06±0.09 0.985 0.03 0.92
Frontal mean LD –0.01±0.03 0.998 –0.02 1.01 0.02±0.08 0.982 -0.02 1.00
Lateral mean LD 0.01±0.05 0.993 0.02 1.00 0.06±0.08 0.986 0.03 0.93
Catheter
Frontal MLD –0.01±0.06 0.991 0.05 0.94 0.00±0.10 0.972 0.01 0.99
Lateral MLD 0.02±0.05 0.993 0.00 1.02 –0.03±0.09 0.983 0.01 1.02
Frontal mean LD –0.01±0.08 0.981 0.06 0.93 0.00±0.07 0.984 0.00 1.00
Lateral mean LD 0.00±0.05 0.991 0.04 0.97 –0.02±0.07 0.989 0.00 1.02
3-D QCA system
Isocentric 
MLD 0.01±0.03 0.997 0.01 1.00 0.01±0.09 0.973 0.06 0.95
Mean LD 0.00±0.03 0.997 –0.04 0.97 0.03±0.06 0.988 0.11 0.93
Catheter
MLD 0.00±0.06 0.986 –0.02 1.03 0.01±0.08 0.973 0.09 0.92
Mean LD –0.01±0.05 0.994 –0.05 1.04 0.03±0.09 0.972 0.11 0.92
LD = luminal diameter; MLD = minimum luminal diameter; OCT = optical coherence tomography; QCA = quantitative coronary angiography
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Table 2. Summary of in vivo validation results of 2-D and 3-D QCA systems (CardiOp-B™) (22 observations)
Measured Accuracy Precision Relative Correlation SEE Intercept Slope p-value of 
diameter (mm) SD* (%) paired t test
2-D QCA
Isocentric
Frontal MLD 1.07 0.10 0.12 11.1 0.968 0.11 0.04 0.88 0.001
Lateral MLD 1.06 0.10 0.08 7.9 0.985 0.07 0.00 0.91 < 0.0001
Frontal mean LD 1.19 –0.03 0.09 7.9 0.983 0.08 0.17 0.88 0.17
Lateral mean LD 1.15 0.01 0.09 7.6 0.987 0.07 0.13 0.88 0.43
Catheter
Frontal MLD 0.98 0.18 0.12 12.4 0.971 0.10 0.01 0.83 < 0.0001
Lateral MLD 1.01 0.16 0.11 11.2 0.977 0.09 0.03 0.84 < 0.0001
Frontal mean LD 1.09 0.07 0.11 9.9 0.980 0.08 0.11 0.84 0.005
Lateral mean LD 1.10 0.06 0.10 9.2 0.984 0.07 0.12 0.84 0.009
3-D QCA
Isocentric
MLD 0.98 0.19 0.13 13.7 0.966 0.10 0.04 0.80 < 0.0001
Mean LD 1.04 0.13 0.10 9.4 0.985 0.07 0.05 0.85 < 0.0001
Catheter
MLD 0.93 0.23 0.14 15.2 0.970 0.09 0.05 0.76 < 0.0001
Mean LD 0.99 0.18 0.13 11.4 0.984 0.07 0.05 0.80 < 0.0001
* (precision/mean of measured diameter value) x 100
LD = luminal diameter; MLD = minimum luminal diameter; OCT, QCA = quantitative coronary angiography; SD = standard deviation
A B 
C D 
Figure 4. Two-dimensional QCA assessment of minimum (continuous black lines) and mean luminal diameter (continuous grey lines) with cali-
bration at the isocenter in frontal (A) and lateral views (B) and with catheter calibration in frontal (C) and lateral views (D). The dashed lines
indicate the line of identity.
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A B 
Figure 5. Three-dimensional QCA assessment of minimum (continuous black lines) and mean luminal diameter (continuous grey lines) with cal-
ibration at the isocenter (A) and with catheter calibration (B). The dashed lines indicate the line of identity.
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Figure 7. A: Linear regression analysis of the phantom lumen diameter versus the cross-sectional luminal diameter measured with OCT. 
B: Representative OCT images of the stenosis phantom with 1.4-mm lumen. Arrow: 1.4-mm lumen for measurement; arrow head: lumen for
guidewire.
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Figure 6. Bland-Altman plots of the differences between the minimum and mean luminal diameter measurements acquired by the 2 systems versus
means of the measurements. A: minimum diameter with calibration at the isocenter. B: mean diameter with calibration at the isocenter. C: minimum
diameter with catheter calibration. D: mean diameter with catheter calibration. The data from the frontal view are used as 2-D QCA measurements.
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Discussion
The results of the present study indicate the following three findings: 
1) the 3-D QCA system significantly underestimated actual phan-
tom diameter values compared to the 2-D system; 2) the 3-D QCA
system showed a good agreement with the 2-D QCA system; 3) the
values of the ex vivo diameter measurements by OCT were almost
identical to the actual phantom diameter values.
As the number of coronary interventions has increased over the years,
the complexity of target lesions has increased concomitantly.
Development of a 3-D visualisation and quantitative analysis system
has been encouraged by the increasing need to better understand the
true vessel structure and the spatial orientation of complex 
features and to quantify vessel morphology more precisely. There 
is a growing interest in applying this new technology as an additional
imaging tool in interventional cardiology. Recently, the feasibility and
potential superiority of 3-D QCA system in the measurement of
38 coronary lesions was reported by comparing it with a 2-D QCA sys-
tem (Medview™, Medcon Telemedicine Technology, Tel Aviv, Israel)3.
However, this 3-D QCA system should be evaluated in comparison
with the largely validated conventional 2-D QCA systems5,7,11,12.
Moreover, the accuracy or limitations of this system can only be appre-
ciated by measuring in vivo vessels of known lumen dimensions. This
is especially important since the accuracy of the reconstruction is not
only the basis for quantitative results but also for producing a correctly
visualised image. In theory the 3-D quantitative analysis should fully
correct for foreshortening and out-of-plane magnification differences.
Systematic underestimation of luminal diameter measurements was
noted for both QCA systems and this was more significant in the 3-D
system. The image acquisition was performed by hand injection of
contrast and this may result in less radiographic opacity of stenotic
segment compared to mechanical injection. Consequently automated
detection of vessel boundaries might have been affected leading to
smaller diameter values than expected having been derived. However,
even with mechanical contrast injection, the angiographic examination
of these high-grade stenosis phantoms cannot always be satisfactory
because of possible intraluminal thrombus that results from the
reduced blood flow or from the presence of intraluminal cellular debris
collected during the insertion of the phantoms. 
The values of the both QCA systems with catheter calibration were
smaller than those obtained with calibration at isocenter. This might
be explained by an out-of-plane magnification phenomenon:
a greater distance between the image intensifier and the catheter tip
than between the image intensifier and the isocenter that would
result in a smaller calibration factor13,14. In the 2-D QCA system, lat-
eral views showed better accuracy and precision than frontal views.
Foreshortened images were more frequently observed in frontal
views than in lateral views. Accordingly, suboptimal contour detec-
tion of frontal images might have occurred. Although theoretically
the 3-D reconstruction should enable the correction of foreshorten-
ing and out-of-plane magnification errors, these improvements
could not be identified in the present analysis.
OCT is a novel imaging modality that provides intravascular images
that have a resolution of approximately 10 - 20 μm. This 10-fold
greater resolution in comparison with IVUS enables visualisation 
of microscopic structures within the coronary arteries15,16. In vivo
dimensional and volumetric measurements of implanted coronary
stents have shown that OCT can produce accurate results that are
comparable to IVUS17. Post-mortem analysis suggested that OCT
can measure the intima-media thickness more accurately than
IVUS18. Currently OCT is regarded as a modality that may surpass
the performance of angiography or IVUS after stent implanta-
tion19,20. The present study provided ex vivo validation of OCT with
respect to diameter measurements. Unfortunately, we could not
compare OCT to IVUS because the IVUS catheter could not cross
phantom lumens smaller than 1.0 mm. Furthermore in vivo exami-
nation would most likely prove difficult in these high-grade stenoses
as the presence of a wire itself might result in the rapid development
of intolerable ischaemic changes for the animals even before the
induction of further ischaemia by the OCT occlusion balloon.
Limitations
This validation test using concentric cylindrical phantoms was origi-
nally designed to test 2-D QCA systems5,7,11,12. The use of phantoms
with a regular circular lumen does not allow the assessment of asym-
metry. Here the use of reconstruction from two projections included
in one 3-D result supplies information of lesion asymmetry more pre-
cisely than that available from 2-D analysis. Since the precise and
validated eccentric phantoms were not readily available, we decided
to conduct the present study with previously established approach
using concentric phantoms5,7,11,12. The 3-D reconstruction is based
on a two imaged diameters that results in an oval cross section
where the 2-D analysis is based on one image results in a single
diameter to be used for a circular cross section. However, densito-
metric analysis available in the 2-D QCA system can provide esti-
mates for cross sectional areas in complex lesions21,22. 
Our results were based on a series of small-size (< 2 mm) lumen
phantoms. From a clinical point of view, validation tests using larg-
er-size (> 2.25 ~ 2.5 mm) phantoms might be more relevant to
investigate whether this 3D system is useful as a tool to determine
the optimal device size, or to confirm the acute post-procedural
results during the interventional procedures.
Conclusions
The minimum and mean luminal diameter measured with the 3-D
QCA system underestimated the true phantom lumen diameter
more than 2-D QCA. However, since there was a strong correlation
with the 2-D QCA system, this system could be a useful alternative
in clinical practice. OCT precisely measured the lumen diameter 
of plexiglass phantoms in this ex vivo experimental setting. In addi-
tion to its usefulness in the quantitative assessment of coronary
plaque, this imaging tool could be developed further as a reliable
device for intravascular quantitative assessment with the advance-
ment of less invasive preparation for the image acquisition.
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A Novel Approach for Quantitative Analysis
of Intracoronary Optical Coherence
Tomography: High Inter-Observer
Agreement With Computer-Assisted
Contour Detection
Shuzou Tanimoto,1 MD, Gaston Rodriguez-Granillo,1 MD, Peter Barlis,1 MBBS, MPH, FRACP,
Sebastiaan de Winter,1 MSc, Nico Bruining,1 PhD, Ronald Hamers,1 PhD, Michiel Knappen,2 PhD,
Stefan Verheye,2 MD, PhD, Patrick W Serruys,1 MD, PhD, and Evelyn Regar,1* MD, PhD
Objective: This study aims to examine observer-related variability of quantitative opti-
cal coherence tomography (OCT) derived measurements from both in vitro and in vivo
pullback data. Background: Intravascular OCT is a new imaging modality using infra-
red light and offering 10 times higher image resolution (15 lm) compared to intravascu-
lar ultrasound. The quantitative analysis of in vivo intracoronary OCT imaging is
complicated by the presence of blood, motion artifacts and the large quantity of infor-
mation that has to be processed. Methods: We developed a standardized, automated
quantification process for intracoronary OCT pullback data with inter-observer variabil-
ity assessed both in vitro by using postmortem human coronary arteries and in vivo by
studying simple and complex coronary pathology and outcomes following stent im-
plantation. The consensus between measurements by two observers was analyzed
using the intraclass and interclass correlation coefficient and the reliability coeffi-
cients. Bland–Altman plots were generated to assess the relationship between variabil-
ity and absolute measurements. Results: In vitro OCT assessment was performed in
nine postmortem coronary arteries. The time needed for semiautomated contour
detection of a 15-mm long coronary segment was 40 min. The absolute and relative
difference between lumen area measurements derived from two observers was low
[0.02 6 0.10 mm2; (0.3 6 0.5)% respectively] with excellent correlation confirmed by
linear regression analysis (R2 5 0.99; P < 0.001). Similarly, in vivo measurements dem-
onstrated a high correlation with the main source of inter-observer variation occurring
as a result of coronary dissection and motion artifact. The absolute and relative
difference between measurements were 0.11 6 0.33 mm2 (1.57 6 0.05)% for
lumen area (R2 5 0.98; P < 0.001), 0.17 6 0.68 mm2 (1.44 6 0.08)% for stent area (R2 5
0.94; P < 0.001), and 0.26 6 0.72 mm2 (14.08 6 0.37)% for neointimal area (R2 5 0.78;
P < 0.001). Conclusions: Highly accurate computer-assisted quantitative analysis
of intracoronary OCT pullbacks is feasible with low inter-observer variability.
The presented approach allows for observer independent analysis of detailed vessel
structures, and may be a valuable tool for future longitudinal studies incorporating
OCT. ' 2008 Wiley-Liss, Inc.
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INTRODUCTION
Optical coherence tomography (OCT) is a light-
based imaging modality that can be used to study bio-
logical tissues in vivo [1]. Recently, the concept of
catheter-based intracoronary OCT has been introduced
[2–4] allowing in vivo imaging of the coronary vessel
wall with a lateral resolution of 15 lm and an axial re-
solution of 25 lm [5]. The currently accepted gold
standard, intravascular ultrasound (IVUS), operates at a
lateral resolution of 120 lm and axial resolution of
80 lm. The unique high-resolution OCT imaging mo-
dality permits the analysis of coronary structures in
greater detail. The measurement accuracy of intracoro-
nary OCT has been established in postmortem human
coronary arteries and showed good correlation to histo-
morphometry [6]. However, compared to ex vivo
imaging, quantitative analysis of in vivo intracoronary
imaging is more complicated due to the presence of
blood and motion artifacts during cardiac cycle. Fur-
thermore, the OCT dataset acquired during motorized
pullback in vivo is much larger than local imaging of
selected cross sections as performed in postmortem
studies. A pullback through the region of interest
(ROI) is necessary in order to visualize the three-
dimensional morphology of the coronary artery. The
present research proposes a standardized automated
quantification process for intracoronary OCT pullback
data. To test its accuracy, inter-observer variability
was assessed in vitro and in vivo including both sim-
ple and complex vessel anatomy, represented by native
coronary arteries before and after stent implantation.
METHODS
OCT Imaging System
We used a commercially available system for intra-
vascular OCT imaging (LightLab Imaging, Westford,
MA). The light source was a 1310-nm broadband
super luminescent diode with an output power in the
range of 8.0 mW. The imaging depth was 1.5 mm
with an axial and lateral resolution of 15 and 25 lm,
respectively. The imaging probe (ImageWireTM Light-
Lab Imaging) had a maximum outer diameter of 0.019
in. and contained a single-mode fiber optic core within
a translucent sheath. The image wire was connected at
its proximal end to the imaging console that permitted
real-time data processing and two-dimensional repre-
sentation of the backscattered light in a cross-sectional
plane. Images were acquired at 15 frames/sec. The
fiber optic core was withdrawn within the catheter
sheath using automated pullback at 1.0 mm/sec.
The accuracy of the OCT system has been recently
reported. Diameters of phantoms with precision-drilled
circular holes were measured in vitro using proprietary
software from LightLab with excellent accuracy
(20.03) and precision (0.02) [7].
Human Coronary Arteries—Postmortem Study
In all cases (n 5 9), the left anterior descending ar-
tery was studied after pressure fixation using 10% buf-
fered formalin. The take off of the first diagonal
branch was used as proximal landmark. Both the prox-
imal and the distal end of the coronary specimen were
sutured to a 6F introducer sheath and positioned in a
saline bath at 378C. The OCT imaging wire was intro-
duced via the proximal sheath into the specimen and
positioned in such a way that the distal OCT catheter
tip was fixed in the distal sheath and an automated
OCT pullback was performed.
Human Coronary Arteries—Clinical Studies
Patients undergoing a stent-implantation procedure
(n 5 10) or a 6-month follow-up angiogram poststent
implantation (n 5 10) were studied. A standard femo-
ral approach with 7F guiding catheters was used. All
patients received weight-adjusted intravenous heparin
in order to maintain the activated clotting time >300
sec and intravenous analgesics before imaging. First, a
dedicated compliant occlusion catheter (Helios, Good-
man, Japan) was introduced into the artery and posi-
tioned proximally to the ROI. The occlusion catheter
allows (a) for limiting the coronary blood flow by very
low-pressure (0.3 atm) inflation of a short (6.0 mm
length) balloon, (b) for simultaneous clearing of the ar-
tery by delivering flush distally to the balloon into the
lumen, and (c) for introduction of the OCT imaging
wire into the artery. After positioning the occlusion
catheter in over the wire technique, the standard
0.014@ guide wire was withdrawn, and the OCT imag-
ing wire introduced via the central lumen distal into
the target vessel. An automated OCT pullback was
then performed. During OCT image acquisition, the ar-
tery was cleared with lactated Ringer’s solution (flow
rate 0.5 ml/sec; temperature 378C). Sufficient occlusion
of the lumen was documented by contrast injection via
the guiding catheter and the balloon pressure increased
to 0.5 atm if necessary.
Quantitative OCT
The digitized tomographic OCT image dataset was
transformed from digital movie file format (AVI) into
the medical DICOM image standard and stored onto a
picture archiving system. Quantitative OCT (QOCT)
analysis was performed using dedicated software
(CURAD vessel analysis, CURAD BV, Wijk bij Duur-
stede, Netherlands) [8] (Fig. 1). Every third frame of
the pullback of long segments was entered. This
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reduced the number of frames in the Curad software
from n to at most (n/2) 1 1 per set. Two blinded
observers experienced in the theory and practice of
OCT performed the analysis. In nonstented arteries,
the lumen area was directly traced and the mean
lumen diameter calculated using a circular model. In
stented arteries, lumen- and stent-area were both
directly traced, the mean lumen- and mean stent-diam-
eter were calculated. Neointimal area was calculated as
stent area minus lumen area.
OCT cross sections with a major side branch (diam-
eter >2 mm; or side branch take off occupying more
than 60 degrees of the lumen circumference of the par-
ent vessel) were excluded from analysis as well as
cross sections, in which the complete lumen circumfer-
ence of 360 degrees could not be visualized due to
motion artifacts during the cardiac cycle.
Statistical Analysis
Statistical analyses were performed using SPSS
12.0.1 for Windows (SPSS, Chicago, IL). Data are
expressed as mean 6 SD or median and inter-quartile
range, if appropriate. Inter-observer agreement was
determined by comparing measurements of each ob-
server (observer 1 vs. observer 2) using the Bland–
Altman method [9]. Data are given as plots showing
the absolute difference between corresponding meas-
urements of both observers (y-axis) against the average
of both observers (x-axis). The relative difference
between measurements (absolute difference divided by
the average) gives the bias; its standard deviation gives
the random variation. The limits of agreement were
calculated as mean bias 6 2 SD. Confidence intervals
(95%) were calculated. In addition, absolute data were
analyzed for correlation by regression analysis as nec-
essary, but not sufficient, condition for agreement. The
regression line was forced through the origin. A P-
value less than 0.05 (two-tailed students t-test) was
considered statistically significant.
RESULTS
In Vitro Coronary Arteries
OCT imaging was successfully performed in all
specimens (n 5 9). Computer-assisted contour detection
Fig. 1. Example of quantitative OCT analysis in an ex vivo
coronary artery. The digitized tomographic OCT image dataset
was transformed from digital movie file format (AVI) into the
medical DICOM image standard and stored onto a picture
archiving system. The dedicated software (CURAD) allows for
simultaneous display of a cross sectional view (A) and two
longitudinal cut planes (B). After a selection of a region of
interest, the lumen contours are traced using automated
contour detection whereby both the cross sectional and the
longitudinal image information is exploited.
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was possible in all pullbacks. In each coronary artery,
a ROI of 15 mm in length was selected for analysis.
The time needed for computer-assisted contour detec-
tion of a 15-mm long coronary segment was 40 min.
Data for lumen dimensions by both observers are given
in Table I. The absolute difference in lumen area
between the observers was low (0.02 6 0.10 mm2).
Linear regression analysis confirmed these observations
and showed excellent correlation between measure-
ments (R2 5 0.99). Bland–Altman plots for lumen area
and lumen diameter are shown in Fig. 2.
In Vivo Native Coronary Arteries
OCT imaging could be successfully performed with-
out complications in all patients. The majority of
patients (90%) developed transient ECG changes indic-
ative of ischemia during imaging.
Ten coronary segments of 28 6 9 mm lengths were
studied. A total of 1,807 frames were included in the
analysis and 399 frames were excluded due to the
presence of a major side branch, or due to incomplete
visualization of the lumen circumference due to motion
artifacts.
OCT data are summarized in Table II. The absolute
difference between observers was low (lumen area
0.04 6 0.14 mm2) and in the same order of magnitude
as for in vitro measurements. Linear regression analy-
sis confirmed these observations and showed high cor-
relation between measurements (R2 5 0.99). Bland–
Altman plots for lumen area and lumen diameter are
shown in Fig. 3. The bias between the observers was
again very low. Main sources of disagreement between
observers were situations, in which lumen borders
were ambiguous due to anatomical factors (e.g., dissec-
tions) or due to motion artifacts during the cardiac
cycle.
In Vivo Stented Coronary Arteries at Follow-Up
Ten coronary segments of 25 6 11 mm lengths
were studied. Stent struts covered by neotinimal tissue
were clearly visible in all segments and in all cross
sections. Inter-observer agreement on the presence of
TABLE I. Comparison of Lumen Measurements in Ex-Vivo Cor-
onary Arteries, n 5 772 Frames
Lumen area Lumen diameter
Observer 1
Median (IQR) 2.48 (1.81) mm2 1.78 (0.64) mm
Mean 6 1 SD 3.03 6 1.95 mm2 1.88 6 0.58 mm
Observer 2
Median (IQR) 2.49 (1.75) mm2 1.78 (0.62) mm
Mean 6 1SD 3.02 6 1.93 mm2 1.87 6 0.58 mm
Absolute difference 0.02 6 0.10 mm2 0.00 6 0.04 mm
Relative difference (0.3 6 0.5)% (0.1 6 0.2)%
Linear regression
Slope 0.9904x 0.9905x
Intercept 0.0125 0.0135
R2 0.9974 0.9957
P <0.001 <0.001
Fig. 2. Bland–Altman plots for measurements in ex vivo coronary arteries. The x-axis shows
the mean cross sectional area, and the y-axis shows the difference between the cross sec-
tional measurements by observer 1 and observer 2. The dotted lines indicate the limits of
agreement (bias 6 2 SD). (A) Lumen area (B) Lumen diameter.
TABLE II. Comparison of Measurements in In-Vivo Coronary
Arteries, n 5 1,807 Frames
Lumen area Lumen diameter
Observer 1
Median (IQR) 4.34 (2.21) mm2 2.35 (0.6) mm
Mean 6 1 SD 4.29 6 1.37 mm2 2.30 6 0.40 mm
Observer 2
Median (IQR) 4.36 (2.19) mm2 2.36 (0.59) mm
Mean 6 1SD 4.25 6 1.34 mm2 2.30 6 0.39 mm
Absolute difference 0.04 6 0.14 mm2 0.01 6 0.04 mm
Relative difference (0.6 6 0.4)% (0.3 6 0.2)%
Linear regression
Slope 0.9755 0.9731
Intercept 0.0647 0.0523
R2 0.9904 0.9894
P <0.001 <0.001
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neointimal tissue was 100%. A total of 2,331 cross
sections were included for analysis. In two patients, a
total of 80 cross sections were excluded from analysis
because of the take-off of a major side branch, and
another 73 cross sections because of incomplete visual-
ization of the lumen circumference due to motion
artifacts.
OCT data for lumen, stent, and neointimal area are
summarized in Table III. Bland–Altman plots for
lumen stent and neointimal area, as well as lumen and
stent diameter are shown in Fig. 4. As expected, the
bias for the calculated variable of neointimal area was
somewhat higher than for directly traced stent and
lumen area with greater variability observed in assess-
ing stent area. This relates to the operator having to
manually trace each individual stent strut compared to
a sharply demarcated lumen/vessel border when assess-
ing lumen area.
DISCUSSION
The main findings of this study are: (1) Inter-ob-
server variability for lumen dimensions as measured
by computer-assisted QOCT is extremely low and in a
similar range for both in vitro as well as for in vivo
studies, despite the occurrence of motion-induced arti-
facts during the acquisition in vivo. (2) Similarly,
inter-observer variability in complex vessel anatomy as
represented by chronic coronary stents was very low.
Optical Coherence Tomography
OCT is a new intravascular imaging technology that
permits the visualization of vascular microstructures
with high precision. Its unique image resolution, in the
range of 15 lm, is in the magnitude of 10 times higher
than the current golden standard, IVUS. Further, the
visualization of plaque morphology in close proximity
to the vessel lumen is superior to that obtained with
IVUS [10]. To date, findings based on single frame
analysis only in distinct areas within the coronary tree
have been published. The clinical application of intra-
coronary OCT has already been demonstrated in both
stable and unstable patients [11]. Potential future appli-
cations are manifold. They may include in vivo visual-
ization of features associated with vulnerable plaque
(e.g., thin fibrous cap) [12], analysis of early athero-
Fig. 3. Bland–Altman plots for measurements in in vivo coronary arteries. The x-axis shows
the mean cross sectional area, and the y-axis shows the difference between the cross sec-
tional measurements by observer 1 and observer 2. The dotted lines indicate the limits of
agreement (bias 6 2 SD). (A) Lumen area (B) Lumen diameter.
TABLE III. Comparison of Measurements in In-Vivo Stented Coronary Arteries, n 5 2,331 Frames
Lumen area Lumen diameter Stent area Stent diameter Neointima area
Observer 1
Median (IQR) 6.1 (3.45) mm2 2.79 (0.815) mm 9.28 (4.055) mm2 3.44 (0.77) mm 2.96 (2.105) mm2
Mean 6 1 SD 5.97 6 2.41 mm2 2.69 6 0.58 mm 9.02 6 2.77 mm2 3.34 6 0.55 mm 3.05 6 1.48 mm2
Observer 2
Median 6.2 (3.63) mm2 2.81 (0.85) mm 9.07 (3.915) mm2 3.4 (0.75) mm 2.77 (2.14) mm2
Mean 6 1 SD 6.07 6 2.46 mm2 2.72 6 0.59 mm 8.84 6 2.63 mm2 3.31 6 0.52 mm 2.79 6 1.53 mm2
Absolute difference 0.11 6 0.33 mm2 0.023 6 0.07 mm 0.17 6 0.68 mm2 0.03 6 0.13 mm 0.26 6 0.72 mm2
Relative difference (1.57 6 0.05)% (0.79 6 0.03)% (1.44 6 0.08)% (0.72 6 0.04)% (14.08 6 0.37)%
Linear regression 0.9699x 1 0.0777 0.9763x 1 0.0416 0.9191x 1 0.5561 0.924x 1 0.2255 0.8556x 1 0.6645
R2 0.9818 0.9849 0.9407 0.9471 0.7827
P <0.001 <0.001 <0.001 <0.001 <0.001
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sclerotic lesions (e.g., local intimal thickening), the
assessment of progression mechanisms of coronary ar-
tery disease and the analysis of the impact of pharma-
cological or catheter-based interventions on plaque
structures, and vessel architecture. Intracoronary OCT
also provides detailed information relating to stent
apposition while allowing the accurate quantification
of neointimal stent coverage at follow-up. Such analy-
ses, however, require OCT studies over relatively long
epicardial artery segments. We, therefore, used a dedi-
cated OCT system that allows for data acquisition over
long coronary segments using an automated motorized
pullback.
Computer-Assisted Analysis Approach
During a motorized OCT pullback a large quantity
of cross-sectional images of the coronary artery are
acquired. For example, at a rate of 15 frames/sec and
Fig. 4. Bland–Altman plots for measurements in in vivo stented coronary arteries. The x-axis
shows the mean cross sectional area, and the y-axis shows the difference between the cross
sectional measurements by observer 1 and observer 2. The dotted lines indicate the limits of
agreement (bias 6 2 SD). (A) Stent area, (B) Lumen area, (C) Neointimal area, (D) Stent diame-
ter, (E) Lumen diameter.
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a pullback speed of 1.0 mm/sec, a ROI of 30 mm will
result in 450 individual cross-sections. Separate analy-
sis of all these individual cross-sections is cumbersome
and time-consuming. In this study, a method similar to
established quantitative IVUS (QCU) was adapted and
applied. This resulted in a user-friendly analysis sys-
tem that allows rapid and observer-independent quanti-
tative analysis. This particular QCU software has been
validated in the past [8] and is in use as the golden
standard for the analysis of IVUS studies, having been
applied in numerous multicenter trials [13–16].
Comparison to Previous Studies
In a study using IVUS, inter-observer agreement for
the presence of neointimal tissue was 62% with dis-
crepancy between observers exclusively in very thin
neointmal layers and a neointimal area <2 mm2 [17].
In the present study, the inter-observer agreement on
the presence of neointimal tissue was 100% with neo-
intima visible in all cross sections, whereby 23% of
cross section had a neointimal area <2 mm2. The
higher resolution of OCT compared to IVUS makes
this imaging modality more sensitive at detecting even
small quantities of intimal tissue, and this remains one
of the major advantages, particularly in the era of
drug-eluting stents.
Recent reports using OCT to assess tissue coverage
after stent implantation [18,19] have used proprietary
off-line software provided by LightLab Imaging. Such
an approach involves the operator individually meas-
uring each stent strut at 1-mm intervals (approximately
each 15 frames) followed by manually tracing both the
stent and lumen area, to derive the neointimal area.
We have found this technique to be quite cumbersome
and heavily operator dependent with each analysis of a
stented segment taking between 120 and 240 min to
complete, depending on the stent length. The method
presented in this study achieves a more robust and
reproducible analysis in a time and cost-effective
fashion.
Clinical Implications
OCT is an unique intravascular imaging modality
with the sensitivity to delineate mural and luminal
structures. As a result, the scope of OCT, as both a
research and clinical tool, remains vast. Such a tech-
nology allows the precise assessment of lumen dimen-
sions, plaques, thrombi, and dissections [20], while
also being able to assess both immediate and late
results of stent implantation. While OCT provides
additional morphologic information than IVUS, a con-
siderable quantity of information still needs to be proc-
essed. Adopting a semiautomated, computer-assisted
approach with contour detection remains pivotal in
making future studies incorporating OCT more reliable
and reproducible with less potential sources of operator
error.
LIMITATIONS
This study is obviously limited by the number of
observations and the narrow range of arterial dimen-
sions evaluated. However, the target vessel dimensions
represent the majority of clinically relevant dimensions
in patients. Motion artifacts during the cardiac cycle
hampered the visualization of the complete vessel cir-
cumference in 9% of the cross sections using the cur-
rent OCT software. Modifications in software, OCT
imaging catheter design and ECG-gated data acquisi-
tion [21] or retrospective image-based gating [22] of
acquired IVUS data might alleviate such limitations in
the future. The high resolution of OCT is at the
expense of penetration depth, which is typically limited
to 1 to 2 mm into the vessel wall limiting analysis
to structures that are relatively close to the inner
lumen border.
CONCLUSIONS
Computer-assisted contour analysis of intracoronary
OCT pullback is feasible and enables OCT morphome-
try with low inter-observer variability. This approach
allows independent QOCT analysis for observer, and
may be a valuable tool for future longitudinal studies
incorporating OCT.
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SUMMARY AND CONCLUSIONS
Part 1: Efficacy of drug eluting stent for complex patients and lesions 
Since percutaneous coronary intervention was introduced as a treatment option for coronary artery 
disease, coronary restenosis has been a significant and vexing problem. To prevent restenosis 
effectively, excessive efforts have been devoted to identifying risk factors and patients group for 
restenosis. In the era of bare metal stents (BMS), acute myocardial infarction, small coronary vessels, 
aorto-ostial lesions, and lesions of chronic total occlusion are high risk for in-stent restenosis (ISR). 
Clinical effects of sirolimus eluting stents (SES) and paclitaxel eluting stents (PES) on patients with these 
high risk factors were analyzed. In Chapter 2, we reviewed the 4 studies, which assessed the 
medium-term (ranged from 6 to 10 months) clinical advantage of SES over BMS in patients with acute 
myocardial infarction, and performed a meta-analysis by compiling the results of these studies. In the 
SES arm, the target vessel revascularization rate was 2.3% (80% relative reduction as compared to the 
BMS arm) and the overall incidence of major adverse cardiac events (MACE) was 10.8% (50% relative 
reduction as compared to the BMS arm). No angiographic stent thrombosis was observed in patients 
treated with SES. These results suggested that SES is a safe and effective device for the prevention of 
restenosis in this clinical setting. In Chapter 3, long-term (3 years) clinical outcome of SES and PES in 
patients with acute myocardial infarction was evaluated. Although SES proved to be superior to BMS at 
1 year in reducing repeat revascularization, the use of SES was no longer superior to BMS in reducing 
MACE in this clinical setting (the 3-year MACE rate was 25.5% in the BMS arm and 17.9% in the SES 
arm). Additionally, PES showed no superior benefit over BMS in reducing the incidence of MACE at 
medium- and long-term follow-up. These findings could be due to the increased rates of stent thrombosis 
in both DES groups (2.7% in the SES group and 2.9% in the PES group) as compared to the BMS group 
(1.6%). In Chapter 4 and 5, the efficacy of SES and PES implantation for small vessel disease was 
assessed. At 2 years, the cumulative incidence of MACE in the SES group was significantly lower than 
that in the PES group (10.3% vs. 23.3%, p = 0.02). Although PES utilization (Hazard ratio [HR] 3.34, 
95% CI 1.07-5.26) was identified as an independent predictor of MACE by multivariate analysis, we 
concluded that there is little and weak information to support this result at present. Chapter 6 examined 
the 7 months angiographic and 2-year clinical outcome of patients treated with PES for aorto-ostial 
lesions. The late lumen loss at 7 months was 0.48mm, resulting in the target vessel revascularization 
rate of 14.5% along with the MACE rate of 31.2% at 2 years. The PES implantation for this complex 
lesion was feasible and associated with favorable angiographic results. However, the gradual increase in 
later adverse events suggests that DES implantation for this specific lesion remains problematic. In 
Chapter 7, SES utilization for chronic total occlusion was analyzed. Although SES was associated with 
favorable 1 year survival free from target lesion revascularization, the use of SES was no longer 
associated with significantly lower rates of target vessel revascularization (12.7% in the BMS group vs. 
9.2% in the SES group) and MACE (18.3% in the BMS group vs. 15.8% in the SES group) after 3 years 
of follow-up compared to BMS. The efficacy of DES for another challenging clinical setting, chronic total 
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occlusion in post bypass surgery patients, was investigated in Chapter 8. Although only a small number 
of patients (N = 24) were enrolled, this trial suggested that DES implantation for saphenous vein graft 
and native coronary artery with chronic total occlusions had relatively favorable 3-year event free 
survival (83.9% in the saphenous vein graft and 81.8% in the native coronary artery).  
Part 2: New concept stents for percutaneous coronary intervention
DES have remarkably reduced the rates of ISR and repeat revascularization. However, the incidence of 
stent thrombosis, especially late stent thrombosis (occurs more than 1 year after stent implantation), is 
the most important drawback of DES. To maintain the favorable benefits of DES and resolve their 
drawbacks, various new concept stents have been developed. One of these stents is the MAHOROBA 
tacrolimus eluting stent (Chapter 9). This is comprised of a cobalt chromium thin strut thickness (75 µm) 
platform coated with bioabsorbable polymer containing tacrolimus, and considered as the next 
generation of DES. The MAHOROBA trial was the first in man study to test the safety and feasibility of 
this stent for de novo coronary lesions. The results of the MAHOROBA trial were reported in Chapter 10. 
The late lumen loss at 4 months was 0.99 mm and the rate of 6 months target lesion revascularization 
was 23.4%. We concluded that the MAHOROBA tacrolimus eluting stent failed to reduce the growth of 
neointimal hyperplasia and establish its effectiveness.  
The bioabsorbable everolimus eluting coronary stent (BVS) is another new concept stent. The BVS is 
composed of a poly-L-lactic acid backbone, coated with a bioabsorbable polymer (poly-D,L-lactic acid) 
containing the antiproliferative drug everolimus, and designed to be fully metabolized and totally 
absorbed in the human body between 2 and 3 years after implantation. Once the BVS is fully absorbed, 
only the healed vessels are left behind with no residual prosthesis, resulting in no potential interactions 
with coronary artery. Therefore, the BVS has the possibility of diminishing chronic inflammation at 
stented lesions and accelerating endothelialization. The first in man trial (the ABSORB trial) was 
conducted to assess the safety and feasibility of the BVS in patient with coronary artery disease. By 
using the data of the ABSORB trial, we investigated the mechanical behavior of the BVS after 
deployment in diseased human coronary arteries. Chapter 11 compared acute stent recoil of the BVS 
with that of the everolimus eluting ‘metallic’ stent (EES). Acute absolute recoil of the BVS and EES was 
0.20±0.21 mm and 0.13±0.21, respectively (p = 0.32), Acute percent recoil of the BVS and EES was 
6.9±7.0% and 4.3±7.1%, respectively (p = 0.25). These results suggested that acute stent recoil of the 
BVS was slightly larger but insignificantly different from that of EES. In Chapter 12, late stent recoil of 
the BVS was evaluated with intravascular ultrasound, which was performed at post-procedure and 6 
months follow-up. Late absolute and percent recoil of the BVS was 0.65±1.71 mm2 and 7.60±23.3%, 
respectively. We concluded that the BVS shrank in size during the follow-up period, which may be 
caused by its stent design and/or intrinsic characteristics. Chapter 13 illustrated several images of 
multi-slice computed tomography (MSCT) coronary angiography in a patient successfully treated with 
one BVS and one drug eluting metallic stent. While metallic struts hampered clear depiction of the 
in-stent lumen due to the “blooming effect”, BVS struts were invisible, therefore clear in-stent images of 
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the BVS was achieved. The polymer stent could be amenable to MSCT that has recently developed as a 
non-invasive imaging modality and will play an important role in the future for evaluating neointimal 
growth and arterial remodeling of the stented segment. In Chapter 14, quantitative MSCT coronary 
angiography analysis of the BVS was performed and compared with already established quantitative 
intravascular analysis. We concluded that non-invasive quantitative MSCT analysis can be used to 
quantify luminal dimensions in patient treated with the BVS.  
Part 3: New imaging modality for coronary intervention
Optical coherence tomography (OCT) is an analogue of intravascular ultrasound with an ultra-high 
resolution superior to any current available imaging modalites. An excellent image of patients presenting 
with ISR of PES was displayed in Chapter 15. Chapter 16 provided ex vivo validation of OCT with 
respect to diameter measurements. OCT-based dimensional values proved to correlate extremely well 
with the real luminal diameter of the phantom (accuracy = -0.03, precision = 0.02, relative standard 
deviation = 1.8%, r = 1.000). Although the measurement accuracy of OCT has been established in 
postmortem human coronary arteries, in vivo quantitative OCT analysis has not been evaluated, 
because in vivo intracoronary imaging is complicated due to the presence of blood and motion artifact 
during cardiac cycle. Chapter 17 revealed that inter-observer variability for lumen dimensions measured 
by quantitative OCT analysis was extremely low and in a similar range for both ex vivo and in vivo 
studies.
Conclusions
Although both SES and PES have been demonstrated to be significantly effective in reducing the rates 
of restenosis and repeat revascularization, even if patients are at high risk for ISR, long term effects of 
these devices for these patients remain uncertain. Long term follow-up are needed to definitively 
address the efficacy and safety of DES in complex patients and lesions. The increased risk of 
thrombosis is the most notable drawback of DES, but the mechanism of this catastrophic complication 
has not been fully understood. To overcome of this drawback, new concept stents have been developed. 
The bioabsorbable drug eluting polymer stents, which is designed to be fully metabolized and absorbed 
in the human body, have the possibility to accelerate good endothelialization at the stented segment and 
reduce the rate of stent thrombosis. Further developments in this technology and larger sample size 
trials are warranted to evaluate the efficacy and safety of this device. OCT is a novel imaging modality 
with an ultra-high resolution, which permits the observation and analysis of detailed coronary structures, 
and can help to understand the mechanism of ISR and late stent thrombosis in the DES era. 
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SAMENVATTING EN CONCLUSIES 
Deel 1: Doelmatigheid van medicijn-gecoate stents in complexe patiënten en 
vernauwingen 
Sinds de introductie van percutane coronaire interventies als een behandelingsoptie voor 
coronaire atherosclerose, is coronaire restenose een belangrijk en groot probleem. Om het probleem 
van restenonse te voorkomen is er uitgebreid en extensief onderzoek gedaan naar mogelijke 
risicofactoren die dit veroorzaken en bij welke patiëntengroepen dit voor zou kunnen komen. In het 
tijdperk van metalen stents (wat bare metal stent in het Engels betekent, afgekort BMS), een acuut 
myocard infarct, kleine coronaire vaten, ostiale vernauwingen en chronisch totale afsluitingen bleken 
hoge risico indicatoren voor in-stent restenoses (ISR) te zijn. In hoofdstuk 1, worden de klinische 
effecten van sirolimus-gecoate (Engels: sirolimus-eluting stents, afgekort SES) en paclitaxel-gecoate 
stents (Engels: paclitaxel-eluting stents, afgekort PES) op patiënten met deze risicofactoren onderzocht 
en beschreven. 
In hoofdstuk 2 beschouwen we 4 studies die de klinische voordelen op de middellange-termijn 
(tussen 6 en 10 maanden) onderzochten van SES tegen BMS gestente patiënten na een acuut myocard 
infarct. Deze beschouwing is uitgevoerd als een meta-analyse op de resultaten van deze studies. In de 
SES arm ondergingen 2.3% van de gestente vaten een herbehandeling (wat een reductie is van 80% 
t.o.v. de BMS groep). De totale reductie van cardiale gebeurtenissen (Engels: major adverse cardiac 
events, afgekort MACE) na stenting was 10.8% (dit is een 50% relatieve reductie t.o.v. de BMS arm). Er 
werden geen angiografische tromboses gevonden in de SES behandele patiënten. Deze resultaten 
suggereren dat SES implantatie een veilige behandeloptie is en restenose kan voorkomen in deze 
patiëntenpopulatie. 
In hoofdstuk 3, worden de lange-termijn effecten van de bovenstaande groep onderzocht en 
beschouwd. Hoewel de behandling met SES superieur was t.o.v. BMS na 1 jaar m.b.t. reductie van 
herhaalde behandelingen, het gebruik van SES was niet beter om het aantal gevallen van MACE te 
reduceren voor deze patiënten (na 3 jaar bedroeg de MACE in de SES groep 17.9% t.o.v. 25.5% voor de 
BMS groep). In additie, PES gestente patiënten hadden geen voordeel t.o.v. BMS gestente patiënten 
m.b.t. reductie van MACE op de middellange- en lange-termijn. Dit zou verzoorzaakt kunnen zijn door 
een toename van stent trombose in de medicijn-gecoate stent patiënten (Engels: drug-eluting-stents, 
afgekort DES) (2.7% in de SES groep, 2.9% in de PES groep en 1.6% in de BMS groep). 
In de hoofdstukken 4 en 5 wordt de effectiviteit van SES en PES stents geïmplanteerd in 
kleine coronaire vaten onderzocht. Na 2 jaar, was de cummulatieve frequentie van MACE in de SES 
groep significant lager dan in de PES groep (10.3% t.o.v. 23.3%, p=0.02). Hoewel het gebruik van PES 
(risico verhouding [HR] 3.34, 95% betrouwbaarheidsinterval [CI] 1.07-5.26) was geïdentificeerd als een 
onafhankelijke riscico voorspeller van MACE bij het toepassen van multivariable analyse, is onze 
conclusie dat de huidige beschikbare informatie  onvoldoende is om dit te kunnen onderbouwen. 
Hoofdstuk 6 onderzoekt de 7 maanden angiografische en 2 jaars klinische uitkomsten van 
patiënten die zijn behandeld met PES voor aorta-ostiale vernauwingen. Het late verlies van lumen 
(Ebgles: late lumen loss) na 7 maanden bedroeg 0.48mm wat tot gevolg had dat in 14.5% van de 
patiënten revascularisatie nodig was en dat bij 31.2% van de patiënten MACE incidenten gerapporteerd 
werden  na 2 jaar. Het implanteren van PES stents was echter goed mogelijk in deze groep met 
complexe vernauwingen en de angiografische resultaten waren goed. Echter de graduele toename in 
late nadelige gebeurtenissen suggereren dat DES implantatie voor deze specifieke groep problematisch 
blijft. 
In hoofdstuk 7 wordt het gebruik van SES voor chronische totale occlusies onderzocht. In de 
SES behandele patiënten waren minder revascularisaties nodig na 1 jaar voor de behandele stenoses, 
echter nieuwe behandeldingen voor het gestente coronaire vat op zich was niet langer significant lager 
(12.7% in de BMS groep t.o.v. 9.2% in de SES groep) en ook het aantal incidenten van MACE (18.3% in 
de BMS groep t.o.v. 15.8% in de SES groep) na 3 jaar  was niet lager vergeleken met de BMS 
behandelde groep. 
Een andere uitdagende en lastige patiëntengroep is de totale chronische occlusies van vaten 
die reeds eerder behandeld zijn met een bypass-operatie. Hoofdstuk 8 onderzoekt de effectiviteit van 
een behandeling met DES stents voor deze groep. Hoewel er maar een kleine groep patënten op deze 
wijze is behandeld (n=24) lijkt deze studie te suggereren dat DES implantatie voor zowel venzeuze 
bypasses als lima or rima na 3 jaar een voordeel  oplevert m.b.t. overleving (83.9% voor de venezeuze 
bypasses en 81.8% in de lima’s en rima’s). 
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Deel 2: Nieuwe stent ontwerpen voor percutane coronaire interventies 
 Het gebruik van DES heeft geleid tot een opmerkelijke daling van ISR en noodzakelijke 
herbehandelingen. Echter, het meest belangrijke negatieve effect van het gebruik van DES zijn 
incidenties van stent trombose, in vele gevallen later dan na 1 jaar. Om dit probleem te voorkomen en de 
positieve eigenschappen van DES te behouden, zijn verschillende nieuwe stent ontwerpen ontwikkeld. 
Één van deze nieuwe stents is de MAHOROBA tacrolimus gecoate-stent (hoofdstuk 9). Deze is 
gemaakt van een mengsel van kobalt en chroom en de stent struts hebben een dikte van 75 micron. De 
struts zijn gecoat met een bioafbreekbare polymeer die tacrolimus bevat en deze ontwerpen worden 
gezien als de nieuwe generatie DES. De MAHOROBA studie was de eerste studie in mensen die de 
veiligheid en toepasbaarheid van dit nieuwe stent ontwerp voor de novo coronaire vernauwingen 
onderzocht.  
 De resultaten van de MAHOROBA worden in hoofdstuk 10 gepresenteerd. Het verlies van 
lumen na 4 maanden bedroeg 0.99mm and revascularisatie was nodig bij 23.4% van de patiënten. De 
conclusie was dat deze nieuwe stent niet bijdroeg in verlaging van het aantal gevallen van restenose en 
dus niet effectief was. De bioafbreekbare everolimus-gecoate stent (BVS) is een ander nieuw ontwerp. 
Deze stent is gemaakt van poly-l-lactic acid en heeft een coating van alweer een bioafbreekbare 
polymeer (poly-D, L-actic acid) die het medicijn everolimus bevat dat weefsel groei zou moeten remmen. 
Deze stent zou na 2 á 3 jaar volledig moeten zijn afgebroken in het menselijk lichaam. Dit heeft als 
voordeel dat er geen artificieël implantaat achterblijft en dus geen nadelige effecten meer zou moeten 
hebben voor het coronaire vat. De BVS stent heeft dus mogelijk als voordeel dat het een chronische 
onsteking in de gestente regio’s zou kunnen voorkomen en het zou de re-endothelialisatie van de 
behandelde vernauwing kunnen bespoedigen. De eerste studie in mensen (de ABSORB studie) met 
deze stent betrof het bestuderen van de veiligheid en de toepasbaarheid van dit ontwerp. De data 
verkregen uit de ABSORB studie is gebruikt om de mechanische eigenschappen van deze stent te 
onderzoeken na implantatie in zieke  coronaire vaten. 
 In hoofdstuk 11 vergelijken we de acute stent krimp van deze BVS stent met die van een 
metalen stent die een vergelijkbare structuur heeft en ook met everolimus is gecoat (EES). De acute 
krimp van de BVS was 0.20±0.21mm tegen 0.13±0.21mm voor de EES stent (p=0.32). Relatief bedroeg 
de krimp voor de BVS stent 6.9±7.0 tegen 4.3±7.1% voor de EES, p=0.25). Deze resultaten suggereren 
dat de acute krimp voor de BVS groter is dan die voor de metalen stent, maar dit verschil is statistisch 
niet significant. 
 In hoofdstuk 12 wordt de late krimp van de BVS stent onderzocht met intravasculair ultrageluid 
(IVUS). De behandele coronairen werden met IVUS bekeken, post-implantatie, na 6 maanden en na 2 
jaar. De late absolute krimp van de BVS stent bedroeg 0.65±1.71mm2 en relatief is dit 7.60±23.3%. 
Hieruit concludeerden we dat de BVS stent kromp tijdens de follow-up periode wat veroorzaakt zou 
kunnen zijn door het ontwerp zelf en/of intrinsieke karakteristieken. 
Hoofdstuk 13 illustreert aan de hand van verschillende beelden gemaakt met een multi-slice 
computed tomograaf (MSCT) de verschillen tussen een BVS en een metalen stent gemaakt in één 
patiënt die met beide stents behandeld is. In deze beelden valt te zien dat de metalen struts het zicht 
verhinderen op het lumen, wat niet geldt voor de BVS stent. Deze struts zijn niet zichtbaar te maken met 
röntgenstraling, wat wellicht in de toekomst een voordeel zou kunnen zijn om met de non-invasieve 
MSCT mogelijk een follow-up te kunnen doen. MSCT zal in de toekomst een grote rol gaan spelen als 
beeldmodaliteit om het proces van neo-intima groei en vasculaire remodellering te kunnen bestuderen. 
In hoofdstuk 14 wordt kwantitatieve MSCT vergeleken met kwantitatieve intravasculaire 
technieken. We concludeerden dat non-invasieve kwantitatieve MSCT analyses gebruikt kunnen worden 
bij patiënten behandeld met een BVS stent. 
Deel 3: Nieuwe beeldvormende modaliteiten voor coronaire interventies 
 Optical coherence tomography (OCT) is een techniek die verwant is met en vergelijkbaar is aan 
IVUS maar met het voordeel dat het de coronaire vaatwand in een hele hoge resolutie (10 maal zo hoog 
als IVUS) zichtbaar kan maken. Een excellent voorbeeld kan worden gevonden in hoofdstuk 15.
Hoofdstuk 16 presenteert een ex-vivo validatie studie waarin gevalideerd wordt hoe 
nauwkeurig de diameter metingen met OCT zijn. OCT gebaseerde metingen bleken extreem goed te 
correleren met de gebruikte gouden standaard, e.g. een fantoom (accuracy = -0.03, precision = 0.02, 
relatieve standaard deviatie = 1.8%, r = 1). Hoewel de meetnauwkeurigheid van OCT is vastgesteld voor 
ex-vivo humane coronaire vaten, in-vivo kwantitatieve OCT validatie is niet onderzocht. Dit omdat in-vivo 
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gebruik van OCT wordt bemoeilijkt door bloed en bewegingen van de catheter tijdens de cardiale cyclus. 
Hoofdstuk 17 laat zien dat de inter- en intra-onderzoeker variabiliteit voor het meten van 
lumen dimensies m.b.v. kwantitatieve OCT extreem laag is voor een vergelijkbare reeks in- en ex-vivo 
studies.
Conclusies
 Hoewel het gebruik van SES en PES hebben aangetoond dat ze effectief zijn in het reduceren 
van restenoses en benodigde herhaalde behandelingen, zelfs voor patiënten in hoge risico groepen voor 
ISR, zijn de lange termijn effecten van deze stents voor deze patiënten groepen onzeker. Lange termijn 
vervolg onderzoeken zijn nodig om definitief vast te kunnen stellen dat het gebruik van DES veilig en 
effectief is voor gebruik in complexe patiënten groepen en vernauwingen. Het verhoogde risico op stent 
trombose is de meest prominente negatieve eigenschap van DES. Het mechanisme hierachter is echter 
nog steeds niet helemaal begrepen. Om deze eigenschap to overkomen zijn nieuwe stent ontworpen. 
De bioabsorbeerbare polymeer-gecoate stents welke volledig door het lichaam afbreekbaar zijn bieden 
de mogelijkheid tot een goede re-endothelialisatie van het gestente deel van het coronaire vat en tot het 
reduceren van stent trombose. Verdere ontwikkelingen van deze technologie en studies met grotere 
patiënten aantallen zijn noodzakelijk om de verdere veiligheid en effectiviteit van dit nieuwe ontwerp te 
kunnen evalueren. OCT is een nieuwe beelvormende intravasculaire techniek met een extreem hoge 
resolutie. Dit biedt de mogelijkheid om met grote detailweergave coronaire sturcturen te observeren en 
analyseren. Dit zou kunnen leiden tot een vergrote kennis van de onderliggende redenen die resulteren 
in stent trombose in het DES tijdperk. 
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